Motif 969 (n=138)
Position-wise Probabilities
Download
uniprot | genes | site | source | protein | function |
---|---|---|---|---|---|
A0A096LP49 | CCDC187 | S775 | ochoa | Coiled-coil domain-containing protein 187 | None |
A0A0B4J1V8 | PPAN-P2RY11 | S238 | ochoa | HCG2039996 (PPAN-P2RY11 readthrough) | None |
A6NF01 | POM121B | S127 | ochoa | Putative nuclear envelope pore membrane protein POM 121B | Putative component of the nuclear pore complex (NPC). The repeat-containing domain may be involved in anchoring components of the pore complex to the pore membrane (By similarity). {ECO:0000250}. |
A8CG34 | POM121C | S520 | ochoa | Nuclear envelope pore membrane protein POM 121C (Nuclear pore membrane protein 121-2) (POM121-2) (Pore membrane protein of 121 kDa C) | Essential component of the nuclear pore complex (NPC). The repeat-containing domain may be involved in anchoring components of the pore complex to the pore membrane. When overexpressed in cells induces the formation of cytoplasmic annulate lamellae (AL). {ECO:0000269|PubMed:17900573}. |
H3BNR1 | BORCS8-MEF2B | S90 | ochoa | BORCS8-MEF2B readthrough | None |
O14617 | AP3D1 | S1068 | ochoa | AP-3 complex subunit delta-1 (AP-3 complex subunit delta) (Adaptor-related protein complex 3 subunit delta-1) (Delta-adaptin) | Part of the AP-3 complex, an adaptor-related complex which is not clathrin-associated. The complex is associated with the Golgi region as well as more peripheral structures. It facilitates the budding of vesicles from the Golgi membrane and may be directly involved in trafficking to lysosomes. Involved in process of CD8+ T-cell and NK cell degranulation (PubMed:26744459). In concert with the BLOC-1 complex, AP-3 is required to target cargos into vesicles assembled at cell bodies for delivery into neurites and nerve terminals (By similarity). {ECO:0000250|UniProtKB:O54774, ECO:0000269|PubMed:26744459}. |
O60315 | ZEB2 | S641 | ochoa | Zinc finger E-box-binding homeobox 2 (Smad-interacting protein 1) (SMADIP1) (Zinc finger homeobox protein 1b) | Transcriptional inhibitor that binds to DNA sequence 5'-CACCT-3' in different promoters (PubMed:16061479, PubMed:20516212). Represses transcription of E-cadherin (PubMed:16061479). Represses expression of MEOX2 (PubMed:20516212). {ECO:0000269|PubMed:16061479, ECO:0000269|PubMed:20516212}. |
O95983 | MBD3 | S144 | ochoa | Methyl-CpG-binding domain protein 3 (Methyl-CpG-binding protein MBD3) | Acts as a component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin (PubMed:12124384, PubMed:16428440, PubMed:28977666). Acts as transcriptional repressor and plays a role in gene silencing (PubMed:10947852, PubMed:18644863). Does not bind to methylated DNA by itself (PubMed:12124384, PubMed:16428440). Binds to a lesser degree DNA containing unmethylated CpG dinucleotides (PubMed:24307175). Recruits histone deacetylases and DNA methyltransferases. {ECO:0000269|PubMed:10947852, ECO:0000269|PubMed:12124384, ECO:0000269|PubMed:16428440, ECO:0000269|PubMed:18644863, ECO:0000269|PubMed:23361464, ECO:0000269|PubMed:24307175, ECO:0000269|PubMed:28977666, ECO:0000269|PubMed:9774669}. |
P00492 | HPRT1 | S104 | ochoa | Hypoxanthine-guanine phosphoribosyltransferase (HGPRT) (HGPRTase) (EC 2.4.2.8) | Converts guanine to guanosine monophosphate, and hypoxanthine to inosine monophosphate. Transfers the 5-phosphoribosyl group from 5-phosphoribosylpyrophosphate onto the purine. Plays a central role in the generation of purine nucleotides through the purine salvage pathway. |
P02810 | PRH1; | S24 | psp | Salivary acidic proline-rich phosphoprotein 1/2 (Db-s) (PRP-1/PRP-2) (Parotid acidic protein) (Pa) (Parotid double-band protein) (Parotid isoelectric focusing variant protein) (PIF-S) (Parotid proline-rich protein 1/2) (Pr1/Pr2) (Protein C) [Cleaved into: Salivary acidic proline-rich phosphoprotein 1/2; Salivary acidic proline-rich phosphoprotein 3/4 (Db-F) (PIF-F) (PRP-3/PRP-4) (Protein A); Peptide P-C] | PRP's act as highly potent inhibitors of crystal growth of calcium phosphates. They provide a protective and reparative environment for dental enamel which is important for the integrity of the teeth. |
P05164 | MPO | S713 | ochoa | Myeloperoxidase (MPO) (EC 1.11.2.2) [Cleaved into: Myeloperoxidase; 89 kDa myeloperoxidase; 84 kDa myeloperoxidase; Myeloperoxidase light chain; Myeloperoxidase heavy chain] | Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity (PubMed:9922160). Mediates the proteolytic cleavage of alpha-1-microglobulin to form t-alpha-1-microglobulin, which potently inhibits oxidation of low-density lipoprotein particles and limits vascular damage (PubMed:25698971). {ECO:0000269|PubMed:25698971, ECO:0000269|PubMed:9922160}. |
P08493 | MGP | S25 | psp | Matrix Gla protein (MGP) (Cell growth-inhibiting gene 36 protein) | Associates with the organic matrix of bone and cartilage. Thought to act as an inhibitor of bone formation. |
P0DMU7 | CT45A6 | T112 | ochoa | Cancer/testis antigen family 45 member A6 (Cancer/testis antigen 45-6) (Cancer/testis antigen 45A6) | None |
P0DMU8 | CT45A5 | T112 | ochoa | Cancer/testis antigen family 45 member A5 (Cancer/testis antigen 45-5) (Cancer/testis antigen 45A5) | None |
P0DMV0 | CT45A7 | T112 | ochoa | Cancer/testis antigen family 45 member A7 (Cancer/testis antigen 45A7) | None |
P12814 | ACTN1 | S471 | ochoa | Alpha-actinin-1 (Alpha-actinin cytoskeletal isoform) (F-actin cross-linking protein) (Non-muscle alpha-actinin-1) | F-actin cross-linking protein which is thought to anchor actin to a variety of intracellular structures. Association with IGSF8 regulates the immune synapse formation and is required for efficient T-cell activation (PubMed:22689882). {ECO:0000269|PubMed:22689882}. |
P21333 | FLNA | S1409 | ochoa | Filamin-A (FLN-A) (Actin-binding protein 280) (ABP-280) (Alpha-filamin) (Endothelial actin-binding protein) (Filamin-1) (Non-muscle filamin) | Promotes orthogonal branching of actin filaments and links actin filaments to membrane glycoproteins. Anchors various transmembrane proteins to the actin cytoskeleton and serves as a scaffold for a wide range of cytoplasmic signaling proteins. Interaction with FLNB may allow neuroblast migration from the ventricular zone into the cortical plate. Tethers cell surface-localized furin, modulates its rate of internalization and directs its intracellular trafficking (By similarity). Involved in ciliogenesis. Plays a role in cell-cell contacts and adherens junctions during the development of blood vessels, heart and brain organs. Plays a role in platelets morphology through interaction with SYK that regulates ITAM- and ITAM-like-containing receptor signaling, resulting in by platelet cytoskeleton organization maintenance (By similarity). During the axon guidance process, required for growth cone collapse induced by SEMA3A-mediated stimulation of neurons (PubMed:25358863). {ECO:0000250, ECO:0000250|UniProtKB:Q8BTM8, ECO:0000269|PubMed:22121117, ECO:0000269|PubMed:25358863}. |
P21860 | ERBB3 | S844 | ochoa | Receptor tyrosine-protein kinase erbB-3 (EC 2.7.10.1) (Proto-oncogene-like protein c-ErbB-3) (Tyrosine kinase-type cell surface receptor HER3) | Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins. Binds to neuregulin-1 (NRG1) and is activated by it; ligand-binding increases phosphorylation on tyrosine residues and promotes its association with the p85 subunit of phosphatidylinositol 3-kinase (PubMed:20682778). May also be activated by CSPG5 (PubMed:15358134). Involved in the regulation of myeloid cell differentiation (PubMed:27416908). {ECO:0000269|PubMed:15358134, ECO:0000269|PubMed:20682778, ECO:0000269|PubMed:27416908}. |
P27348 | YWHAQ | S210 | ochoa | 14-3-3 protein theta (14-3-3 protein T-cell) (14-3-3 protein tau) (Protein HS1) | Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. Negatively regulates the kinase activity of PDPK1. {ECO:0000269|PubMed:12177059}. |
P31946 | YWHAB | S212 | ochoa | 14-3-3 protein beta/alpha (Protein 1054) (Protein kinase C inhibitor protein 1) (KCIP-1) [Cleaved into: 14-3-3 protein beta/alpha, N-terminally processed] | Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. Negative regulator of osteogenesis. Blocks the nuclear translocation of the phosphorylated form (by AKT1) of SRPK2 and antagonizes its stimulatory effect on cyclin D1 expression resulting in blockage of neuronal apoptosis elicited by SRPK2. Negative regulator of signaling cascades that mediate activation of MAP kinases via AKAP13. {ECO:0000269|PubMed:17717073, ECO:0000269|PubMed:19592491, ECO:0000269|PubMed:21224381}. |
P35372 | OPRM1 | S268 | psp | Mu-type opioid receptor (M-OR-1) (MOR-1) (Mu opiate receptor) (Mu opioid receptor) (MOP) (hMOP) | Receptor for endogenous opioids such as beta-endorphin and endomorphin (PubMed:10529478, PubMed:12589820, PubMed:7891175, PubMed:7905839, PubMed:7957926, PubMed:9689128). Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone (PubMed:10529478, PubMed:10836142, PubMed:12589820, PubMed:19300905, PubMed:7891175, PubMed:7905839, PubMed:7957926, PubMed:9689128). Also activated by enkephalin peptides, such as Met-enkephalin or Met-enkephalin-Arg-Phe, with higher affinity for Met-enkephalin-Arg-Phe (By similarity). Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors (PubMed:7905839). The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extent to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15 (PubMed:12068084). They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B (By similarity). Also couples to adenylate cyclase stimulatory G alpha proteins (By similarity). The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4 (By similarity). Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization (By similarity). Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction (By similarity). The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins (By similarity). The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation (By similarity). Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling (By similarity). Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling (By similarity). Endogenous ligands induce rapid desensitization, endocytosis and recycling (By similarity). Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties (By similarity). {ECO:0000250|UniProtKB:P33535, ECO:0000269|PubMed:10529478, ECO:0000269|PubMed:12068084, ECO:0000269|PubMed:12589820, ECO:0000269|PubMed:7891175, ECO:0000269|PubMed:7905839, ECO:0000269|PubMed:7957926, ECO:0000269|PubMed:9689128, ECO:0000303|PubMed:10836142, ECO:0000303|PubMed:19300905}.; FUNCTION: [Isoform 12]: Couples to GNAS and is proposed to be involved in excitatory effects. {ECO:0000269|PubMed:20525224}.; FUNCTION: [Isoform 16]: Does not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity. {ECO:0000269|PubMed:16580639}.; FUNCTION: [Isoform 17]: Does not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity. {ECO:0000269|PubMed:16580639}. |
P35579 | MYH9 | S1290 | ochoa | Myosin-9 (Cellular myosin heavy chain, type A) (Myosin heavy chain 9) (Myosin heavy chain, non-muscle IIa) (Non-muscle myosin heavy chain A) (NMMHC-A) (Non-muscle myosin heavy chain IIa) (NMMHC II-a) (NMMHC-IIA) | Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping. Required for cortical actin clearance prior to oocyte exocytosis (By similarity). Promotes cell motility in conjunction with S100A4 (PubMed:16707441). During cell spreading, plays an important role in cytoskeleton reorganization, focal contact formation (in the margins but not the central part of spreading cells), and lamellipodial retraction; this function is mechanically antagonized by MYH10 (PubMed:20052411). {ECO:0000250|UniProtKB:Q8VDD5, ECO:0000269|PubMed:16707441, ECO:0000269|PubMed:20052411}.; FUNCTION: (Microbial infection) Acts as a receptor for herpes simplex virus 1/HHV-1 envelope glycoprotein B. {ECO:0000269|PubMed:20944748, ECO:0000269|PubMed:39048823}. |
P37173 | TGFBR2 | S548 | ochoa | TGF-beta receptor type-2 (TGFR-2) (EC 2.7.11.30) (TGF-beta type II receptor) (Transforming growth factor-beta receptor type II) (TGF-beta receptor type II) (TbetaR-II) | Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and thus regulates a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. {ECO:0000269|PubMed:7774578}.; FUNCTION: [Isoform 1]: Has transforming growth factor beta-activated receptor activity. {ECO:0000269|PubMed:8635485}.; FUNCTION: [Isoform 2]: Has transforming growth factor beta-activated receptor activity. {ECO:0000269|PubMed:8635485}.; FUNCTION: [Isoform 3]: Binds TGFB1, TGFB2 and TGFB3 in the picomolar affinity range without the participation of additional receptors. Blocks activation of SMAD2 and SMAD3 by TGFB1. {ECO:0000269|PubMed:34568316}. |
P38398 | BRCA1 | S423 | ochoa | Breast cancer type 1 susceptibility protein (EC 2.3.2.27) (RING finger protein 53) (RING-type E3 ubiquitin transferase BRCA1) | E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage (PubMed:10500182, PubMed:12887909, PubMed:12890688, PubMed:14976165, PubMed:16818604, PubMed:17525340, PubMed:19261748). It is unclear whether it also mediates the formation of other types of polyubiquitin chains (PubMed:12890688). The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability (PubMed:12890688, PubMed:14976165, PubMed:20351172). Regulates centrosomal microtubule nucleation (PubMed:18056443). Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle (PubMed:10724175, PubMed:11836499, PubMed:12183412, PubMed:19261748). Required for FANCD2 targeting to sites of DNA damage (PubMed:12887909). Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation (PubMed:16326698). Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks (PubMed:19369211). Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination of RBBP8 (PubMed:16818604). Acts as a transcriptional activator (PubMed:20160719). {ECO:0000269|PubMed:10500182, ECO:0000269|PubMed:10724175, ECO:0000269|PubMed:11836499, ECO:0000269|PubMed:12183412, ECO:0000269|PubMed:12887909, ECO:0000269|PubMed:12890688, ECO:0000269|PubMed:14976165, ECO:0000269|PubMed:16326698, ECO:0000269|PubMed:16818604, ECO:0000269|PubMed:17525340, ECO:0000269|PubMed:18056443, ECO:0000269|PubMed:19261748, ECO:0000269|PubMed:19369211, ECO:0000269|PubMed:20160719, ECO:0000269|PubMed:20351172}. |
P38398 | BRCA1 | S1577 | ochoa | Breast cancer type 1 susceptibility protein (EC 2.3.2.27) (RING finger protein 53) (RING-type E3 ubiquitin transferase BRCA1) | E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage (PubMed:10500182, PubMed:12887909, PubMed:12890688, PubMed:14976165, PubMed:16818604, PubMed:17525340, PubMed:19261748). It is unclear whether it also mediates the formation of other types of polyubiquitin chains (PubMed:12890688). The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability (PubMed:12890688, PubMed:14976165, PubMed:20351172). Regulates centrosomal microtubule nucleation (PubMed:18056443). Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle (PubMed:10724175, PubMed:11836499, PubMed:12183412, PubMed:19261748). Required for FANCD2 targeting to sites of DNA damage (PubMed:12887909). Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation (PubMed:16326698). Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks (PubMed:19369211). Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination of RBBP8 (PubMed:16818604). Acts as a transcriptional activator (PubMed:20160719). {ECO:0000269|PubMed:10500182, ECO:0000269|PubMed:10724175, ECO:0000269|PubMed:11836499, ECO:0000269|PubMed:12183412, ECO:0000269|PubMed:12887909, ECO:0000269|PubMed:12890688, ECO:0000269|PubMed:14976165, ECO:0000269|PubMed:16326698, ECO:0000269|PubMed:16818604, ECO:0000269|PubMed:17525340, ECO:0000269|PubMed:18056443, ECO:0000269|PubMed:19261748, ECO:0000269|PubMed:19369211, ECO:0000269|PubMed:20160719, ECO:0000269|PubMed:20351172}. |
P49327 | FASN | S1028 | psp | Fatty acid synthase (EC 2.3.1.85) (Type I fatty acid synthase) [Includes: [Acyl-carrier-protein] S-acetyltransferase (EC 2.3.1.38); [Acyl-carrier-protein] S-malonyltransferase (EC 2.3.1.39); 3-oxoacyl-[acyl-carrier-protein] synthase (EC 2.3.1.41); 3-oxoacyl-[acyl-carrier-protein] reductase (EC 1.1.1.100); 3-hydroxyacyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.59); Enoyl-[acyl-carrier-protein] reductase (EC 1.3.1.39); Acyl-[acyl-carrier-protein] hydrolase (EC 3.1.2.14)] | Fatty acid synthetase is a multifunctional enzyme that catalyzes the de novo biosynthesis of long-chain saturated fatty acids starting from acetyl-CoA and malonyl-CoA in the presence of NADPH. This multifunctional protein contains 7 catalytic activities and a site for the binding of the prosthetic group 4'-phosphopantetheine of the acyl carrier protein ([ACP]) domain. {ECO:0000269|PubMed:16215233, ECO:0000269|PubMed:16969344, ECO:0000269|PubMed:26851298, ECO:0000269|PubMed:7567999, ECO:0000269|PubMed:8962082, ECO:0000269|PubMed:9356448}.; FUNCTION: (Microbial infection) Fatty acid synthetase activity is required for SARS coronavirus-2/SARS-CoV-2 replication. {ECO:0000269|PubMed:34320401}. |
P49589 | CARS1 | S305 | ochoa | Cysteine--tRNA ligase, cytoplasmic (EC 6.1.1.16) (Cysteinyl-tRNA synthetase) (CysRS) | Catalyzes the ATP-dependent ligation of cysteine to tRNA(Cys). {ECO:0000269|PubMed:11347887, ECO:0000269|PubMed:30824121}. |
P49790 | NUP153 | S297 | ochoa | Nuclear pore complex protein Nup153 (153 kDa nucleoporin) (Nucleoporin Nup153) | Component of the nuclear pore complex (NPC), a complex required for the trafficking across the nuclear envelope. Functions as a scaffolding element in the nuclear phase of the NPC essential for normal nucleocytoplasmic transport of proteins and mRNAs. Involved in the quality control and retention of unspliced mRNAs in the nucleus; in association with TPR, regulates the nuclear export of unspliced mRNA species bearing constitutive transport element (CTE) in a NXF1- and KHDRBS1-independent manner. Mediates TPR anchoring to the nuclear membrane at NPC. The repeat-containing domain may be involved in anchoring other components of the NPC to the pore membrane. Possible DNA-binding subunit of the nuclear pore complex (NPC). {ECO:0000269|PubMed:12802065, ECO:0000269|PubMed:15229283, ECO:0000269|PubMed:22253824}.; FUNCTION: (Microbial infection) Interacts with HIV-1 caspid protein P24 and thereby promotes the integration of the virus in the nucleus of non-dividing cells (in vitro). {ECO:0000269|PubMed:23523133, ECO:0000269|PubMed:24130490, ECO:0000269|PubMed:29997211}.; FUNCTION: (Microbial infection) Binds HIV-2 protein vpx and thereby promotes the nuclear translocation of the lentiviral genome (in vitro). {ECO:0000269|PubMed:24130490, ECO:0000269|PubMed:31913756}. |
P52948 | NUP98 | S656 | ochoa | Nuclear pore complex protein Nup98-Nup96 (EC 3.4.21.-) [Cleaved into: Nuclear pore complex protein Nup98 (98 kDa nucleoporin) (Nucleoporin Nup98) (Nup98); Nuclear pore complex protein Nup96 (96 kDa nucleoporin) (Nucleoporin Nup96) (Nup96)] | Plays a role in the nuclear pore complex (NPC) assembly and/or maintenance. NUP98 and NUP96 are involved in the bidirectional transport across the NPC (PubMed:33097660). May anchor NUP153 and TPR to the NPC. In cooperation with DHX9, plays a role in transcription and alternative splicing activation of a subset of genes (PubMed:28221134). Involved in the localization of DHX9 in discrete intranuclear foci (GLFG-body) (PubMed:28221134). {ECO:0000269|PubMed:15229283, ECO:0000269|PubMed:33097660}.; FUNCTION: (Microbial infection) Interacts with HIV-1 capsid protein P24 and nucleocapsid protein P7 and may thereby promote the integration of the virus in the host nucleus (in vitro) (PubMed:23523133). Binding affinity to HIV-1 CA-NC complexes bearing the capsid change Asn-74-Asp is reduced (in vitro) (PubMed:23523133). {ECO:0000269|PubMed:23523133}. |
P54105 | CLNS1A | S193 | ochoa | Methylosome subunit pICln (Chloride channel, nucleotide sensitive 1A) (Chloride conductance regulatory protein ICln) (I(Cln)) (Chloride ion current inducer protein) (ClCI) (Reticulocyte pICln) | Involved in both the assembly of spliceosomal snRNPs and the methylation of Sm proteins (PubMed:10330151, PubMed:11713266, PubMed:18984161, PubMed:21081503). Chaperone that regulates the assembly of spliceosomal U1, U2, U4 and U5 small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome, and thereby plays an important role in the splicing of cellular pre-mRNAs (PubMed:10330151, PubMed:18984161). Most spliceosomal snRNPs contain a common set of Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG that assemble in a heptameric protein ring on the Sm site of the small nuclear RNA to form the core snRNP (Sm core) (PubMed:10330151). In the cytosol, the Sm proteins SNRPD1, SNRPD2, SNRPE, SNRPF and SNRPG are trapped in an inactive 6S pICln-Sm complex by the chaperone CLNS1A that controls the assembly of the core snRNP (PubMed:10330151, PubMed:18984161). Dissociation by the SMN complex of CLNS1A from the trapped Sm proteins and their transfer to an SMN-Sm complex triggers the assembly of core snRNPs and their transport to the nucleus (PubMed:10330151, PubMed:18984161). {ECO:0000269|PubMed:10330151, ECO:0000269|PubMed:11713266, ECO:0000269|PubMed:18984161, ECO:0000269|PubMed:21081503}. |
P61981 | YWHAG | S215 | ochoa | 14-3-3 protein gamma (Protein kinase C inhibitor protein 1) (KCIP-1) [Cleaved into: 14-3-3 protein gamma, N-terminally processed] | Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways (PubMed:15696159, PubMed:16511572, PubMed:36732624). Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif (PubMed:15696159, PubMed:16511572, PubMed:36732624). Binding generally results in the modulation of the activity of the binding partner (PubMed:16511572). Promotes inactivation of WDR24 component of the GATOR2 complex by binding to phosphorylated WDR24 (PubMed:36732624). Participates in the positive regulation of NMDA glutamate receptor activity by promoting the L-glutamate secretion through interaction with BEST1 (PubMed:29121962). Reduces keratinocyte intercellular adhesion, via interacting with PKP1 and sequestering it in the cytoplasm, thereby reducing its incorporation into desmosomes (PubMed:29678907). Plays a role in mitochondrial protein catabolic process (also named MALM) that promotes the degradation of damaged proteins inside mitochondria (PubMed:22532927). {ECO:0000269|PubMed:15696159, ECO:0000269|PubMed:16511572, ECO:0000269|PubMed:22532927, ECO:0000269|PubMed:29121962, ECO:0000269|PubMed:29678907, ECO:0000269|PubMed:36732624}. |
P62258 | YWHAE | S213 | ochoa | 14-3-3 protein epsilon (14-3-3E) | Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways (PubMed:21189250). Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif (PubMed:35343654). Binding generally results in the modulation of the activity of the binding partner (By similarity). Positively regulates phosphorylated protein HSF1 nuclear export to the cytoplasm (PubMed:12917326). Plays a positive role in the antiviral signaling pathway upstream of TBK1 via interaction with RIGI (PubMed:37555661). Mechanistically, directs RIGI redistribution from the cytosol to mitochondrial associated membranes where it mediates MAVS-dependent innate immune signaling during viral infection (PubMed:22607805). Plays a role in proliferation inhibition and cell cycle arrest by exporting HNRNPC from the nucleus to the cytoplasm to be degraded by ubiquitination (PubMed:37599448). {ECO:0000250|UniProtKB:P62261, ECO:0000269|PubMed:12917326, ECO:0000269|PubMed:21189250, ECO:0000269|PubMed:22607805, ECO:0000269|PubMed:35343654, ECO:0000269|PubMed:37555661, ECO:0000269|PubMed:37599448}. |
P62314 | SNRPD1 | S59 | ochoa | Small nuclear ribonucleoprotein Sm D1 (Sm-D1) (Sm-D autoantigen) (snRNP core protein D1) | Plays a role in pre-mRNA splicing as a core component of the spliceosomal U1, U2, U4 and U5 small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome (PubMed:11991638, PubMed:18984161, PubMed:19325628, PubMed:23333303, PubMed:25555158, PubMed:26912367, PubMed:28076346, PubMed:28502770, PubMed:28781166, PubMed:32494006). Component of both the pre-catalytic spliceosome B complex and activated spliceosome C complexes (PubMed:11991638, PubMed:26912367, PubMed:28076346, PubMed:28502770, PubMed:28781166). As a component of the minor spliceosome, involved in the splicing of U12-type introns in pre-mRNAs (PubMed:15146077). May act as a charged protein scaffold to promote snRNP assembly or strengthen snRNP-snRNP interactions through non-specific electrostatic contacts with RNA (PubMed:23333303). {ECO:0000269|PubMed:11991638, ECO:0000269|PubMed:15146077, ECO:0000269|PubMed:18984161, ECO:0000269|PubMed:19325628, ECO:0000269|PubMed:23333303, ECO:0000269|PubMed:25555158, ECO:0000269|PubMed:26912367, ECO:0000269|PubMed:28076346, ECO:0000269|PubMed:28502770, ECO:0000269|PubMed:28781166, ECO:0000269|PubMed:32494006, ECO:0000305|PubMed:23333303}. |
P63104 | YWHAZ | S210 | ochoa | 14-3-3 protein zeta/delta (Protein kinase C inhibitor protein 1) (KCIP-1) | Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways (PubMed:14578935, PubMed:15071501, PubMed:15644438, PubMed:16376338, PubMed:16959763, PubMed:31024343, PubMed:9360956). Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif (PubMed:35662396). Binding generally results in the modulation of the activity of the binding partner (PubMed:35662396). Promotes cytosolic retention and inactivation of TFEB transcription factor by binding to phosphorylated TFEB (PubMed:35662396). Induces ARHGEF7 activity on RAC1 as well as lamellipodia and membrane ruffle formation (PubMed:16959763). In neurons, regulates spine maturation through the modulation of ARHGEF7 activity (By similarity). {ECO:0000250|UniProtKB:O55043, ECO:0000269|PubMed:14578935, ECO:0000269|PubMed:15071501, ECO:0000269|PubMed:15644438, ECO:0000269|PubMed:16376338, ECO:0000269|PubMed:16959763, ECO:0000269|PubMed:31024343, ECO:0000269|PubMed:35662396, ECO:0000269|PubMed:9360956}. |
P69891 | HBG1 | S51 | ochoa | Hemoglobin subunit gamma-1 (Gamma-1-globin) (Hb F Agamma) (Hemoglobin gamma-1 chain) (Hemoglobin gamma-A chain) | Gamma chains make up the fetal hemoglobin F, in combination with alpha chains. {ECO:0000269|PubMed:11514664, ECO:0000269|PubMed:22096240, ECO:0000269|PubMed:6198905}. |
P69892 | HBG2 | S51 | ochoa | Hemoglobin subunit gamma-2 (Gamma-2-globin) (Hb F Ggamma) (Hemoglobin gamma-2 chain) (Hemoglobin gamma-G chain) | Gamma chains make up the fetal hemoglobin F, in combination with alpha chains. {ECO:0000269|PubMed:19065339, ECO:0000269|PubMed:21561349, ECO:0000269|PubMed:24502349}. |
P78527 | PRKDC | S2827 | ochoa | DNA-dependent protein kinase catalytic subunit (DNA-PK catalytic subunit) (DNA-PKcs) (EC 2.7.11.1) (DNPK1) (Ser-473 kinase) (S473K) (p460) | Serine/threonine-protein kinase that acts as a molecular sensor for DNA damage (PubMed:11955432, PubMed:12649176, PubMed:14734805, PubMed:33854234). Involved in DNA non-homologous end joining (NHEJ) required for double-strand break (DSB) repair and V(D)J recombination (PubMed:11955432, PubMed:12649176, PubMed:14734805, PubMed:33854234, PubMed:34352203). Must be bound to DNA to express its catalytic properties (PubMed:11955432). Promotes processing of hairpin DNA structures in V(D)J recombination by activation of the hairpin endonuclease artemis (DCLRE1C) (PubMed:11955432). Recruited by XRCC5 and XRCC6 to DNA ends and is required to (1) protect and align broken ends of DNA, thereby preventing their degradation, (2) and sequester the DSB for repair by NHEJ (PubMed:11955432, PubMed:12649176, PubMed:14734805, PubMed:15574326, PubMed:33854234). Acts as a scaffold protein to aid the localization of DNA repair proteins to the site of damage (PubMed:11955432, PubMed:12649176, PubMed:14734805, PubMed:15574326). The assembly of the DNA-PK complex at DNA ends is also required for the NHEJ ligation step (PubMed:11955432, PubMed:12649176, PubMed:14734805, PubMed:15574326). Found at the ends of chromosomes, suggesting a further role in the maintenance of telomeric stability and the prevention of chromosomal end fusion (By similarity). Also involved in modulation of transcription (PubMed:11955432, PubMed:12649176, PubMed:14734805, PubMed:15574326). As part of the DNA-PK complex, involved in the early steps of ribosome assembly by promoting the processing of precursor rRNA into mature 18S rRNA in the small-subunit processome (PubMed:32103174). Binding to U3 small nucleolar RNA, recruits PRKDC and XRCC5/Ku86 to the small-subunit processome (PubMed:32103174). Recognizes the substrate consensus sequence [ST]-Q (PubMed:11955432, PubMed:12649176, PubMed:14734805, PubMed:15574326). Phosphorylates 'Ser-139' of histone variant H2AX, thereby regulating DNA damage response mechanism (PubMed:14627815, PubMed:16046194). Phosphorylates ASF1A, DCLRE1C, c-Abl/ABL1, histone H1, HSPCA, c-jun/JUN, p53/TP53, PARP1, POU2F1, DHX9, FH, SRF, NHEJ1/XLF, XRCC1, XRCC4, XRCC5, XRCC6, WRN, MYC and RFA2 (PubMed:10026262, PubMed:10467406, PubMed:11889123, PubMed:12509254, PubMed:14599745, PubMed:14612514, PubMed:14704337, PubMed:15177042, PubMed:1597196, PubMed:16397295, PubMed:18644470, PubMed:2247066, PubMed:2507541, PubMed:26237645, PubMed:26666690, PubMed:28712728, PubMed:29478807, PubMed:30247612, PubMed:8407951, PubMed:8464713, PubMed:9139719, PubMed:9362500). Can phosphorylate C1D not only in the presence of linear DNA but also in the presence of supercoiled DNA (PubMed:9679063). Ability to phosphorylate p53/TP53 in the presence of supercoiled DNA is dependent on C1D (PubMed:9363941). Acts as a regulator of the phosphatidylinositol 3-kinase/protein kinase B signal transduction by mediating phosphorylation of 'Ser-473' of protein kinase B (PKB/AKT1, PKB/AKT2, PKB/AKT3), promoting their activation (PubMed:15262962). Contributes to the determination of the circadian period length by antagonizing phosphorylation of CRY1 'Ser-588' and increasing CRY1 protein stability, most likely through an indirect mechanism (By similarity). Plays a role in the regulation of DNA virus-mediated innate immune response by assembling into the HDP-RNP complex, a complex that serves as a platform for IRF3 phosphorylation and subsequent innate immune response activation through the cGAS-STING pathway (PubMed:28712728). Also regulates the cGAS-STING pathway by catalyzing phosphorylation of CGAS, thereby impairing CGAS oligomerization and activation (PubMed:33273464). Also regulates the cGAS-STING pathway by mediating phosphorylation of PARP1 (PubMed:35460603). {ECO:0000250|UniProtKB:P97313, ECO:0000269|PubMed:10026262, ECO:0000269|PubMed:10467406, ECO:0000269|PubMed:11889123, ECO:0000269|PubMed:11955432, ECO:0000269|PubMed:12509254, ECO:0000269|PubMed:12649176, ECO:0000269|PubMed:14599745, ECO:0000269|PubMed:14612514, ECO:0000269|PubMed:14627815, ECO:0000269|PubMed:14704337, ECO:0000269|PubMed:14734805, ECO:0000269|PubMed:15177042, ECO:0000269|PubMed:15262962, ECO:0000269|PubMed:15574326, ECO:0000269|PubMed:1597196, ECO:0000269|PubMed:16046194, ECO:0000269|PubMed:16397295, ECO:0000269|PubMed:18644470, ECO:0000269|PubMed:2247066, ECO:0000269|PubMed:2507541, ECO:0000269|PubMed:26237645, ECO:0000269|PubMed:26666690, ECO:0000269|PubMed:28712728, ECO:0000269|PubMed:29478807, ECO:0000269|PubMed:30247612, ECO:0000269|PubMed:32103174, ECO:0000269|PubMed:33273464, ECO:0000269|PubMed:33854234, ECO:0000269|PubMed:34352203, ECO:0000269|PubMed:35460603, ECO:0000269|PubMed:8407951, ECO:0000269|PubMed:8464713, ECO:0000269|PubMed:9139719, ECO:0000269|PubMed:9362500, ECO:0000269|PubMed:9363941, ECO:0000269|PubMed:9679063}. |
P78559 | MAP1A | S1324 | ochoa | Microtubule-associated protein 1A (MAP-1A) (Proliferation-related protein p80) [Cleaved into: MAP1A heavy chain; MAP1 light chain LC2] | Structural protein involved in the filamentous cross-bridging between microtubules and other skeletal elements. |
Q00403 | GTF2B | S81 | ochoa | Transcription initiation factor IIB (EC 2.3.1.48) (General transcription factor TFIIB) (S300-II) | General transcription factor that plays a role in transcription initiation by RNA polymerase II (Pol II). Involved in the pre-initiation complex (PIC) formation and Pol II recruitment at promoter DNA (PubMed:12931194, PubMed:1517211, PubMed:1876184, PubMed:1946368, PubMed:27193682, PubMed:3029109, PubMed:3818643, PubMed:7601352, PubMed:8413225, PubMed:8515820, PubMed:8516311, PubMed:8516312, PubMed:9420329). Together with the TATA box-bound TBP forms the core initiation complex and provides a bridge between TBP and the Pol II-TFIIF complex (PubMed:8413225, PubMed:8504927, PubMed:8515820, PubMed:8516311, PubMed:8516312). Released from the PIC early following the onset of transcription during the initiation and elongation transition and reassociates with TBP during the next transcription cycle (PubMed:7601352). Associates with chromatin to core promoter-specific regions (PubMed:12931194, PubMed:24441171). Binds to two distinct DNA core promoter consensus sequence elements in a TBP-independent manner; these IIB-recognition elements (BREs) are localized immediately upstream (BREu), 5'-[GC][GC][GA]CGCC-3', and downstream (BREd), 5'-[GA]T[TGA][TG][GT][TG][TG]-3', of the TATA box element (PubMed:10619841, PubMed:16230532, PubMed:7675079, PubMed:9420329). Modulates transcription start site selection (PubMed:10318856). Also exhibits autoacetyltransferase activity that contributes to the activated transcription (PubMed:12931194). {ECO:0000269|PubMed:10318856, ECO:0000269|PubMed:10619841, ECO:0000269|PubMed:12931194, ECO:0000269|PubMed:1517211, ECO:0000269|PubMed:16230532, ECO:0000269|PubMed:1876184, ECO:0000269|PubMed:1946368, ECO:0000269|PubMed:24441171, ECO:0000269|PubMed:27193682, ECO:0000269|PubMed:3029109, ECO:0000269|PubMed:3818643, ECO:0000269|PubMed:7601352, ECO:0000269|PubMed:7675079, ECO:0000269|PubMed:8413225, ECO:0000269|PubMed:8504927, ECO:0000269|PubMed:8515820, ECO:0000269|PubMed:8516311, ECO:0000269|PubMed:8516312, ECO:0000269|PubMed:9420329}. |
Q02080 | MEF2B | S73 | ochoa | Myocyte-specific enhancer factor 2B (RSRFR2) (Serum response factor-like protein 2) | Transcriptional activator which binds specifically to the MEF2 element, 5'-YTA[AT](4)TAR-3', found in numerous muscle-specific genes. Activates transcription via this element. May be involved in muscle-specific and/or growth factor-related transcription. |
Q02952 | AKAP12 | S885 | ochoa | A-kinase anchor protein 12 (AKAP-12) (A-kinase anchor protein 250 kDa) (AKAP 250) (Gravin) (Myasthenia gravis autoantigen) | Anchoring protein that mediates the subcellular compartmentation of protein kinase A (PKA) and protein kinase C (PKC). |
Q04206 | RELA | S281 | psp | Transcription factor p65 (Nuclear factor NF-kappa-B p65 subunit) (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3) | NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The heterodimeric RELA-NFKB1 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. The NF-kappa-B heterodimeric RELA-NFKB1 and RELA-REL complexes, for instance, function as transcriptional activators. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. The inhibitory effect of I-kappa-B on NF-kappa-B through retention in the cytoplasm is exerted primarily through the interaction with RELA. RELA shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Besides its activity as a direct transcriptional activator, it is also able to modulate promoters accessibility to transcription factors and thereby indirectly regulate gene expression. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1. Essential for cytokine gene expression in T-cells (PubMed:15790681). The NF-kappa-B homodimeric RELA-RELA complex appears to be involved in invasin-mediated activation of IL-8 expression. Key transcription factor regulating the IFN response during SARS-CoV-2 infection (PubMed:33440148). {ECO:0000269|PubMed:10928981, ECO:0000269|PubMed:12748188, ECO:0000269|PubMed:15790681, ECO:0000269|PubMed:17000776, ECO:0000269|PubMed:17620405, ECO:0000269|PubMed:19058135, ECO:0000269|PubMed:19103749, ECO:0000269|PubMed:20547752, ECO:0000269|PubMed:33440148}. |
Q07157 | TJP1 | S275 | ochoa | Tight junction protein 1 (Tight junction protein ZO-1) (Zona occludens protein 1) (Zonula occludens protein 1) | TJP1, TJP2, and TJP3 are closely related scaffolding proteins that link tight junction (TJ) transmembrane proteins such as claudins, junctional adhesion molecules, and occludin to the actin cytoskeleton (PubMed:7798316, PubMed:9792688). Forms a multistranded TJP1/ZO1 condensate which elongates to form a tight junction belt, the belt is anchored at the apical cell membrane via interaction with PATJ (By similarity). The tight junction acts to limit movement of substances through the paracellular space and as a boundary between the compositionally distinct apical and basolateral plasma membrane domains of epithelial and endothelial cells. Necessary for lumenogenesis, and particularly efficient epithelial polarization and barrier formation (By similarity). Plays a role in the regulation of cell migration by targeting CDC42BPB to the leading edge of migrating cells (PubMed:21240187). Plays an important role in podosome formation and associated function, thus regulating cell adhesion and matrix remodeling (PubMed:20930113). With TJP2 and TJP3, participates in the junctional retention and stability of the transcription factor DBPA, but is not involved in its shuttling to the nucleus (By similarity). May play a role in mediating cell morphology changes during ameloblast differentiation via its role in tight junctions (By similarity). {ECO:0000250|UniProtKB:O97758, ECO:0000250|UniProtKB:P39447, ECO:0000269|PubMed:20930113, ECO:0000269|PubMed:21240187}. |
Q07812 | BAX | S163 | psp | Apoptosis regulator BAX (Bcl-2-like protein 4) (Bcl2-L-4) | Plays a role in the mitochondrial apoptotic process (PubMed:10772918, PubMed:11060313, PubMed:16113678, PubMed:16199525, PubMed:18948948, PubMed:21199865, PubMed:21458670, PubMed:25609812, PubMed:36361894, PubMed:8358790, PubMed:8521816). Under normal conditions, BAX is largely cytosolic via constant retrotranslocation from mitochondria to the cytosol mediated by BCL2L1/Bcl-xL, which avoids accumulation of toxic BAX levels at the mitochondrial outer membrane (MOM) (PubMed:21458670). Under stress conditions, undergoes a conformation change that causes translocation to the mitochondrion membrane, leading to the release of cytochrome c that then triggers apoptosis (PubMed:10772918, PubMed:11060313, PubMed:16113678, PubMed:16199525, PubMed:18948948, PubMed:21199865, PubMed:21458670, PubMed:25609812, PubMed:8358790, PubMed:8521816). Promotes activation of CASP3, and thereby apoptosis (PubMed:10772918, PubMed:11060313, PubMed:16113678, PubMed:16199525, PubMed:18948948, PubMed:21199865, PubMed:21458670, PubMed:25609812, PubMed:8358790, PubMed:8521816). {ECO:0000269|PubMed:10772918, ECO:0000269|PubMed:11060313, ECO:0000269|PubMed:16113678, ECO:0000269|PubMed:16199525, ECO:0000269|PubMed:18948948, ECO:0000269|PubMed:21199865, ECO:0000269|PubMed:21458670, ECO:0000269|PubMed:25609812, ECO:0000269|PubMed:36361894, ECO:0000269|PubMed:8358790, ECO:0000269|PubMed:8521816}. |
Q07955 | SRSF1 | S182 | ochoa | Serine/arginine-rich splicing factor 1 (Alternative-splicing factor 1) (ASF-1) (Splicing factor, arginine/serine-rich 1) (pre-mRNA-splicing factor SF2, P33 subunit) | Plays a role in preventing exon skipping, ensuring the accuracy of splicing and regulating alternative splicing. Interacts with other spliceosomal components, via the RS domains, to form a bridge between the 5'- and 3'-splice site binding components, U1 snRNP and U2AF. Can stimulate binding of U1 snRNP to a 5'-splice site-containing pre-mRNA. Binds to purine-rich RNA sequences, either the octamer, 5'-RGAAGAAC-3' (r=A or G) or the decamers, AGGACAGAGC/AGGACGAAGC. Binds preferentially to the 5'-CGAGGCG-3' motif in vitro. Three copies of the octamer constitute a powerful splicing enhancer in vitro, the ASF/SF2 splicing enhancer (ASE) which can specifically activate ASE-dependent splicing. Isoform ASF-2 and isoform ASF-3 act as splicing repressors. May function as export adapter involved in mRNA nuclear export through the TAP/NXF1 pathway. {ECO:0000269|PubMed:8139654}. |
Q08043 | ACTN3 | S319 | ochoa | Alpha-actinin-3 (Alpha-actinin skeletal muscle isoform 3) (F-actin cross-linking protein) | F-actin cross-linking protein which is thought to anchor actin to a variety of intracellular structures. This is a bundling protein. |
Q12888 | TP53BP1 | S78 | ochoa | TP53-binding protein 1 (53BP1) (p53-binding protein 1) (p53BP1) | Double-strand break (DSB) repair protein involved in response to DNA damage, telomere dynamics and class-switch recombination (CSR) during antibody genesis (PubMed:12364621, PubMed:17190600, PubMed:21144835, PubMed:22553214, PubMed:23333306, PubMed:27153538, PubMed:28241136, PubMed:31135337, PubMed:37696958). Plays a key role in the repair of double-strand DNA breaks (DSBs) in response to DNA damage by promoting non-homologous end joining (NHEJ)-mediated repair of DSBs and specifically counteracting the function of the homologous recombination (HR) repair protein BRCA1 (PubMed:22553214, PubMed:23333306, PubMed:23727112, PubMed:27153538, PubMed:31135337). In response to DSBs, phosphorylation by ATM promotes interaction with RIF1 and dissociation from NUDT16L1/TIRR, leading to recruitment to DSBs sites (PubMed:28241136). Recruited to DSBs sites by recognizing and binding histone H2A monoubiquitinated at 'Lys-15' (H2AK15Ub) and histone H4 dimethylated at 'Lys-20' (H4K20me2), two histone marks that are present at DSBs sites (PubMed:17190600, PubMed:23760478, PubMed:27153538, PubMed:28241136). Required for immunoglobulin class-switch recombination (CSR) during antibody genesis, a process that involves the generation of DNA DSBs (PubMed:23345425). Participates in the repair and the orientation of the broken DNA ends during CSR (By similarity). In contrast, it is not required for classic NHEJ and V(D)J recombination (By similarity). Promotes NHEJ of dysfunctional telomeres via interaction with PAXIP1 (PubMed:23727112). {ECO:0000250|UniProtKB:P70399, ECO:0000269|PubMed:12364621, ECO:0000269|PubMed:17190600, ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:22553214, ECO:0000269|PubMed:23333306, ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112, ECO:0000269|PubMed:23760478, ECO:0000269|PubMed:27153538, ECO:0000269|PubMed:28241136, ECO:0000269|PubMed:31135337, ECO:0000269|PubMed:37696958}. |
Q12888 | TP53BP1 | S103 | ochoa | TP53-binding protein 1 (53BP1) (p53-binding protein 1) (p53BP1) | Double-strand break (DSB) repair protein involved in response to DNA damage, telomere dynamics and class-switch recombination (CSR) during antibody genesis (PubMed:12364621, PubMed:17190600, PubMed:21144835, PubMed:22553214, PubMed:23333306, PubMed:27153538, PubMed:28241136, PubMed:31135337, PubMed:37696958). Plays a key role in the repair of double-strand DNA breaks (DSBs) in response to DNA damage by promoting non-homologous end joining (NHEJ)-mediated repair of DSBs and specifically counteracting the function of the homologous recombination (HR) repair protein BRCA1 (PubMed:22553214, PubMed:23333306, PubMed:23727112, PubMed:27153538, PubMed:31135337). In response to DSBs, phosphorylation by ATM promotes interaction with RIF1 and dissociation from NUDT16L1/TIRR, leading to recruitment to DSBs sites (PubMed:28241136). Recruited to DSBs sites by recognizing and binding histone H2A monoubiquitinated at 'Lys-15' (H2AK15Ub) and histone H4 dimethylated at 'Lys-20' (H4K20me2), two histone marks that are present at DSBs sites (PubMed:17190600, PubMed:23760478, PubMed:27153538, PubMed:28241136). Required for immunoglobulin class-switch recombination (CSR) during antibody genesis, a process that involves the generation of DNA DSBs (PubMed:23345425). Participates in the repair and the orientation of the broken DNA ends during CSR (By similarity). In contrast, it is not required for classic NHEJ and V(D)J recombination (By similarity). Promotes NHEJ of dysfunctional telomeres via interaction with PAXIP1 (PubMed:23727112). {ECO:0000250|UniProtKB:P70399, ECO:0000269|PubMed:12364621, ECO:0000269|PubMed:17190600, ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:22553214, ECO:0000269|PubMed:23333306, ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112, ECO:0000269|PubMed:23760478, ECO:0000269|PubMed:27153538, ECO:0000269|PubMed:28241136, ECO:0000269|PubMed:31135337, ECO:0000269|PubMed:37696958}. |
Q12888 | TP53BP1 | S580 | ochoa | TP53-binding protein 1 (53BP1) (p53-binding protein 1) (p53BP1) | Double-strand break (DSB) repair protein involved in response to DNA damage, telomere dynamics and class-switch recombination (CSR) during antibody genesis (PubMed:12364621, PubMed:17190600, PubMed:21144835, PubMed:22553214, PubMed:23333306, PubMed:27153538, PubMed:28241136, PubMed:31135337, PubMed:37696958). Plays a key role in the repair of double-strand DNA breaks (DSBs) in response to DNA damage by promoting non-homologous end joining (NHEJ)-mediated repair of DSBs and specifically counteracting the function of the homologous recombination (HR) repair protein BRCA1 (PubMed:22553214, PubMed:23333306, PubMed:23727112, PubMed:27153538, PubMed:31135337). In response to DSBs, phosphorylation by ATM promotes interaction with RIF1 and dissociation from NUDT16L1/TIRR, leading to recruitment to DSBs sites (PubMed:28241136). Recruited to DSBs sites by recognizing and binding histone H2A monoubiquitinated at 'Lys-15' (H2AK15Ub) and histone H4 dimethylated at 'Lys-20' (H4K20me2), two histone marks that are present at DSBs sites (PubMed:17190600, PubMed:23760478, PubMed:27153538, PubMed:28241136). Required for immunoglobulin class-switch recombination (CSR) during antibody genesis, a process that involves the generation of DNA DSBs (PubMed:23345425). Participates in the repair and the orientation of the broken DNA ends during CSR (By similarity). In contrast, it is not required for classic NHEJ and V(D)J recombination (By similarity). Promotes NHEJ of dysfunctional telomeres via interaction with PAXIP1 (PubMed:23727112). {ECO:0000250|UniProtKB:P70399, ECO:0000269|PubMed:12364621, ECO:0000269|PubMed:17190600, ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:22553214, ECO:0000269|PubMed:23333306, ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112, ECO:0000269|PubMed:23760478, ECO:0000269|PubMed:27153538, ECO:0000269|PubMed:28241136, ECO:0000269|PubMed:31135337, ECO:0000269|PubMed:37696958}. |
Q13572 | ITPK1 | S72 | ochoa | Inositol-tetrakisphosphate 1-kinase (EC 2.7.1.134) (Inositol 1,3,4-trisphosphate 5/6-kinase) (Inositol-triphosphate 5/6-kinase) (Ins(1,3,4)P(3) 5/6-kinase) (EC 2.7.1.159) | Kinase that can phosphorylate various inositol polyphosphate such as Ins(3,4,5,6)P4 or Ins(1,3,4)P3 (PubMed:11042108, PubMed:8662638). Phosphorylates Ins(3,4,5,6)P4 at position 1 to form Ins(1,3,4,5,6)P5 (PubMed:11042108). This reaction is thought to have regulatory importance, since Ins(3,4,5,6)P4 is an inhibitor of plasma membrane Ca(2+)-activated Cl(-) channels, while Ins(1,3,4,5,6)P5 is not. Also phosphorylates Ins(1,3,4)P3 on O-5 and O-6 to form Ins(1,3,4,6)P4, an essential molecule in the hexakisphosphate (InsP6) pathway (PubMed:11042108, PubMed:8662638). Also acts as an inositol polyphosphate phosphatase that dephosphorylates Ins(1,3,4,5)P4 and Ins(1,3,4,6)P4 to Ins(1,3,4)P3, and Ins(1,3,4,5,6)P5 to Ins(3,4,5,6)P4 (PubMed:11909533, PubMed:17616525). May also act as an isomerase that interconverts the inositol tetrakisphosphate isomers Ins(1,3,4,5)P4 and Ins(1,3,4,6)P4 in the presence of ADP and magnesium (PubMed:11909533). Probably acts as the rate-limiting enzyme of the InsP6 pathway. Modifies TNF-alpha-induced apoptosis by interfering with the activation of TNFRSF1A-associated death domain (PubMed:11909533, PubMed:12925536, PubMed:17616525). Plays an important role in MLKL-mediated necroptosis. Produces highly phosphorylated inositol phosphates such as inositolhexakisphosphate (InsP6) which bind to MLKL mediating the release of an N-terminal auto-inhibitory region leading to its activation. Essential for activated phospho-MLKL to oligomerize and localize to the cell membrane during necroptosis (PubMed:17616525). {ECO:0000269|PubMed:11042108, ECO:0000269|PubMed:11909533, ECO:0000269|PubMed:12925536, ECO:0000269|PubMed:17616525, ECO:0000269|PubMed:8662638}. |
Q14008 | CKAP5 | S1471 | ochoa | Cytoskeleton-associated protein 5 (Colonic and hepatic tumor overexpressed gene protein) (Ch-TOG) | Binds to the plus end of microtubules and regulates microtubule dynamics and microtubule organization. Acts as a processive microtubule polymerase. Promotes cytoplasmic microtubule nucleation and elongation. Plays a major role in organizing spindle poles. In spindle formation protects kinetochore microtubules from depolymerization by KIF2C and has an essential role in centrosomal microtubule assembly independently of KIF2C activity. Contributes to centrosome integrity. Acts as a component of the TACC3/ch-TOG/clathrin complex proposed to contribute to stabilization of kinetochore fibers of the mitotic spindle by acting as inter-microtubule bridge. The TACC3/ch-TOG/clathrin complex is required for the maintenance of kinetochore fiber tension (PubMed:23532825). Enhances the strength of NDC80 complex-mediated kinetochore-tip microtubule attachments (PubMed:27156448). {ECO:0000269|PubMed:12569123, ECO:0000269|PubMed:18809577, ECO:0000269|PubMed:21297582, ECO:0000269|PubMed:21646404, ECO:0000269|PubMed:23532825, ECO:0000269|PubMed:27156448, ECO:0000269|PubMed:9570755}. |
Q14694 | USP10 | S547 | ochoa | Ubiquitin carboxyl-terminal hydrolase 10 (EC 3.4.19.12) (Deubiquitinating enzyme 10) (Ubiquitin thioesterase 10) (Ubiquitin-specific-processing protease 10) | Hydrolase that can remove conjugated ubiquitin from target proteins such as p53/TP53, RPS2/us5, RPS3/us3, RPS10/eS10, BECN1, SNX3 and CFTR (PubMed:11439350, PubMed:18632802, PubMed:31981475). Acts as an essential regulator of p53/TP53 stability: in unstressed cells, specifically deubiquitinates p53/TP53 in the cytoplasm, leading to counteract MDM2 action and stabilize p53/TP53 (PubMed:20096447). Following DNA damage, translocates to the nucleus and deubiquitinates p53/TP53, leading to regulate the p53/TP53-dependent DNA damage response (PubMed:20096447). Component of a regulatory loop that controls autophagy and p53/TP53 levels: mediates deubiquitination of BECN1, a key regulator of autophagy, leading to stabilize the PIK3C3/VPS34-containing complexes (PubMed:21962518). In turn, PIK3C3/VPS34-containing complexes regulate USP10 stability, suggesting the existence of a regulatory system by which PIK3C3/VPS34-containing complexes regulate p53/TP53 protein levels via USP10 and USP13 (PubMed:21962518). Does not deubiquitinate MDM2 (PubMed:20096447). Plays a key role in 40S ribosome subunit recycling when a ribosome has stalled during translation: acts both by inhibiting formation of stress granules, which store stalled translation pre-initiation complexes, and mediating deubiquitination of 40S ribosome subunits (PubMed:27022092, PubMed:31981475, PubMed:34348161, PubMed:34469731). Acts as a negative regulator of stress granules formation by lowering G3BP1 and G3BP2 valence, thereby preventing G3BP1 and G3BP2 ability to undergo liquid-liquid phase separation (LLPS) and assembly of stress granules (PubMed:11439350, PubMed:27022092, PubMed:32302570). Promotes 40S ribosome subunit recycling following ribosome dissociation in response to ribosome stalling by mediating deubiquitination of 40S ribosomal proteins RPS2/us5, RPS3/us3 and RPS10/eS10, thereby preventing their degradation by the proteasome (PubMed:31981475, PubMed:34348161, PubMed:34469731). Part of a ribosome quality control that takes place when ribosomes have stalled during translation initiation (iRQC): USP10 acts by removing monoubiquitination of RPS2/us5 and RPS3/us3, promoting 40S ribosomal subunit recycling (PubMed:34469731). Deubiquitinates CFTR in early endosomes, enhancing its endocytic recycling (PubMed:19398555). Involved in a TANK-dependent negative feedback response to attenuate NF-kappa-B activation via deubiquitinating IKBKG or TRAF6 in response to interleukin-1-beta (IL1B) stimulation or upon DNA damage (PubMed:25861989). Deubiquitinates TBX21 leading to its stabilization (PubMed:24845384). Plays a negative role in the RLR signaling pathway upon RNA virus infection by blocking the RIGI-mediated MAVS activation. Mechanistically, removes the unanchored 'Lys-63'-linked polyubiquitin chains of MAVS to inhibit its aggregation, essential for its activation (PubMed:37582970). {ECO:0000269|PubMed:11439350, ECO:0000269|PubMed:18632802, ECO:0000269|PubMed:19398555, ECO:0000269|PubMed:20096447, ECO:0000269|PubMed:21962518, ECO:0000269|PubMed:24845384, ECO:0000269|PubMed:25861989, ECO:0000269|PubMed:27022092, ECO:0000269|PubMed:31981475, ECO:0000269|PubMed:32302570, ECO:0000269|PubMed:34348161, ECO:0000269|PubMed:34469731, ECO:0000269|PubMed:37582970}. |
Q14789 | GOLGB1 | S673 | ochoa | Golgin subfamily B member 1 (372 kDa Golgi complex-associated protein) (GCP372) (Giantin) (Macrogolgin) | May participate in forming intercisternal cross-bridges of the Golgi complex. |
Q15139 | PRKD1 | S223 | psp | Serine/threonine-protein kinase D1 (EC 2.7.11.13) (Protein kinase C mu type) (Protein kinase D) (nPKC-D1) (nPKC-mu) | Serine/threonine-protein kinase that converts transient diacylglycerol (DAG) signals into prolonged physiological effects downstream of PKC, and is involved in the regulation of MAPK8/JNK1 and Ras signaling, Golgi membrane integrity and trafficking, cell survival through NF-kappa-B activation, cell migration, cell differentiation by mediating HDAC7 nuclear export, cell proliferation via MAPK1/3 (ERK1/2) signaling, and plays a role in cardiac hypertrophy, VEGFA-induced angiogenesis, genotoxic-induced apoptosis and flagellin-stimulated inflammatory response (PubMed:10764790, PubMed:12505989, PubMed:12637538, PubMed:17442957, PubMed:18509061, PubMed:19135240, PubMed:19211839). Phosphorylates the epidermal growth factor receptor (EGFR) on dual threonine residues, which leads to the suppression of epidermal growth factor (EGF)-induced MAPK8/JNK1 activation and subsequent JUN phosphorylation (PubMed:10523301). Phosphorylates RIN1, inducing RIN1 binding to 14-3-3 proteins YWHAB, YWHAE and YWHAZ and increased competition with RAF1 for binding to GTP-bound form of Ras proteins (NRAS, HRAS and KRAS). Acts downstream of the heterotrimeric G-protein beta/gamma-subunit complex to maintain the structural integrity of the Golgi membranes, and is required for protein transport along the secretory pathway. In the trans-Golgi network (TGN), regulates the fission of transport vesicles that are on their way to the plasma membrane. May act by activating the lipid kinase phosphatidylinositol 4-kinase beta (PI4KB) at the TGN for the local synthesis of phosphorylated inositol lipids, which induces a sequential production of DAG, phosphatidic acid (PA) and lyso-PA (LPA) that are necessary for membrane fission and generation of specific transport carriers to the cell surface. Under oxidative stress, is phosphorylated at Tyr-463 via SRC-ABL1 and contributes to cell survival by activating IKK complex and subsequent nuclear translocation and activation of NFKB1 (PubMed:12505989). Involved in cell migration by regulating integrin alpha-5/beta-3 recycling and promoting its recruitment in newly forming focal adhesion. In osteoblast differentiation, mediates the bone morphogenetic protein 2 (BMP2)-induced nuclear export of HDAC7, which results in the inhibition of HDAC7 transcriptional repression of RUNX2 (PubMed:18509061). In neurons, plays an important role in neuronal polarity by regulating the biogenesis of TGN-derived dendritic vesicles, and is involved in the maintenance of dendritic arborization and Golgi structure in hippocampal cells. May potentiate mitogenesis induced by the neuropeptide bombesin or vasopressin by mediating an increase in the duration of MAPK1/3 (ERK1/2) signaling, which leads to accumulation of immediate-early gene products including FOS that stimulate cell cycle progression. Plays an important role in the proliferative response induced by low calcium in keratinocytes, through sustained activation of MAPK1/3 (ERK1/2) pathway. Downstream of novel PKC signaling, plays a role in cardiac hypertrophy by phosphorylating HDAC5, which in turn triggers XPO1/CRM1-dependent nuclear export of HDAC5, MEF2A transcriptional activation and induction of downstream target genes that promote myocyte hypertrophy and pathological cardiac remodeling (PubMed:18332134). Mediates cardiac troponin I (TNNI3) phosphorylation at the PKA sites, which results in reduced myofilament calcium sensitivity, and accelerated crossbridge cycling kinetics. The PRKD1-HDAC5 pathway is also involved in angiogenesis by mediating VEGFA-induced specific subset of gene expression, cell migration, and tube formation (PubMed:19211839). In response to VEGFA, is necessary and required for HDAC7 phosphorylation which induces HDAC7 nuclear export and endothelial cell proliferation and migration. During apoptosis induced by cytarabine and other genotoxic agents, PRKD1 is cleaved by caspase-3 at Asp-378, resulting in activation of its kinase function and increased sensitivity of cells to the cytotoxic effects of genotoxic agents (PubMed:10764790). In epithelial cells, is required for transducing flagellin-stimulated inflammatory responses by binding and phosphorylating TLR5, which contributes to MAPK14/p38 activation and production of inflammatory cytokines (PubMed:17442957). Acts as an activator of NLRP3 inflammasome assembly by mediating phosphorylation of NLRP3 (By similarity). May play a role in inflammatory response by mediating activation of NF-kappa-B. May be involved in pain transmission by directly modulating TRPV1 receptor (PubMed:15471852). Plays a role in activated KRAS-mediated stabilization of ZNF304 in colorectal cancer (CRC) cells (PubMed:24623306). Regulates nuclear translocation of transcription factor TFEB in macrophages upon live S.enterica infection (By similarity). {ECO:0000250|UniProtKB:Q62101, ECO:0000269|PubMed:10523301, ECO:0000269|PubMed:10764790, ECO:0000269|PubMed:12505989, ECO:0000269|PubMed:12637538, ECO:0000269|PubMed:15471852, ECO:0000269|PubMed:17442957, ECO:0000269|PubMed:18332134, ECO:0000269|PubMed:18509061, ECO:0000269|PubMed:19135240, ECO:0000269|PubMed:19211839, ECO:0000269|PubMed:24623306}. |
Q15149 | PLEC | S3853 | ochoa | Plectin (PCN) (PLTN) (Hemidesmosomal protein 1) (HD1) (Plectin-1) | Interlinks intermediate filaments with microtubules and microfilaments and anchors intermediate filaments to desmosomes or hemidesmosomes. Could also bind muscle proteins such as actin to membrane complexes in muscle. May be involved not only in the filaments network, but also in the regulation of their dynamics. Structural component of muscle. Isoform 9 plays a major role in the maintenance of myofiber integrity. {ECO:0000269|PubMed:12482924, ECO:0000269|PubMed:21109228}. |
Q15149 | PLEC | S3975 | ochoa | Plectin (PCN) (PLTN) (Hemidesmosomal protein 1) (HD1) (Plectin-1) | Interlinks intermediate filaments with microtubules and microfilaments and anchors intermediate filaments to desmosomes or hemidesmosomes. Could also bind muscle proteins such as actin to membrane complexes in muscle. May be involved not only in the filaments network, but also in the regulation of their dynamics. Structural component of muscle. Isoform 9 plays a major role in the maintenance of myofiber integrity. {ECO:0000269|PubMed:12482924, ECO:0000269|PubMed:21109228}. |
Q16706 | MAN2A1 | S80 | ochoa | Alpha-mannosidase 2 (EC 3.2.1.114) (Golgi alpha-mannosidase II) (AMan II) (Man II) (Mannosidase alpha class 2A member 1) (Mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase) | Catalyzes the first committed step in the biosynthesis of complex N-glycans. It controls conversion of high mannose to complex N-glycans; the final hydrolytic step in the N-glycan maturation pathway. {ECO:0000250|UniProtKB:P28494}. |
Q4KMP7 | TBC1D10B | S277 | ochoa | TBC1 domain family member 10B (Rab27A-GAP-beta) | Acts as a GTPase-activating protein for RAB3A, RAB22A, RAB27A, and RAB35. Does not act on RAB2A and RAB6A. {ECO:0000269|PubMed:16923811, ECO:0000269|PubMed:19077034}. |
Q5BJF6 | ODF2 | S115 | ochoa | Outer dense fiber protein 2 (Cenexin) (Outer dense fiber of sperm tails protein 2) | Seems to be a major component of sperm tail outer dense fibers (ODF). ODFs are filamentous structures located on the outside of the axoneme in the midpiece and principal piece of the mammalian sperm tail and may help to maintain the passive elastic structures and elastic recoil of the sperm tail. May have a modulating influence on sperm motility. Functions as a general scaffold protein that is specifically localized at the distal/subdistal appendages of mother centrioles. Component of the centrosome matrix required for the localization of PLK1 and NIN to the centrosomes. Required for the formation and/or maintenance of normal CETN1 assembly. {ECO:0000269|PubMed:16966375}. |
Q5HYN5 | CT45A1 | T112 | ochoa | Cancer/testis antigen family 45 member A1 (Cancer/testis antigen 45-1) (Cancer/testis antigen 45A1) | None |
Q5JSZ5 | PRRC2B | S166 | ochoa | Protein PRRC2B (HLA-B-associated transcript 2-like 1) (Proline-rich coiled-coil protein 2B) | None |
Q5THJ4 | VPS13D | S1707 | ochoa | Intermembrane lipid transfer protein VPS13D (Vacuolar protein sorting-associated protein 13D) | Mediates the transfer of lipids between membranes at organelle contact sites (By similarity). Functions in promoting mitochondrial clearance by mitochondrial autophagy (mitophagy), also possibly by positively regulating mitochondrial fission (PubMed:29307555, PubMed:29604224). Mitophagy plays an important role in regulating cell health and mitochondrial size and homeostasis. {ECO:0000250|UniProtKB:Q07878, ECO:0000269|PubMed:29307555, ECO:0000269|PubMed:29604224}. |
Q5THK1 | PRR14L | S1969 | ochoa | Protein PRR14L (Proline rich 14-like protein) | None |
Q658Y4 | FAM91A1 | S671 | ochoa | Protein FAM91A1 | As component of the WDR11 complex acts together with TBC1D23 to facilitate the golgin-mediated capture of vesicles generated using AP-1. {ECO:0000269|PubMed:29426865}. |
Q68CZ2 | TNS3 | S337 | ochoa | Tensin-3 (EC 3.1.3.-) (Tensin-like SH2 domain-containing protein 1) (Tumor endothelial marker 6) | May act as a protein phosphatase and/or a lipid phosphatase (Probable). Involved in the dissociation of the integrin-tensin-actin complex (PubMed:17643115). EGF activates TNS4 and down-regulates TNS3 which results in capping the tail of ITGB1 (PubMed:17643115). Increases DOCK5 guanine nucleotide exchange activity towards Rac and plays a role in osteoclast podosome organization (By similarity). Enhances RHOA activation in the presence of DLC1 (PubMed:26427649). Required for growth factor-induced epithelial cell migration; growth factor stimulation induces TNS3 phosphorylation which changes its binding preference from DLC1 to the p85 regulatory subunit of the PI3K kinase complex, displacing PI3K inhibitor PTEN and resulting in translocation of the TNS3-p85 complex to the leading edge of migrating cells to promote RAC1 activation (PubMed:26166433). Meanwhile, PTEN switches binding preference from p85 to DLC1 and the PTEN-DLC1 complex translocates to the posterior of migrating cells to activate RHOA (PubMed:26166433). Acts as an adapter protein by bridging the association of scaffolding protein PEAK1 with integrins ITGB1, ITGB3 and ITGB5 which contributes to the promotion of cell migration (PubMed:35687021). Controls tonsil-derived mesenchymal stem cell proliferation and differentiation by regulating the activity of integrin ITGB1 (PubMed:31905841). {ECO:0000250|UniProtKB:Q5SSZ5, ECO:0000269|PubMed:17643115, ECO:0000269|PubMed:26166433, ECO:0000269|PubMed:26427649, ECO:0000269|PubMed:31905841, ECO:0000269|PubMed:35687021, ECO:0000305}. |
Q68EM7 | ARHGAP17 | S845 | ochoa | Rho GTPase-activating protein 17 (Rho-type GTPase-activating protein 17) (RhoGAP interacting with CIP4 homologs protein 1) (RICH-1) | Rho GTPase-activating protein involved in the maintenance of tight junction by regulating the activity of CDC42, thereby playing a central role in apical polarity of epithelial cells. Specifically acts as a GTPase activator for the CDC42 GTPase by converting it to an inactive GDP-bound state. The complex formed with AMOT acts by regulating the uptake of polarity proteins at tight junctions, possibly by deciding whether tight junction transmembrane proteins are recycled back to the plasma membrane or sent elsewhere. Participates in the Ca(2+)-dependent regulation of exocytosis, possibly by catalyzing GTPase activity of Rho family proteins and by inducing the reorganization of the cortical actin filaments. Acts as a GTPase activator in vitro for RAC1. {ECO:0000269|PubMed:11431473, ECO:0000269|PubMed:16678097}. |
Q6P996 | PDXDC1 | S736 | ochoa | Pyridoxal-dependent decarboxylase domain-containing protein 1 (EC 4.1.1.-) | None |
Q6WKZ4 | RAB11FIP1 | S266 | ochoa | Rab11 family-interacting protein 1 (Rab11-FIP1) (Rab-coupling protein) | A Rab11 effector protein involved in the endosomal recycling process. Also involved in controlling membrane trafficking along the phagocytic pathway and in phagocytosis. Interaction with RAB14 may function in the process of neurite formation (PubMed:26032412). {ECO:0000269|PubMed:11786538, ECO:0000269|PubMed:15181150, ECO:0000269|PubMed:15355514, ECO:0000269|PubMed:16920206, ECO:0000269|PubMed:26032412}. |
Q6ZU65 | UBN2 | S631 | ochoa | Ubinuclein-2 | None |
Q6ZVM7 | TOM1L2 | S424 | ochoa | TOM1-like protein 2 (Target of Myb-like protein 2) | Acts as a MYO6/Myosin VI adapter protein that targets myosin VI to endocytic structures (PubMed:23023224). May also play a role in recruiting clathrin to endosomes (PubMed:16412388). May regulate growth factor-induced mitogenic signaling (PubMed:16479011). {ECO:0000269|PubMed:16412388, ECO:0000269|PubMed:16479011, ECO:0000269|PubMed:23023224}. |
Q7Z2T5 | TRMT1L | S707 | ochoa | tRNA (guanine(27)-N(2))-dimethyltransferase (EC 2.1.1.-) (tRNA methyltransferase 1-like protein) (TRMT1-like protein) | Specifically dimethylates a single guanine residue at position 27 of tRNA(Tyr) using S-adenosyl-L-methionine as donor of the methyl groups (PubMed:39786990, PubMed:39786998). Dimethylation at position 27 of tRNA(Tyr) is required for efficient translation of tyrosine codons (PubMed:39786990, PubMed:39786998). Also required to maintain 3-(3-amino-3-carboxypropyl)uridine (acp3U) in the D-loop of several cytoplasmic tRNAs (PubMed:39786990, PubMed:39786998). {ECO:0000269|PubMed:39786990, ECO:0000269|PubMed:39786998}. |
Q7Z2Z1 | TICRR | S923 | ochoa | Treslin (TopBP1-interacting checkpoint and replication regulator) (TopBP1-interacting, replication-stimulating protein) | Regulator of DNA replication and S/M and G2/M checkpoints. Regulates the triggering of DNA replication initiation via its interaction with TOPBP1 by participating in CDK2-mediated loading of CDC45L onto replication origins. Required for the transition from pre-replication complex (pre-RC) to pre-initiation complex (pre-IC). Required to prevent mitotic entry after treatment with ionizing radiation. {ECO:0000269|PubMed:20116089}. |
Q7Z3B3 | KANSL1 | S115 | ochoa | KAT8 regulatory NSL complex subunit 1 (MLL1/MLL complex subunit KANSL1) (MSL1 homolog 1) (hMSL1v1) (NSL complex protein NSL1) (Non-specific lethal 1 homolog) | Non-catalytic component of the NSL histone acetyltransferase complex, a multiprotein complex that mediates histone H4 acetylation at 'Lys-5'- and 'Lys-8' (H4K5ac and H4K8ac) at transcription start sites and promotes transcription initiation (PubMed:20018852, PubMed:22547026, PubMed:33657400). The NSL complex also acts as a regulator of gene expression in mitochondria (PubMed:27768893). In addition to its role in transcription, KANSL1 also plays an essential role in spindle assembly during mitosis (PubMed:26243146). Associates with microtubule ends and contributes to microtubule stability (PubMed:26243146). {ECO:0000269|PubMed:20018852, ECO:0000269|PubMed:22547026, ECO:0000269|PubMed:26243146, ECO:0000269|PubMed:27768893, ECO:0000269|PubMed:33657400}. |
Q7Z3T8 | ZFYVE16 | S168 | ochoa | Zinc finger FYVE domain-containing protein 16 (Endofin) (Endosome-associated FYVE domain protein) | May be involved in regulating membrane trafficking in the endosomal pathway. Overexpression induces endosome aggregation. Required to target TOM1 to endosomes. {ECO:0000269|PubMed:11546807, ECO:0000269|PubMed:14613930}. |
Q86UX7 | FERMT3 | S328 | ochoa | Fermitin family homolog 3 (Kindlin-3) (MIG2-like protein) (Unc-112-related protein 2) | Plays a central role in cell adhesion in hematopoietic cells (PubMed:19234463, PubMed:26359933). Acts by activating the integrin beta-1-3 (ITGB1, ITGB2 and ITGB3) (By similarity). Required for integrin-mediated platelet adhesion and leukocyte adhesion to endothelial cells (PubMed:19234460). Required for activation of integrin beta-2 (ITGB2) in polymorphonuclear granulocytes (PMNs) (By similarity). {ECO:0000250|UniProtKB:Q8K1B8, ECO:0000269|PubMed:19234460, ECO:0000269|PubMed:19234463, ECO:0000269|PubMed:26359933}.; FUNCTION: Isoform 2 may act as a repressor of NF-kappa-B and apoptosis. {ECO:0000269|PubMed:19064721, ECO:0000269|PubMed:19234460, ECO:0000269|PubMed:19234463}. |
Q86XZ4 | SPATS2 | S210 | ochoa | Spermatogenesis-associated serine-rich protein 2 (Serine-rich spermatocytes and round spermatid 59 kDa protein) (p59scr) | None |
Q86Y13 | DZIP3 | S707 | ochoa | E3 ubiquitin-protein ligase DZIP3 (EC 2.3.2.27) (DAZ-interacting protein 3) (RING-type E3 ubiquitin transferase DZIP3) (RNA-binding ubiquitin ligase of 138 kDa) (hRUL138) | E3 Ubiquitin ligase proteins mediate ubiquitination and subsequent proteasomal degradation of target proteins. E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. Able to specifically bind RNA. {ECO:0000269|PubMed:12538761}. |
Q8N9U0 | TC2N | S172 | ochoa | Tandem C2 domains nuclear protein (Membrane targeting tandem C2 domain-containing protein 1) (Tandem C2 protein in nucleus) (Tac2-N) | None |
Q8NF91 | SYNE1 | S8663 | ochoa | Nesprin-1 (Enaptin) (KASH domain-containing protein 1) (KASH1) (Myocyte nuclear envelope protein 1) (Myne-1) (Nuclear envelope spectrin repeat protein 1) (Synaptic nuclear envelope protein 1) (Syne-1) | Multi-isomeric modular protein which forms a linking network between organelles and the actin cytoskeleton to maintain the subcellular spatial organization. As a component of the LINC (LInker of Nucleoskeleton and Cytoskeleton) complex involved in the connection between the nuclear lamina and the cytoskeleton. The nucleocytoplasmic interactions established by the LINC complex play an important role in the transmission of mechanical forces across the nuclear envelope and in nuclear movement and positioning. May be involved in nucleus-centrosome attachment and nuclear migration in neural progenitors implicating LINC complex association with SUN1/2 and probably association with cytoplasmic dynein-dynactin motor complexes; SYNE1 and SYNE2 may act redundantly. Required for centrosome migration to the apical cell surface during early ciliogenesis. May be involved in nuclear remodeling during sperm head formation in spermatogenesis; a probable SUN3:SYNE1/KASH1 LINC complex may tether spermatid nuclei to posterior cytoskeletal structures such as the manchette. {ECO:0000250|UniProtKB:Q6ZWR6, ECO:0000269|PubMed:11792814, ECO:0000269|PubMed:18396275}. |
Q8NFG4 | FLCN | S537 | psp | Folliculin (BHD skin lesion fibrofolliculoma protein) (Birt-Hogg-Dube syndrome protein) | Multi-functional protein, involved in both the cellular response to amino acid availability and in the regulation of glycolysis (PubMed:17028174, PubMed:18663353, PubMed:21209915, PubMed:24081491, PubMed:24095279, PubMed:31672913, PubMed:31704029, PubMed:32612235, PubMed:34381247, PubMed:36103527, PubMed:37079666). GTPase-activating protein that plays a key role in the cellular response to amino acid availability through regulation of the non-canonical mTORC1 signaling cascade controlling the MiT/TFE factors TFEB and TFE3 (PubMed:17028174, PubMed:18663353, PubMed:21209915, PubMed:24081491, PubMed:24095279, PubMed:24448649, PubMed:31672913, PubMed:31704029, PubMed:32612235, PubMed:36103527, PubMed:37079666). Activates mTORC1 by acting as a GTPase-activating protein: specifically stimulates GTP hydrolysis by RagC/RRAGC or RagD/RRAGD, promoting the conversion to the GDP-bound state of RagC/RRAGC or RagD/RRAGD, and thereby activating the kinase activity of mTORC1 (PubMed:24095279, PubMed:31672913, PubMed:31704029, PubMed:32612235, PubMed:37079666). The GTPase-activating activity is inhibited during starvation and activated in presence of nutrients (PubMed:31672913, PubMed:32612235). Acts as a key component for non-canonical mTORC1-dependent control of the MiT/TFE factors TFEB and TFE3, while it is not involved in mTORC1-dependent phosphorylation of canonical RPS6KB1/S6K1 and EIF4EBP1/4E-BP1 (PubMed:21209915, PubMed:24081491, PubMed:31672913, PubMed:32612235). In low-amino acid conditions, the lysosomal folliculin complex (LFC) is formed on the membrane of lysosomes, which inhibits the GTPase-activating activity of FLCN, inactivates mTORC1 and maximizes nuclear translocation of TFEB and TFE3 (PubMed:31672913). Upon amino acid restimulation, RagA/RRAGA (or RagB/RRAGB) nucleotide exchange promotes disassembly of the LFC complex and liberates the GTPase-activating activity of FLCN, leading to activation of mTORC1 and subsequent cytoplasmic retention of TFEB and TFE3 (PubMed:31672913). Indirectly acts as a positive regulator of Wnt signaling by promoting mTOR-dependent cytoplasmic retention of MiT/TFE factor TFE3 (PubMed:31272105). Required for the exit of hematopoietic stem cell from pluripotency by promoting mTOR-dependent cytoplasmic retention of TFE3, thereby increasing Wnt signaling (PubMed:30733432). Acts as an inhibitor of browning of adipose tissue by regulating mTOR-dependent cytoplasmic retention of TFE3 (By similarity). Involved in the control of embryonic stem cells differentiation; together with LAMTOR1 it is necessary to recruit and activate RagC/RRAGC and RagD/RRAGD at the lysosomes, and to induce exit of embryonic stem cells from pluripotency via non-canonical, mTOR-independent TFE3 inactivation (By similarity). In response to flow stress, regulates STK11/LKB1 accumulation and mTORC1 activation through primary cilia: may act by recruiting STK11/LKB1 to primary cilia for activation of AMPK resided at basal bodies, causing mTORC1 down-regulation (PubMed:27072130). Together with FNIP1 and/or FNIP2, regulates autophagy: following phosphorylation by ULK1, interacts with GABARAP and promotes autophagy (PubMed:25126726). Required for starvation-induced perinuclear clustering of lysosomes by promoting association of RILP with its effector RAB34 (PubMed:27113757). Regulates glycolysis by binding to lactate dehydrogenase LDHA, acting as an uncompetitive inhibitor (PubMed:34381247). {ECO:0000250|UniProtKB:Q8QZS3, ECO:0000269|PubMed:17028174, ECO:0000269|PubMed:18663353, ECO:0000269|PubMed:21209915, ECO:0000269|PubMed:24081491, ECO:0000269|PubMed:24095279, ECO:0000269|PubMed:24448649, ECO:0000269|PubMed:25126726, ECO:0000269|PubMed:27072130, ECO:0000269|PubMed:27113757, ECO:0000269|PubMed:30733432, ECO:0000269|PubMed:31272105, ECO:0000269|PubMed:31672913, ECO:0000269|PubMed:31704029, ECO:0000269|PubMed:32612235, ECO:0000269|PubMed:34381247, ECO:0000269|PubMed:36103527, ECO:0000269|PubMed:37079666}. |
Q8NHU0 | CT45A3 | T112 | ochoa | Cancer/testis antigen family 45 member A3 (Cancer/testis antigen 45-3) (Cancer/testis antigen 45-4) (Cancer/testis antigen 45A3) (Cancer/testis antigen 45A4) (Cancer/testis antigen family 45 member A4) | None |
Q8TCU6 | PREX1 | S1200 | ochoa | Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 1 protein (P-Rex1) (PtdIns(3,4,5)-dependent Rac exchanger 1) | Functions as a RAC guanine nucleotide exchange factor (GEF), which activates the Rac proteins by exchanging bound GDP for free GTP. Its activity is synergistically activated by phosphatidylinositol 3,4,5-trisphosphate and the beta gamma subunits of heterotrimeric G protein. May function downstream of heterotrimeric G proteins in neutrophils. |
Q8TDD1 | DDX54 | S696 | ochoa | ATP-dependent RNA helicase DDX54 (EC 3.6.4.13) (ATP-dependent RNA helicase DP97) (DEAD box RNA helicase 97 kDa) (DEAD box protein 54) | Has RNA-dependent ATPase activity. Represses the transcriptional activity of nuclear receptors. {ECO:0000269|PubMed:12466272}. |
Q8WZA1 | POMGNT1 | S66 | ochoa | Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1 (POMGnT1) (EC 2.4.1.-) (UDP-GlcNAc:alpha-D-mannoside beta-1,2-N-acetylglucosaminyltransferase I.2) (GnT I.2) | Participates in O-mannosyl glycosylation by catalyzing the addition of N-acetylglucosamine to O-linked mannose on glycoproteins (PubMed:11709191, PubMed:27493216, PubMed:28512129). Catalyzes the synthesis of the GlcNAc(beta1-2)Man(alpha1-)O-Ser/Thr moiety on alpha-dystroglycan and other O-mannosylated proteins, providing the necessary basis for the addition of further carbohydrate moieties (PubMed:11709191, PubMed:27493216). Is specific for alpha linked terminal mannose and does not have MGAT3, MGAT4, MGAT5, MGAT7 or MGAT8 activity. {ECO:0000269|PubMed:11709191, ECO:0000269|PubMed:11742540, ECO:0000269|PubMed:26908613, ECO:0000269|PubMed:27391550, ECO:0000269|PubMed:27493216, ECO:0000269|PubMed:28512129}. |
Q969U7 | PSMG2 | S37 | ochoa | Proteasome assembly chaperone 2 (PAC-2) (Hepatocellular carcinoma-susceptibility protein 3) (Tumor necrosis factor superfamily member 5-induced protein 1) | Chaperone protein which promotes assembly of the 20S proteasome as part of a heterodimer with PSMG1. The PSMG1-PSMG2 heterodimer binds to the PSMA5 and PSMA7 proteasome subunits, promotes assembly of the proteasome alpha subunits into the heteroheptameric alpha ring and prevents alpha ring dimerization. {ECO:0000269|PubMed:16251969, ECO:0000269|PubMed:17707236}. |
Q96EV2 | RBM33 | S54 | ochoa | RNA-binding protein 33 (Proline-rich protein 8) (RNA-binding motif protein 33) | RNA reader protein, which recognizes and binds specific RNAs, thereby regulating RNA metabolic processes, such as mRNA export, mRNA stability and/or translation (PubMed:35589130, PubMed:37257451). Binds a subset of intronless RNAs containing GC-rich elements, such as NORAD, and promotes their nuclear export by recruiting target RNAs to components of the NXF1-NXT1 RNA export machinery (PubMed:35589130). Specifically recognizes and binds N6-methyladenosine (m6A)-containing mRNAs, promoting their demethylation by ALKBH5 (PubMed:37257451). Acts as an molecular adapter, which (1) promotes ALKBH5 recruitment to m6A-containing transcripts and (2) activates ALKBH5 demethylase activity by recruiting SENP1, leading to ALKBH5 deSUMOylation and subsequent activation (PubMed:37257451). {ECO:0000269|PubMed:35589130, ECO:0000269|PubMed:37257451}. |
Q96HA1 | POM121 | S543 | ochoa | Nuclear envelope pore membrane protein POM 121 (Nuclear envelope pore membrane protein POM 121A) (Nucleoporin Nup121) (Pore membrane protein of 121 kDa) | Essential component of the nuclear pore complex (NPC). The repeat-containing domain may be involved in anchoring components of the pore complex to the pore membrane. When overexpressed in cells induces the formation of cytoplasmic annulate lamellae (AL). {ECO:0000269|PubMed:17900573}. |
Q96JN0 | LCOR | S72 | ochoa | Ligand-dependent corepressor (LCoR) (Mblk1-related protein 2) | May act as transcription activator that binds DNA elements with the sequence 5'-CCCTATCGATCGATCTCTACCT-3' (By similarity). Repressor of ligand-dependent transcription activation by target nuclear receptors. Repressor of ligand-dependent transcription activation by ESR1, ESR2, NR3C1, PGR, RARA, RARB, RARG, RXRA and VDR. {ECO:0000250, ECO:0000269|PubMed:12535528}. |
Q9BSC4 | NOL10 | S632 | ochoa | Nucleolar protein 10 | None |
Q9BVJ6 | UTP14A | S29 | ochoa | U3 small nucleolar RNA-associated protein 14 homolog A (Antigen NY-CO-16) (Serologically defined colon cancer antigen 16) | May be required for ribosome biogenesis. {ECO:0000250}. |
Q9H0K1 | SIK2 | S512 | psp | Serine/threonine-protein kinase SIK2 (EC 2.7.11.1) (Qin-induced kinase) (Salt-inducible kinase 2) (SIK-2) (Serine/threonine-protein kinase SNF1-like kinase 2) | Serine/threonine-protein kinase that plays a role in many biological processes such as fatty acid oxidation, autophagy, immune response or glucose metabolism (PubMed:23322770, PubMed:26983400). Phosphorylates 'Ser-794' of IRS1 in insulin-stimulated adipocytes, potentially modulating the efficiency of insulin signal transduction. Inhibits CREB activity by phosphorylating and repressing TORCs, the CREB-specific coactivators (PubMed:15454081). Phosphorylates EP300 and thus inhibits its histone acetyltransferase activity (PubMed:21084751, PubMed:26983400). In turn, regulates the DNA-binding ability of several transcription factors such as PPARA or MLXIPL (PubMed:21084751, PubMed:26983400). Also plays a role in thymic T-cell development (By similarity). {ECO:0000250|UniProtKB:Q8CFH6, ECO:0000269|PubMed:15454081, ECO:0000269|PubMed:21084751, ECO:0000269|PubMed:23322770, ECO:0000269|PubMed:26983400}. |
Q9H1A4 | ANAPC1 | S555 | ochoa | Anaphase-promoting complex subunit 1 (APC1) (Cyclosome subunit 1) (Mitotic checkpoint regulator) (Testis-specific gene 24 protein) | Component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle (PubMed:18485873). The APC/C complex acts by mediating ubiquitination and subsequent degradation of target proteins: it mainly mediates the formation of 'Lys-11'-linked polyubiquitin chains and, to a lower extent, the formation of 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains (PubMed:18485873). The APC/C complex catalyzes assembly of branched 'Lys-11'-/'Lys-48'-linked branched ubiquitin chains on target proteins (PubMed:29033132). {ECO:0000269|PubMed:18485873, ECO:0000269|PubMed:29033132}. |
Q9H2Y7 | ZNF106 | S554 | ochoa | Zinc finger protein 106 (Zfp-106) (Zinc finger protein 474) | RNA-binding protein. Specifically binds to 5'-GGGGCC-3' sequence repeats in RNA. Essential for maintenance of peripheral motor neuron and skeletal muscle function. Required for normal expression and/or alternative splicing of a number of genes in spinal cord and skeletal muscle, including the neurite outgrowth inhibitor RTN4. Also contributes to normal mitochondrial respiratory function in motor neurons, via an unknown mechanism. {ECO:0000250|UniProtKB:O88466}. |
Q9H792 | PEAK1 | S212 | ochoa | Inactive tyrosine-protein kinase PEAK1 (Pseudopodium-enriched atypical kinase 1) (Sugen kinase 269) (Tyrosine-protein kinase SgK269) | Probable catalytically inactive kinase. Scaffolding protein that regulates the cytoskeleton to control cell spreading and migration by modulating focal adhesion dynamics (PubMed:20534451, PubMed:23105102, PubMed:35687021). Acts as a scaffold for mediating EGFR signaling (PubMed:23846654). {ECO:0000269|PubMed:20534451, ECO:0000269|PubMed:23105102, ECO:0000269|PubMed:23846654, ECO:0000269|PubMed:35687021}. |
Q9H8M2 | BRD9 | S43 | ochoa | Bromodomain-containing protein 9 (Rhabdomyosarcoma antigen MU-RMS-40.8) | Plays a role in chromatin remodeling and regulation of transcription (PubMed:22464331, PubMed:26365797). Acts as a chromatin reader that recognizes and binds acylated histones: binds histones that are acetylated and/or butyrylated (PubMed:26365797). Component of SWI/SNF chromatin remodeling subcomplex GBAF that carries out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner (PubMed:29374058). Also orchestrates the RAD51-RAD54 complex formation and thereby plays a role in homologous recombination (HR) (PubMed:32457312). {ECO:0000269|PubMed:22464331, ECO:0000269|PubMed:26365797, ECO:0000269|PubMed:29374058, ECO:0000269|PubMed:32457312}. |
Q9H9L4 | KANSL2 | S134 | ochoa | KAT8 regulatory NSL complex subunit 2 (NSL complex protein NSL2) (Non-specific lethal 2 homolog) | Non-catalytic component of the NSL histone acetyltransferase complex, a multiprotein complex that mediates histone H4 acetylation at 'Lys-5'- and 'Lys-8' (H4K5ac and H4K8ac) at transcription start sites and promotes transcription initiation (PubMed:20018852, PubMed:33657400). Required for NSL complex stability and for transcription of intraciliary transport genes in both ciliated and non-ciliated cells by regulating histone H4 acetylation at 'Lys-5'- and 'Lys-12' (H4K5ac and H4K12ac) (By similarity). This is necessary for cilium assembly in ciliated cells and for organization of the microtubule cytoskeleton in non-ciliated cells (By similarity). Required within the NSL complex to maintain nuclear architecture stability by promoting KAT8-mediated acetylation of lamin LMNA (By similarity). {ECO:0000250|UniProtKB:Q8BQR4, ECO:0000269|PubMed:20018852, ECO:0000269|PubMed:33657400}. |
Q9HB19 | PLEKHA2 | S273 | ochoa | Pleckstrin homology domain-containing family A member 2 (PH domain-containing family A member 2) (Tandem PH domain-containing protein 2) (TAPP-2) | Binds specifically to phosphatidylinositol 3,4-diphosphate (PtdIns3,4P2), but not to other phosphoinositides. May recruit other proteins to the plasma membrane (By similarity). {ECO:0000250}. |
Q9NPG3 | UBN1 | S321 | ochoa | Ubinuclein-1 (HIRA-binding protein) (Protein VT4) (Ubiquitously expressed nuclear protein) | Acts as a novel regulator of senescence. Involved in the formation of senescence-associated heterochromatin foci (SAHF), which represses expression of proliferation-promoting genes. Binds to proliferation-promoting genes. May be required for replication-independent chromatin assembly. {ECO:0000269|PubMed:14718166, ECO:0000269|PubMed:19029251}. |
Q9NQ55 | PPAN | S238 | ochoa | Suppressor of SWI4 1 homolog (Ssf-1) (Brix domain-containing protein 3) (Peter Pan homolog) | May have a role in cell growth. |
Q9NRF8 | CTPS2 | S562 | ochoa | CTP synthase 2 (EC 6.3.4.2) (CTP synthetase 2) (UTP--ammonia ligase 2) | Catalyzes the ATP-dependent amination of UTP to CTP with either L-glutamine or ammonia as the source of nitrogen. Constitutes the rate-limiting enzyme in the synthesis of cytosine nucleotides. {ECO:0000269|PubMed:10899599, ECO:0000269|PubMed:16179339}. |
Q9NS91 | RAD18 | S55 | ochoa | E3 ubiquitin-protein ligase RAD18 (EC 2.3.2.27) (Postreplication repair protein RAD18) (hHR18) (hRAD18) (RING finger protein 73) (RING-type E3 ubiquitin transferase RAD18) | E3 ubiquitin-protein ligase involved in postreplication repair of UV-damaged DNA. Postreplication repair functions in gap-filling of a daughter strand on replication of damaged DNA. Associates to the E2 ubiquitin conjugating enzyme UBE2B to form the UBE2B-RAD18 ubiquitin ligase complex involved in mono-ubiquitination of DNA-associated PCNA on 'Lys-164'. Has ssDNA binding activity. {ECO:0000269|PubMed:17108083, ECO:0000269|PubMed:21659603}. |
Q9NSI6 | BRWD1 | S1276 | ochoa | Bromodomain and WD repeat-containing protein 1 (WD repeat-containing protein 9) | May be a transcriptional activator. May be involved in chromatin remodeling (By similarity). Plays a role in the regulation of cell morphology and cytoskeletal organization. Required in the control of cell shape. {ECO:0000250, ECO:0000269|PubMed:21834987}. |
Q9NX02 | NLRP2 | S669 | ochoa | NACHT, LRR and PYD domains-containing protein 2 (Nucleotide-binding site protein 1) (PYRIN domain and NACHT domain-containing protein 1) (PYRIN-containing APAF1-like protein 2) | Suppresses TNF- and CD40-induced NFKB1 activity at the level of the IKK complex, by inhibiting NFKBIA degradation induced by TNF. When associated with PYCARD, activates CASP1, leading to the secretion of mature pro-inflammatory cytokine IL1B. May be a component of the inflammasome, a protein complex which also includes PYCARD, CARD8 and CASP1 and whose function would be the activation of pro-inflammatory caspases. {ECO:0000269|PubMed:15456791}. |
Q9NZ63 | C9orf78 | S101 | ochoa | Splicing factor C9orf78 (Hepatocellular carcinoma-associated antigen 59) | Plays a role in pre-mRNA splicing by promoting usage of the upstream 3'-splice site at alternative NAGNAG splice sites; these are sites featuring alternative acceptor motifs separated by only a few nucleotides (PubMed:35241646). May also modulate exon inclusion events (PubMed:35241646). Plays a role in spliceosomal remodeling by displacing WBP4 from SNRNP200 and may act to inhibit SNRNP200 helicase activity (PubMed:35241646). Binds U5 snRNA (PubMed:35241646). Required for proper chromosome segregation (PubMed:35167828). Not required for splicing of shelterin components (PubMed:35167828). {ECO:0000269|PubMed:35167828, ECO:0000269|PubMed:35241646}. |
Q9UGU0 | TCF20 | S1303 | ochoa | Transcription factor 20 (TCF-20) (Nuclear factor SPBP) (Protein AR1) (Stromelysin-1 PDGF-responsive element-binding protein) (SPRE-binding protein) | Transcriptional activator that binds to the regulatory region of MMP3 and thereby controls stromelysin expression. It stimulates the activity of various transcriptional activators such as JUN, SP1, PAX6 and ETS1, suggesting a function as a coactivator. {ECO:0000269|PubMed:10995766}. |
Q9UHD2 | TBK1 | S509 | ochoa | Serine/threonine-protein kinase TBK1 (EC 2.7.11.1) (NF-kappa-B-activating kinase) (T2K) (TANK-binding kinase 1) | Serine/threonine kinase that plays an essential role in regulating inflammatory responses to foreign agents (PubMed:10581243, PubMed:11839743, PubMed:12692549, PubMed:12702806, PubMed:14703513, PubMed:15367631, PubMed:15485837, PubMed:18583960, PubMed:21138416, PubMed:23453971, PubMed:23453972, PubMed:23746807, PubMed:25636800, PubMed:26611359, PubMed:32404352, PubMed:34363755, PubMed:32298923). Following activation of toll-like receptors by viral or bacterial components, associates with TRAF3 and TANK and phosphorylates interferon regulatory factors (IRFs) IRF3 and IRF7 as well as DDX3X (PubMed:12692549, PubMed:12702806, PubMed:14703513, PubMed:15367631, PubMed:18583960, PubMed:25636800). This activity allows subsequent homodimerization and nuclear translocation of the IRFs leading to transcriptional activation of pro-inflammatory and antiviral genes including IFNA and IFNB (PubMed:12702806, PubMed:15367631, PubMed:25636800, PubMed:32972995). In order to establish such an antiviral state, TBK1 form several different complexes whose composition depends on the type of cell and cellular stimuli (PubMed:23453971, PubMed:23453972, PubMed:23746807). Plays a key role in IRF3 activation: acts by first phosphorylating innate adapter proteins MAVS, STING1 and TICAM1 on their pLxIS motif, leading to recruitment of IRF3, thereby licensing IRF3 for phosphorylation by TBK1 (PubMed:25636800, PubMed:30842653, PubMed:37926288). Phosphorylated IRF3 dissociates from the adapter proteins, dimerizes, and then enters the nucleus to induce expression of interferons (PubMed:25636800). Thus, several scaffolding molecules including FADD, TRADD, MAVS, AZI2, TANK or TBKBP1/SINTBAD can be recruited to the TBK1-containing-complexes (PubMed:21931631). Under particular conditions, functions as a NF-kappa-B effector by phosphorylating NF-kappa-B inhibitor alpha/NFKBIA, IKBKB or RELA to translocate NF-Kappa-B to the nucleus (PubMed:10783893, PubMed:15489227). Restricts bacterial proliferation by phosphorylating the autophagy receptor OPTN/Optineurin on 'Ser-177', thus enhancing LC3 binding affinity and antibacterial autophagy (PubMed:21617041). Phosphorylates SMCR8 component of the C9orf72-SMCR8 complex, promoting autophagosome maturation (PubMed:27103069). Phosphorylates ATG8 proteins MAP1LC3C and GABARAPL2, thereby preventing their delipidation and premature removal from nascent autophagosomes (PubMed:31709703). Seems to play a role in energy balance regulation by sustaining a state of chronic, low-grade inflammation in obesity, which leads to a negative impact on insulin sensitivity (By similarity). Attenuates retroviral budding by phosphorylating the endosomal sorting complex required for transport-I (ESCRT-I) subunit VPS37C (PubMed:21270402). Phosphorylates Borna disease virus (BDV) P protein (PubMed:16155125). Plays an essential role in the TLR3- and IFN-dependent control of herpes virus HSV-1 and HSV-2 infections in the central nervous system (PubMed:22851595). Acts both as a positive and negative regulator of the mTORC1 complex, depending on the context: activates mTORC1 in response to growth factors by catalyzing phosphorylation of MTOR, while it limits the mTORC1 complex by promoting phosphorylation of RPTOR (PubMed:29150432, PubMed:31530866). Acts as a positive regulator of the mTORC2 complex by mediating phosphorylation of MTOR, leading to increased phosphorylation and activation of AKT1 (By similarity). Phosphorylates and activates AKT1 (PubMed:21464307). Involved in the regulation of TNF-induced RIPK1-mediated cell death, probably acting via CYLD phosphorylation that in turn controls RIPK1 ubiquitination status (PubMed:34363755). Also participates in the differentiation of T follicular regulatory cells together with the receptor ICOS (PubMed:27135603). {ECO:0000250|UniProtKB:Q9WUN2, ECO:0000269|PubMed:10581243, ECO:0000269|PubMed:10783893, ECO:0000269|PubMed:11839743, ECO:0000269|PubMed:12692549, ECO:0000269|PubMed:12702806, ECO:0000269|PubMed:14703513, ECO:0000269|PubMed:15367631, ECO:0000269|PubMed:15485837, ECO:0000269|PubMed:15489227, ECO:0000269|PubMed:16155125, ECO:0000269|PubMed:18583960, ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:21270402, ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:21617041, ECO:0000269|PubMed:21931631, ECO:0000269|PubMed:22851595, ECO:0000269|PubMed:23453971, ECO:0000269|PubMed:23453972, ECO:0000269|PubMed:23746807, ECO:0000269|PubMed:25636800, ECO:0000269|PubMed:26611359, ECO:0000269|PubMed:27103069, ECO:0000269|PubMed:27135603, ECO:0000269|PubMed:29150432, ECO:0000269|PubMed:30842653, ECO:0000269|PubMed:31530866, ECO:0000269|PubMed:31709703, ECO:0000269|PubMed:32298923, ECO:0000269|PubMed:32972995, ECO:0000269|PubMed:34363755, ECO:0000269|PubMed:37926288}. |
Q9UJV9 | DDX41 | S66 | ochoa | Probable ATP-dependent RNA helicase DDX41 (EC 3.6.4.13) (DEAD box protein 41) (DEAD box protein abstrakt homolog) | Multifunctional protein that participates in many aspects of cellular RNA metabolism. Plays pivotal roles in innate immune sensing and hematopoietic homeostasis (PubMed:34473945). Recognizes foreign or self-nucleic acids generated during microbial infection, thereby initiating anti-pathogen responses (PubMed:23222971). Mechanistically, phosphorylation by BTK allows binding to dsDNA leading to interaction with STING1 (PubMed:25704810). Modulates the homeostasis of dsDNA through its ATP-dependent DNA-unwinding activity and ATP-independent strand-annealing activity (PubMed:35613581). In turn, induces STING1-mediated type I interferon and cytokine responses to DNA and DNA viruses (PubMed:35613581). Selectively modulates the transcription of certain immunity-associated genes by regulating their alternative splicing (PubMed:33650667). Binds to RNA (R)-loops, structures consisting of DNA/RNA hybrids and a displaced strand of DNA that occur during transcription, and prevents their accumulation, thereby maintaining genome stability (PubMed:36229594). Also participates in pre-mRNA splicing, translational regulation and snoRNA processing, which is essential for ribosome biogenesis (PubMed:36229594, PubMed:36780110). {ECO:0000250|UniProtKB:Q91VN6, ECO:0000269|PubMed:23222971, ECO:0000269|PubMed:25704810, ECO:0000269|PubMed:25920683, ECO:0000269|PubMed:33650667, ECO:0000269|PubMed:34473945, ECO:0000269|PubMed:35613581, ECO:0000269|PubMed:36229594, ECO:0000269|PubMed:36780110}. |
Q9UK58 | CCNL1 | S65 | ochoa | Cyclin-L1 (Cyclin-L) | Involved in pre-mRNA splicing. Functions in association with cyclin-dependent kinases (CDKs) (PubMed:18216018). Inhibited by the CDK-specific inhibitor CDKN1A/p21 (PubMed:11980906). May play a role in the regulation of RNA polymerase II (pol II). May be a candidate proto-oncogene in head and neck squamous cell carcinomas (HNSCC) (PubMed:12414649, PubMed:15700036). {ECO:0000269|PubMed:11980906, ECO:0000269|PubMed:12414649, ECO:0000269|PubMed:15700036, ECO:0000269|PubMed:18216018}. |
Q9ULH0 | KIDINS220 | S1526 | ochoa | Kinase D-interacting substrate of 220 kDa (Ankyrin repeat-rich membrane-spanning protein) | Promotes a prolonged MAP-kinase signaling by neurotrophins through activation of a Rap1-dependent mechanism. Provides a docking site for the CRKL-C3G complex, resulting in Rap1-dependent sustained ERK activation. May play an important role in regulating postsynaptic signal transduction through the syntrophin-mediated localization of receptor tyrosine kinases such as EPHA4. In cooperation with SNTA1 can enhance EPHA4-induced JAK/STAT activation. Plays a role in nerve growth factor (NGF)-induced recruitment of RAPGEF2 to late endosomes and neurite outgrowth. May play a role in neurotrophin- and ephrin-mediated neuronal outgrowth and in axon guidance during neural development and in neuronal regeneration (By similarity). Modulates stress-induced apoptosis of melanoma cells via regulation of the MEK/ERK signaling pathway. {ECO:0000250, ECO:0000269|PubMed:18089783}. |
Q9UPM8 | AP4E1 | S855 | ochoa | AP-4 complex subunit epsilon-1 (AP-4 adaptor complex subunit epsilon) (Adaptor-related protein complex 4 subunit epsilon-1) (Epsilon subunit of AP-4) (Epsilon-adaptin) | Component of the adaptor protein complex 4 (AP-4). Adaptor protein complexes are vesicle coat components involved both in vesicle formation and cargo selection. They control the vesicular transport of proteins in different trafficking pathways (PubMed:10066790, PubMed:10436028). AP-4 forms a non clathrin-associated coat on vesicles departing the trans-Golgi network (TGN) and may be involved in the targeting of proteins from the trans-Golgi network (TGN) to the endosomal-lysosomal system. It is also involved in protein sorting to the basolateral membrane in epithelial cells and the proper asymmetric localization of somatodendritic proteins in neurons. AP-4 is involved in the recognition and binding of tyrosine-based sorting signals found in the cytoplasmic part of cargos, but may also recognize other types of sorting signal (Probable). {ECO:0000269|PubMed:10066790, ECO:0000269|PubMed:10436028, ECO:0000305|PubMed:10066790, ECO:0000305|PubMed:10436028}. |
Q9Y2H0 | DLGAP4 | S707 | ochoa | Disks large-associated protein 4 (DAP-4) (PSD-95/SAP90-binding protein 4) (SAP90/PSD-95-associated protein 4) (SAPAP-4) | May play a role in the molecular organization of synapses and neuronal cell signaling. Could be an adapter protein linking ion channel to the subsynaptic cytoskeleton. May induce enrichment of PSD-95/SAP90 at the plasma membrane. |
Q9Y2H5 | PLEKHA6 | S919 | ochoa | Pleckstrin homology domain-containing family A member 6 (PH domain-containing family A member 6) (Phosphoinositol 3-phosphate-binding protein 3) (PEPP-3) | None |
P07737 | PFN1 | S85 | Sugiyama | Profilin-1 (Epididymis tissue protein Li 184a) (Profilin I) | Binds to actin and affects the structure of the cytoskeleton. At high concentrations, profilin prevents the polymerization of actin, whereas it enhances it at low concentrations. By binding to PIP2, it inhibits the formation of IP3 and DG. Inhibits androgen receptor (AR) and HTT aggregation and binding of G-actin is essential for its inhibition of AR. {ECO:0000269|PubMed:18573880}. |
P07602 | PSAP | S29 | Sugiyama | Prosaposin (Proactivator polypeptide) [Cleaved into: Saposin-A (Protein A); Saposin-B-Val; Saposin-B (Cerebroside sulfate activator) (CSAct) (Dispersin) (Sphingolipid activator protein 1) (SAP-1) (Sulfatide/GM1 activator); Saposin-C (A1 activator) (Co-beta-glucosidase) (Glucosylceramidase activator) (Sphingolipid activator protein 2) (SAP-2); Saposin-D (Component C) (Protein C)] | Saposin-A and saposin-C stimulate the hydrolysis of glucosylceramide by beta-glucosylceramidase (EC 3.2.1.45) and galactosylceramide by beta-galactosylceramidase (EC 3.2.1.46). Saposin-C apparently acts by combining with the enzyme and acidic lipid to form an activated complex, rather than by solubilizing the substrate.; FUNCTION: Saposin-B stimulates the hydrolysis of galacto-cerebroside sulfate by arylsulfatase A (EC 3.1.6.8), GM1 gangliosides by beta-galactosidase (EC 3.2.1.23) and globotriaosylceramide by alpha-galactosidase A (EC 3.2.1.22). Saposin-B forms a solubilizing complex with the substrates of the sphingolipid hydrolases.; FUNCTION: Saposin-D is a specific sphingomyelin phosphodiesterase activator (EC 3.1.4.12).; FUNCTION: [Prosaposin]: Behaves as a myelinotrophic and neurotrophic factor, these effects are mediated by its G-protein-coupled receptors, GPR37 and GPR37L1, undergoing ligand-mediated internalization followed by ERK phosphorylation signaling. {ECO:0000250|UniProtKB:Q61207, ECO:0000269|PubMed:10383054}.; FUNCTION: Saposins are specific low-molecular mass non-enzymic proteins, they participate in the lysosomal degradation of sphingolipids, which takes place by the sequential action of specific hydrolases. |
Q13242 | SRSF9 | S172 | Sugiyama | Serine/arginine-rich splicing factor 9 (Pre-mRNA-splicing factor SRp30C) (Splicing factor, arginine/serine-rich 9) | Plays a role in constitutive splicing and can modulate the selection of alternative splice sites. Represses the splicing of MAPT/Tau exon 10. {ECO:0000269|PubMed:10196175, ECO:0000269|PubMed:11875052, ECO:0000269|PubMed:12024014, ECO:0000269|PubMed:12604611, ECO:0000269|PubMed:15009090, ECO:0000269|PubMed:15009664, ECO:0000269|PubMed:15695522, ECO:0000269|PubMed:7556075}. |
O00116 | AGPS | S174 | Sugiyama | Alkyldihydroxyacetonephosphate synthase, peroxisomal (Alkyl-DHAP synthase) (EC 2.5.1.26) (Aging-associated gene 5 protein) (Alkylglycerone-phosphate synthase) | Catalyzes the exchange of the acyl chain in acyl-dihydroxyacetonephosphate (acyl-DHAP) for a long chain fatty alcohol, yielding the first ether linked intermediate, i.e. alkyl-dihydroxyacetonephosphate (alkyl-DHAP), in the pathway of ether lipid biosynthesis. {ECO:0000269|PubMed:8399344, ECO:0000269|PubMed:9553082}. |
P49327 | FASN | S2465 | Sugiyama | Fatty acid synthase (EC 2.3.1.85) (Type I fatty acid synthase) [Includes: [Acyl-carrier-protein] S-acetyltransferase (EC 2.3.1.38); [Acyl-carrier-protein] S-malonyltransferase (EC 2.3.1.39); 3-oxoacyl-[acyl-carrier-protein] synthase (EC 2.3.1.41); 3-oxoacyl-[acyl-carrier-protein] reductase (EC 1.1.1.100); 3-hydroxyacyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.59); Enoyl-[acyl-carrier-protein] reductase (EC 1.3.1.39); Acyl-[acyl-carrier-protein] hydrolase (EC 3.1.2.14)] | Fatty acid synthetase is a multifunctional enzyme that catalyzes the de novo biosynthesis of long-chain saturated fatty acids starting from acetyl-CoA and malonyl-CoA in the presence of NADPH. This multifunctional protein contains 7 catalytic activities and a site for the binding of the prosthetic group 4'-phosphopantetheine of the acyl carrier protein ([ACP]) domain. {ECO:0000269|PubMed:16215233, ECO:0000269|PubMed:16969344, ECO:0000269|PubMed:26851298, ECO:0000269|PubMed:7567999, ECO:0000269|PubMed:8962082, ECO:0000269|PubMed:9356448}.; FUNCTION: (Microbial infection) Fatty acid synthetase activity is required for SARS coronavirus-2/SARS-CoV-2 replication. {ECO:0000269|PubMed:34320401}. |
Q04864 | REL | S516 | GPS6 | Proto-oncogene c-Rel | Proto-oncogene that may play a role in differentiation and lymphopoiesis. NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. The NF-kappa-B heterodimer RELA/p65-c-Rel is a transcriptional activator. |
P13489 | RNH1 | S208 | Sugiyama | Ribonuclease inhibitor (Placental ribonuclease inhibitor) (Placental RNase inhibitor) (Ribonuclease/angiogenin inhibitor 1) (RAI) | Ribonuclease inhibitor which inhibits RNASE1, RNASE2 and angiogenin (ANG) (PubMed:12578357, PubMed:14515218, PubMed:3219362, PubMed:3243277, PubMed:3470787, PubMed:9050852). May play a role in redox homeostasis (PubMed:17292889). Required to inhibit the cytotoxic tRNA ribonuclease activity of ANG in the cytoplasm in absence of stress (PubMed:23843625, PubMed:32510170). Relocates to the nucleus in response to stress, relieving inhibition of ANG in the cytoplasm, and inhibiting the angiogenic activity of ANG in the nucleus (PubMed:23843625). {ECO:0000269|PubMed:12578357, ECO:0000269|PubMed:14515218, ECO:0000269|PubMed:17292889, ECO:0000269|PubMed:23843625, ECO:0000269|PubMed:3219362, ECO:0000269|PubMed:3243277, ECO:0000269|PubMed:32510170, ECO:0000269|PubMed:3470787, ECO:0000269|PubMed:9050852}. |
O15111 | CHUK | S356 | Sugiyama | Inhibitor of nuclear factor kappa-B kinase subunit alpha (I-kappa-B kinase alpha) (IKK-A) (IKK-alpha) (IkBKA) (IkappaB kinase) (EC 2.7.11.10) (Conserved helix-loop-helix ubiquitous kinase) (I-kappa-B kinase 1) (IKK-1) (IKK1) (Nuclear factor NF-kappa-B inhibitor kinase alpha) (NFKBIKA) (Transcription factor 16) (TCF-16) | Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses (PubMed:18626576, PubMed:9244310, PubMed:9252186, PubMed:9346484). Acts as a part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on serine residues (PubMed:18626576, PubMed:35952808, PubMed:9244310, PubMed:9252186, PubMed:9346484). These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome (PubMed:18626576, PubMed:9244310, PubMed:9252186, PubMed:9346484). In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis (PubMed:18626576, PubMed:9244310, PubMed:9252186, PubMed:9346484). Negatively regulates the pathway by phosphorylating the scaffold protein TAXBP1 and thus promoting the assembly of the A20/TNFAIP3 ubiquitin-editing complex (composed of A20/TNFAIP3, TAX1BP1, and the E3 ligases ITCH and RNF11) (PubMed:21765415). Therefore, CHUK plays a key role in the negative feedback of NF-kappa-B canonical signaling to limit inflammatory gene activation. As part of the non-canonical pathway of NF-kappa-B activation, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes (PubMed:20501937). In turn, these complexes regulate genes encoding molecules involved in B-cell survival and lymphoid organogenesis. Also participates in the negative feedback of the non-canonical NF-kappa-B signaling pathway by phosphorylating and destabilizing MAP3K14/NIK. Within the nucleus, phosphorylates CREBBP and consequently increases both its transcriptional and histone acetyltransferase activities (PubMed:17434128). Modulates chromatin accessibility at NF-kappa-B-responsive promoters by phosphorylating histones H3 at 'Ser-10' that are subsequently acetylated at 'Lys-14' by CREBBP (PubMed:12789342). Additionally, phosphorylates the CREBBP-interacting protein NCOA3. Also phosphorylates FOXO3 and may regulate this pro-apoptotic transcription factor (PubMed:15084260). Phosphorylates RIPK1 at 'Ser-25' which represses its kinase activity and consequently prevents TNF-mediated RIPK1-dependent cell death (By similarity). Phosphorylates AMBRA1 following mitophagy induction, promoting AMBRA1 interaction with ATG8 family proteins and its mitophagic activity (PubMed:30217973). {ECO:0000250|UniProtKB:Q60680, ECO:0000269|PubMed:12789342, ECO:0000269|PubMed:15084260, ECO:0000269|PubMed:17434128, ECO:0000269|PubMed:20434986, ECO:0000269|PubMed:20501937, ECO:0000269|PubMed:21765415, ECO:0000269|PubMed:30217973, ECO:0000269|PubMed:35952808, ECO:0000269|PubMed:9244310, ECO:0000269|PubMed:9252186, ECO:0000269|PubMed:9346484, ECO:0000303|PubMed:18626576}. |
O15146 | MUSK | S567 | Sugiyama | Muscle, skeletal receptor tyrosine-protein kinase (EC 2.7.10.1) (Muscle-specific tyrosine-protein kinase receptor) (MuSK) (Muscle-specific kinase receptor) | Receptor tyrosine kinase which plays a central role in the formation and the maintenance of the neuromuscular junction (NMJ), the synapse between the motor neuron and the skeletal muscle (PubMed:25537362). Recruitment of AGRIN by LRP4 to the MUSK signaling complex induces phosphorylation and activation of MUSK, the kinase of the complex. The activation of MUSK in myotubes regulates the formation of NMJs through the regulation of different processes including the specific expression of genes in subsynaptic nuclei, the reorganization of the actin cytoskeleton and the clustering of the acetylcholine receptors (AChR) in the postsynaptic membrane. May regulate AChR phosphorylation and clustering through activation of ABL1 and Src family kinases which in turn regulate MUSK. DVL1 and PAK1 that form a ternary complex with MUSK are also important for MUSK-dependent regulation of AChR clustering. May positively regulate Rho family GTPases through FNTA. Mediates the phosphorylation of FNTA which promotes prenylation, recruitment to membranes and activation of RAC1 a regulator of the actin cytoskeleton and of gene expression. Other effectors of the MUSK signaling include DNAJA3 which functions downstream of MUSK. May also play a role within the central nervous system by mediating cholinergic responses, synaptic plasticity and memory formation (By similarity). {ECO:0000250, ECO:0000269|PubMed:25537362}. |
Q13049 | TRIM32 | S55 | SIGNOR | E3 ubiquitin-protein ligase TRIM32 (EC 2.3.2.27) (72 kDa Tat-interacting protein) (RING-type E3 ubiquitin transferase TRIM32) (Tripartite motif-containing protein 32) (Zinc finger protein HT2A) | E3 ubiquitin ligase that plays a role in various biological processes including neural stem cell differentiation, innate immunity, inflammatory resonse and autophagy (PubMed:19349376, PubMed:31123703). Plays a role in virus-triggered induction of IFN-beta and TNF-alpha by mediating the ubiquitination of STING1. Mechanistically, targets STING1 for 'Lys-63'-linked ubiquitination which promotes the interaction of STING1 with TBK1 (PubMed:22745133). Regulates bacterial clearance and promotes autophagy in Mycobacterium tuberculosis-infected macrophages (PubMed:37543647). Negatively regulates TLR3/4-mediated innate immune and inflammatory response by triggering the autophagic degradation of TICAM1 in an E3 activity-independent manner (PubMed:28898289). Plays an essential role in oxidative stress induced cell death by inducing loss of transmembrane potential and enhancing mitochondrial reactive oxygen species (ROS) production during oxidative stress conditions (PubMed:32918979). Ubiquitinates XIAP and targets it for proteasomal degradation (PubMed:21628460). Ubiquitinates DTNBP1 (dysbindin) and promotes its degradation (PubMed:19349376). May ubiquitinate BBS2 (PubMed:22500027). Ubiquitinates PIAS4/PIASY and promotes its degradation in keratinocytes treated with UVB and TNF-alpha (By similarity). Also acts as a regulator of autophagy by mediating formation of unanchored 'Lys-63'-linked polyubiquitin chains that activate ULK1: interaction with AMBRA1 is required for ULK1 activation (PubMed:31123703). Positively regulates dendritic branching by promoting ubiquitination and subsequent degradation of the epigenetic factor CDYL (PubMed:34888944). Under metabolic stress and phosphorylation by CHK2, mediates 'Lys-63'-linked ubiquitination of ATG7 at 'Lys-45' to initiate autophagy (PubMed:37943659). {ECO:0000250|UniProtKB:Q8CH72, ECO:0000269|PubMed:19349376, ECO:0000269|PubMed:21628460, ECO:0000269|PubMed:22500027, ECO:0000269|PubMed:22745133, ECO:0000269|PubMed:28898289, ECO:0000269|PubMed:31123703, ECO:0000269|PubMed:32918979, ECO:0000269|PubMed:34888944, ECO:0000269|PubMed:37543647, ECO:0000269|PubMed:37943659}.; FUNCTION: (Microbial infection) May play a significant role in mediating the biological activity of the HIV-1 Tat protein in vivo (PubMed:7778269). Binds specifically to the activation domain of HIV-1 Tat and can also interact with the HIV-2 and EIAV Tat proteins in vivo (PubMed:7778269). {ECO:0000269|PubMed:7778269}. |
Q04917 | YWHAH | S215 | Sugiyama | 14-3-3 protein eta (Protein AS1) | Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. Negatively regulates the kinase activity of PDPK1. {ECO:0000269|PubMed:12177059}. |
P05771 | PRKCB | S476 | Sugiyama | Protein kinase C beta type (PKC-B) (PKC-beta) (EC 2.7.11.13) | Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase involved in various cellular processes such as regulation of the B-cell receptor (BCR) signalosome, oxidative stress-induced apoptosis, androgen receptor-dependent transcription regulation, insulin signaling and endothelial cells proliferation. Plays a key role in B-cell activation by regulating BCR-induced NF-kappa-B activation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11/CARMA1 at 'Ser-559', 'Ser-644' and 'Ser-652'. Phosphorylation induces CARD11/CARMA1 association with lipid rafts and recruitment of the BCL10-MALT1 complex as well as MAP3K7/TAK1, which then activates IKK complex, resulting in nuclear translocation and activation of NFKB1. Plays a direct role in the negative feedback regulation of the BCR signaling, by down-modulating BTK function via direct phosphorylation of BTK at 'Ser-180', which results in the alteration of BTK plasma membrane localization and in turn inhibition of BTK activity (PubMed:11598012). Involved in apoptosis following oxidative damage: in case of oxidative conditions, specifically phosphorylates 'Ser-36' of isoform p66Shc of SHC1, leading to mitochondrial accumulation of p66Shc, where p66Shc acts as a reactive oxygen species producer. Acts as a coactivator of androgen receptor (AR)-dependent transcription, by being recruited to AR target genes and specifically mediating phosphorylation of 'Thr-6' of histone H3 (H3T6ph), a specific tag for epigenetic transcriptional activation that prevents demethylation of histone H3 'Lys-4' (H3K4me) by LSD1/KDM1A (PubMed:20228790). In insulin signaling, may function downstream of IRS1 in muscle cells and mediate insulin-dependent DNA synthesis through the RAF1-MAPK/ERK signaling cascade. Participates in the regulation of glucose transport in adipocytes by negatively modulating the insulin-stimulated translocation of the glucose transporter SLC2A4/GLUT4. Phosphorylates SLC2A1/GLUT1, promoting glucose uptake by SLC2A1/GLUT1 (PubMed:25982116). Under high glucose in pancreatic beta-cells, is probably involved in the inhibition of the insulin gene transcription, via regulation of MYC expression. In endothelial cells, activation of PRKCB induces increased phosphorylation of RB1, increased VEGFA-induced cell proliferation, and inhibits PI3K/AKT-dependent nitric oxide synthase (NOS3/eNOS) regulation by insulin, which causes endothelial dysfunction. Also involved in triglyceride homeostasis (By similarity). Phosphorylates ATF2 which promotes cooperation between ATF2 and JUN, activating transcription (PubMed:19176525). Phosphorylates KLHL3 in response to angiotensin II signaling, decreasing the interaction between KLHL3 and WNK4 (PubMed:25313067). Phosphorylates and activates LRRK1, which phosphorylates RAB proteins involved in intracellular trafficking (PubMed:36040231). {ECO:0000250|UniProtKB:P68404, ECO:0000269|PubMed:11598012, ECO:0000269|PubMed:19176525, ECO:0000269|PubMed:20228790, ECO:0000269|PubMed:25313067, ECO:0000269|PubMed:25982116, ECO:0000269|PubMed:36040231}. |
P17252 | PRKCA | S473 | Sugiyama | Protein kinase C alpha type (PKC-A) (PKC-alpha) (EC 2.7.11.13) | Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that is involved in positive and negative regulation of cell proliferation, apoptosis, differentiation, migration and adhesion, tumorigenesis, cardiac hypertrophy, angiogenesis, platelet function and inflammation, by directly phosphorylating targets such as RAF1, BCL2, CSPG4, TNNT2/CTNT, or activating signaling cascade involving MAPK1/3 (ERK1/2) and RAP1GAP. Involved in cell proliferation and cell growth arrest by positive and negative regulation of the cell cycle. Can promote cell growth by phosphorylating and activating RAF1, which mediates the activation of the MAPK/ERK signaling cascade, and/or by up-regulating CDKN1A, which facilitates active cyclin-dependent kinase (CDK) complex formation in glioma cells. In intestinal cells stimulated by the phorbol ester PMA, can trigger a cell cycle arrest program which is associated with the accumulation of the hyper-phosphorylated growth-suppressive form of RB1 and induction of the CDK inhibitors CDKN1A and CDKN1B. Exhibits anti-apoptotic function in glioma cells and protects them from apoptosis by suppressing the p53/TP53-mediated activation of IGFBP3, and in leukemia cells mediates anti-apoptotic action by phosphorylating BCL2. During macrophage differentiation induced by macrophage colony-stimulating factor (CSF1), is translocated to the nucleus and is associated with macrophage development. After wounding, translocates from focal contacts to lamellipodia and participates in the modulation of desmosomal adhesion. Plays a role in cell motility by phosphorylating CSPG4, which induces association of CSPG4 with extensive lamellipodia at the cell periphery and polarization of the cell accompanied by increases in cell motility. During chemokine-induced CD4(+) T cell migration, phosphorylates CDC42-guanine exchange factor DOCK8 resulting in its dissociation from LRCH1 and the activation of GTPase CDC42 (PubMed:28028151). Is highly expressed in a number of cancer cells where it can act as a tumor promoter and is implicated in malignant phenotypes of several tumors such as gliomas and breast cancers. Negatively regulates myocardial contractility and positively regulates angiogenesis, platelet aggregation and thrombus formation in arteries. Mediates hypertrophic growth of neonatal cardiomyocytes, in part through a MAPK1/3 (ERK1/2)-dependent signaling pathway, and upon PMA treatment, is required to induce cardiomyocyte hypertrophy up to heart failure and death, by increasing protein synthesis, protein-DNA ratio and cell surface area. Regulates cardiomyocyte function by phosphorylating cardiac troponin T (TNNT2/CTNT), which induces significant reduction in actomyosin ATPase activity, myofilament calcium sensitivity and myocardial contractility. In angiogenesis, is required for full endothelial cell migration, adhesion to vitronectin (VTN), and vascular endothelial growth factor A (VEGFA)-dependent regulation of kinase activation and vascular tube formation. Involved in the stabilization of VEGFA mRNA at post-transcriptional level and mediates VEGFA-induced cell proliferation. In the regulation of calcium-induced platelet aggregation, mediates signals from the CD36/GP4 receptor for granule release, and activates the integrin heterodimer ITGA2B-ITGB3 through the RAP1GAP pathway for adhesion. During response to lipopolysaccharides (LPS), may regulate selective LPS-induced macrophage functions involved in host defense and inflammation. But in some inflammatory responses, may negatively regulate NF-kappa-B-induced genes, through IL1A-dependent induction of NF-kappa-B inhibitor alpha (NFKBIA/IKBA). Upon stimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA), phosphorylates EIF4G1, which modulates EIF4G1 binding to MKNK1 and may be involved in the regulation of EIF4E phosphorylation. Phosphorylates KIT, leading to inhibition of KIT activity. Phosphorylates ATF2 which promotes cooperation between ATF2 and JUN, activating transcription. Phosphorylates SOCS2 at 'Ser-52' facilitating its ubiquitination and proteasomal degradation (By similarity). Phosphorylates KLHL3 in response to angiotensin II signaling, decreasing the interaction between KLHL3 and WNK4 (PubMed:25313067). Phosphorylates and activates LRRK1, which phosphorylates RAB proteins involved in intracellular trafficking (PubMed:36040231). {ECO:0000250|UniProtKB:P20444, ECO:0000269|PubMed:10848585, ECO:0000269|PubMed:11909826, ECO:0000269|PubMed:12724315, ECO:0000269|PubMed:12832403, ECO:0000269|PubMed:15016832, ECO:0000269|PubMed:15504744, ECO:0000269|PubMed:15526160, ECO:0000269|PubMed:18056764, ECO:0000269|PubMed:19176525, ECO:0000269|PubMed:21576361, ECO:0000269|PubMed:21806543, ECO:0000269|PubMed:23990668, ECO:0000269|PubMed:25313067, ECO:0000269|PubMed:28028151, ECO:0000269|PubMed:36040231, ECO:0000269|PubMed:9738012, ECO:0000269|PubMed:9830023, ECO:0000269|PubMed:9873035, ECO:0000269|PubMed:9927633}. |
O00443 | PIK3C2A | S58 | Sugiyama | Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha (PI3K-C2-alpha) (PtdIns-3-kinase C2 subunit alpha) (EC 2.7.1.137) (EC 2.7.1.153) (EC 2.7.1.154) (Phosphoinositide 3-kinase-C2-alpha) | Generates phosphatidylinositol 3-phosphate (PtdIns3P) and phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P2) that act as second messengers. Has a role in several intracellular trafficking events. Functions in insulin signaling and secretion. Required for translocation of the glucose transporter SLC2A4/GLUT4 to the plasma membrane and glucose uptake in response to insulin-mediated RHOQ activation. Regulates insulin secretion through two different mechanisms: involved in glucose-induced insulin secretion downstream of insulin receptor in a pathway that involves AKT1 activation and TBC1D4/AS160 phosphorylation, and participates in the late step of insulin granule exocytosis probably in insulin granule fusion. Synthesizes PtdIns3P in response to insulin signaling. Functions in clathrin-coated endocytic vesicle formation and distribution. Regulates dynamin-independent endocytosis, probably by recruiting EEA1 to internalizing vesicles. In neurosecretory cells synthesizes PtdIns3P on large dense core vesicles. Participates in calcium induced contraction of vascular smooth muscle by regulating myosin light chain (MLC) phosphorylation through a mechanism involving Rho kinase-dependent phosphorylation of the MLCP-regulatory subunit MYPT1. May play a role in the EGF signaling cascade. May be involved in mitosis and UV-induced damage response. Required for maintenance of normal renal structure and function by supporting normal podocyte function. Involved in the regulation of ciliogenesis and trafficking of ciliary components (PubMed:31034465). {ECO:0000269|PubMed:10766823, ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:11239472, ECO:0000269|PubMed:12719431, ECO:0000269|PubMed:16215232, ECO:0000269|PubMed:21081650, ECO:0000269|PubMed:31034465, ECO:0000269|PubMed:9337861}. |
P31947 | SFN | S212 | Sugiyama | 14-3-3 protein sigma (Epithelial cell marker protein 1) (Stratifin) | Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways (PubMed:15731107, PubMed:22634725, PubMed:28202711, PubMed:37797010). Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif (PubMed:15731107, PubMed:22634725, PubMed:28202711, PubMed:37797010). Binding generally results in the modulation of the activity of the binding partner (PubMed:15731107, PubMed:22634725, PubMed:28202711, PubMed:37797010). Promotes cytosolic retention of GBP1 GTPase by binding to phosphorylated GBP1, thereby inhibiting the innate immune response (PubMed:37797010). Also acts as a TP53/p53-regulated inhibitor of G2/M progression (PubMed:9659898). When bound to KRT17, regulates protein synthesis and epithelial cell growth by stimulating Akt/mTOR pathway (By similarity). Acts to maintain desmosome cell junction adhesion in epithelial cells via interacting with and sequestering PKP3 to the cytoplasm, thereby restricting its translocation to existing desmosome structures and therefore maintaining desmosome protein homeostasis (PubMed:24124604). Also acts to facilitate PKP3 exchange at desmosome plaques, thereby maintaining keratinocyte intercellular adhesion (PubMed:29678907). May also regulate MDM2 autoubiquitination and degradation and thereby activate p53/TP53 (PubMed:18382127). {ECO:0000250|UniProtKB:O70456, ECO:0000269|PubMed:15731107, ECO:0000269|PubMed:18382127, ECO:0000269|PubMed:22634725, ECO:0000269|PubMed:24124604, ECO:0000269|PubMed:28202711, ECO:0000269|PubMed:29678907, ECO:0000269|PubMed:37797010, ECO:0000269|PubMed:9659898}. |
P09619 | PDGFRB | S980 | Sugiyama | Platelet-derived growth factor receptor beta (PDGF-R-beta) (PDGFR-beta) (EC 2.7.10.1) (Beta platelet-derived growth factor receptor) (Beta-type platelet-derived growth factor receptor) (CD140 antigen-like family member B) (Platelet-derived growth factor receptor 1) (PDGFR-1) (CD antigen CD140b) | Tyrosine-protein kinase that acts as a cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of pericytes and smooth muscle cells to endothelial cells. Plays a role in the migration of vascular smooth muscle cells and the formation of neointima at vascular injury sites. Required for normal development of the cardiovascular system. Required for normal recruitment of pericytes (mesangial cells) in the kidney glomerulus, and for normal formation of a branched network of capillaries in kidney glomeruli. Promotes rearrangement of the actin cytoskeleton and the formation of membrane ruffles. Binding of its cognate ligands - homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFD -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PLCG1, PIK3R1, PTPN11, RASA1/GAP, CBL, SHC1 and NCK1. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leads to the activation of the AKT1 signaling pathway. Phosphorylation of SHC1, or of the C-terminus of PTPN11, creates a binding site for GRB2, resulting in the activation of HRAS, RAF1 and down-stream MAP kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation and activation of SRC family kinases. Promotes phosphorylation of PDCD6IP/ALIX and STAM. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor. {ECO:0000269|PubMed:11297552, ECO:0000269|PubMed:11331881, ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:1653029, ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:1846866, ECO:0000269|PubMed:20494825, ECO:0000269|PubMed:20529858, ECO:0000269|PubMed:21098708, ECO:0000269|PubMed:21679854, ECO:0000269|PubMed:21733313, ECO:0000269|PubMed:2554309, ECO:0000269|PubMed:26599395, ECO:0000269|PubMed:2835772, ECO:0000269|PubMed:2850496, ECO:0000269|PubMed:7685273, ECO:0000269|PubMed:7691811, ECO:0000269|PubMed:7692233, ECO:0000269|PubMed:8195171}. |
P41743 | PRKCI | S388 | Sugiyama | Protein kinase C iota type (EC 2.7.11.13) (Atypical protein kinase C-lambda/iota) (PRKC-lambda/iota) (aPKC-lambda/iota) (nPKC-iota) | Calcium- and diacylglycerol-independent serine/ threonine-protein kinase that plays a general protective role against apoptotic stimuli, is involved in NF-kappa-B activation, cell survival, differentiation and polarity, and contributes to the regulation of microtubule dynamics in the early secretory pathway. Is necessary for BCR-ABL oncogene-mediated resistance to apoptotic drug in leukemia cells, protecting leukemia cells against drug-induced apoptosis. In cultured neurons, prevents amyloid beta protein-induced apoptosis by interrupting cell death process at a very early step. In glioblastoma cells, may function downstream of phosphatidylinositol 3-kinase (PI(3)K) and PDPK1 in the promotion of cell survival by phosphorylating and inhibiting the pro-apoptotic factor BAD. Can form a protein complex in non-small cell lung cancer (NSCLC) cells with PARD6A and ECT2 and regulate ECT2 oncogenic activity by phosphorylation, which in turn promotes transformed growth and invasion. In response to nerve growth factor (NGF), acts downstream of SRC to phosphorylate and activate IRAK1, allowing the subsequent activation of NF-kappa-B and neuronal cell survival. Functions in the organization of the apical domain in epithelial cells by phosphorylating EZR. This step is crucial for activation and normal distribution of EZR at the early stages of intestinal epithelial cell differentiation. Forms a protein complex with LLGL1 and PARD6B independently of PARD3 to regulate epithelial cell polarity. Plays a role in microtubule dynamics in the early secretory pathway through interaction with RAB2A and GAPDH and recruitment to vesicular tubular clusters (VTCs). In human coronary artery endothelial cells (HCAEC), is activated by saturated fatty acids and mediates lipid-induced apoptosis. Involved in early synaptic long term potentiation phase in CA1 hippocampal cells and short term memory formation (By similarity). {ECO:0000250|UniProtKB:F1M7Y5, ECO:0000269|PubMed:10356400, ECO:0000269|PubMed:10467349, ECO:0000269|PubMed:10906326, ECO:0000269|PubMed:11042363, ECO:0000269|PubMed:11724794, ECO:0000269|PubMed:12871960, ECO:0000269|PubMed:14684752, ECO:0000269|PubMed:15994303, ECO:0000269|PubMed:18270268, ECO:0000269|PubMed:19327373, ECO:0000269|PubMed:21189248, ECO:0000269|PubMed:21419810, ECO:0000269|PubMed:8226978, ECO:0000269|PubMed:9346882}. |
P42684 | ABL2 | S962 | Sugiyama | Tyrosine-protein kinase ABL2 (EC 2.7.10.2) (Abelson murine leukemia viral oncogene homolog 2) (Abelson tyrosine-protein kinase 2) (Abelson-related gene protein) (Tyrosine-protein kinase ARG) | Non-receptor tyrosine-protein kinase that plays an ABL1-overlapping role in key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion and receptor endocytosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like MYH10 (involved in movement); CTTN (involved in signaling); or TUBA1 and TUBB (microtubule subunits). Binds directly F-actin and regulates actin cytoskeletal structure through its F-actin-bundling activity. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as CRK, CRKL, DOK1 or ARHGAP35. Adhesion-dependent phosphorylation of ARHGAP35 promotes its association with RASA1, resulting in recruitment of ARHGAP35 to the cell periphery where it inhibits RHO. Phosphorylates multiple receptor tyrosine kinases like PDGFRB and other substrates which are involved in endocytosis regulation such as RIN1. In brain, may regulate neurotransmission by phosphorylating proteins at the synapse. ABL2 also acts as a regulator of multiple pathological signaling cascades during infection. Pathogens can highjack ABL2 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1. Positively regulates chemokine-mediated T-cell migration, polarization, and homing to lymph nodes and immune-challenged tissues, potentially via activation of NEDD9/HEF1 and RAP1 (By similarity). {ECO:0000250|UniProtKB:Q4JIM5, ECO:0000269|PubMed:15735735, ECO:0000269|PubMed:15886098, ECO:0000269|PubMed:16678104, ECO:0000269|PubMed:17306540, ECO:0000269|PubMed:18945674}. |
O60563 | CCNT1 | S444 | Sugiyama | Cyclin-T1 (CycT1) (Cyclin-T) | Regulatory subunit of the cyclin-dependent kinase pair (CDK9/cyclin-T1) complex, also called positive transcription elongation factor B (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNA Pol II) (PubMed:16109376, PubMed:16109377, PubMed:30134174, PubMed:35393539). Required to activate the protein kinase activity of CDK9: acts by mediating formation of liquid-liquid phase separation (LLPS) that enhances binding of P-TEFb to the CTD of RNA Pol II (PubMed:29849146, PubMed:35393539). {ECO:0000269|PubMed:16109376, ECO:0000269|PubMed:16109377, ECO:0000269|PubMed:29849146, ECO:0000269|PubMed:30134174, ECO:0000269|PubMed:35393539}.; FUNCTION: (Microbial infection) In case of HIV or SIV infections, binds to the transactivation domain of the viral nuclear transcriptional activator, Tat, thereby increasing Tat's affinity for the transactivating response RNA element (TAR RNA). Serves as an essential cofactor for Tat, by promoting RNA Pol II activation, allowing transcription of viral genes. {ECO:0000269|PubMed:10329125, ECO:0000269|PubMed:10329126}. |
Q13459 | MYO9B | S1308 | Sugiyama | Unconventional myosin-IXb (Unconventional myosin-9b) | Myosins are actin-based motor molecules with ATPase activity. Unconventional myosins serve in intracellular movements. Binds actin with high affinity both in the absence and presence of ATP and its mechanochemical activity is inhibited by calcium ions (PubMed:9490638). Also acts as a GTPase activator for RHOA (PubMed:26529257, PubMed:9490638). Plays a role in the regulation of cell migration via its role as RHOA GTPase activator. This is regulated by its interaction with the SLIT2 receptor ROBO1; interaction with ROBO1 impairs interaction with RHOA and subsequent activation of RHOA GTPase activity, and thereby leads to increased levels of active, GTP-bound RHOA (PubMed:26529257). {ECO:0000269|PubMed:26529257, ECO:0000269|PubMed:9490638}. |
O75828 | CBR3 | S69 | Sugiyama | Carbonyl reductase [NADPH] 3 (EC 1.1.1.184) (NADPH-dependent carbonyl reductase 3) (Quinone reductase CBR3) (EC 1.6.5.10) (Short chain dehydrogenase/reductase family 21C member 2) | Catalyzes the NADPH-dependent reduction of carbonyl compounds to their corresponding alcohols (PubMed:18493841). Has low NADPH-dependent oxidoreductase activity. Acts on several orthoquinones, acts as well on non-quinone compounds, such as isatin or on the anticancer drug oracin (PubMed:15537833, PubMed:18493841, PubMed:19841672). Best substrates for CBR3 is 1,2- naphthoquinone, hence could play a role in protection against cytotoxicity of exogenous quinones (PubMed:19841672). Exerts activity toward ortho-quinones but not paraquinones. No endogenous substrate for CBR3 except isatin has been identified (PubMed:19841672). {ECO:0000269|PubMed:15537833, ECO:0000269|PubMed:18493841, ECO:0000269|PubMed:19841672}. |
P16152 | CBR1 | S69 | Sugiyama | Carbonyl reductase [NADPH] 1 (EC 1.1.1.184) (15-hydroxyprostaglandin dehydrogenase [NADP(+)]) (EC 1.1.1.196, EC 1.1.1.197) (20-beta-hydroxysteroid dehydrogenase) (Alcohol dehydrogenase [NAD(P)+] CBR1) (EC 1.1.1.71) (NADPH-dependent carbonyl reductase 1) (Prostaglandin 9-ketoreductase) (PG-9-KR) (Prostaglandin-E(2) 9-reductase) (EC 1.1.1.189) (Short chain dehydrogenase/reductase family 21C member 1) | NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol (PubMed:15799708, PubMed:17344335, PubMed:17912391, PubMed:18449627, PubMed:18826943, PubMed:1921984, PubMed:7005231). Can convert prostaglandin E to prostaglandin F2-alpha (By similarity). Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione (PubMed:17344335, PubMed:18826943). In addition, participates in the glucocorticoid metabolism by catalyzing the NADPH-dependent cortisol/corticosterone into 20beta-dihydrocortisol (20b-DHF) or 20beta-corticosterone (20b-DHB), which are weak agonists of NR3C1 and NR3C2 in adipose tissue (PubMed:28878267). {ECO:0000250|UniProtKB:Q28960, ECO:0000269|PubMed:15799708, ECO:0000269|PubMed:17344335, ECO:0000269|PubMed:17912391, ECO:0000269|PubMed:18449627, ECO:0000269|PubMed:18826943, ECO:0000269|PubMed:1921984, ECO:0000269|PubMed:28878267, ECO:0000269|PubMed:7005231}. |
Q5S007 | LRRK2 | S1536 | EPSD|PSP | Leucine-rich repeat serine/threonine-protein kinase 2 (EC 2.7.11.1) (EC 3.6.5.-) (Dardarin) | Serine/threonine-protein kinase which phosphorylates a broad range of proteins involved in multiple processes such as neuronal plasticity, innate immunity, autophagy, and vesicle trafficking (PubMed:17114044, PubMed:20949042, PubMed:21850687, PubMed:22012985, PubMed:23395371, PubMed:24687852, PubMed:25201882, PubMed:26014385, PubMed:26824392, PubMed:27830463, PubMed:28720718, PubMed:29125462, PubMed:29127255, PubMed:29212815, PubMed:30398148, PubMed:30635421). Is a key regulator of RAB GTPases by regulating the GTP/GDP exchange and interaction partners of RABs through phosphorylation (PubMed:26824392, PubMed:28720718, PubMed:29125462, PubMed:29127255, PubMed:29212815, PubMed:30398148, PubMed:30635421). Phosphorylates RAB3A, RAB3B, RAB3C, RAB3D, RAB5A, RAB5B, RAB5C, RAB8A, RAB8B, RAB10, RAB12, RAB29, RAB35, and RAB43 (PubMed:23395371, PubMed:26824392, PubMed:28720718, PubMed:29125462, PubMed:29127255, PubMed:29212815, PubMed:30398148, PubMed:30635421, PubMed:38127736). Regulates the RAB3IP-catalyzed GDP/GTP exchange for RAB8A through the phosphorylation of 'Thr-72' on RAB8A (PubMed:26824392). Inhibits the interaction between RAB8A and GDI1 and/or GDI2 by phosphorylating 'Thr-72' on RAB8A (PubMed:26824392). Regulates primary ciliogenesis through phosphorylation of RAB8A and RAB10, which promotes SHH signaling in the brain (PubMed:29125462, PubMed:30398148). Together with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose-6-phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner (PubMed:23395371). Regulates neuronal process morphology in the intact central nervous system (CNS) (PubMed:17114044). Plays a role in synaptic vesicle trafficking (PubMed:24687852). Plays an important role in recruiting SEC16A to endoplasmic reticulum exit sites (ERES) and in regulating ER to Golgi vesicle-mediated transport and ERES organization (PubMed:25201882). Positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway (PubMed:22012985). The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes (PubMed:22012985). Phosphorylates PRDX3 (PubMed:21850687). By phosphorylating APP on 'Thr-743', which promotes the production and the nuclear translocation of the APP intracellular domain (AICD), regulates dopaminergic neuron apoptosis (PubMed:28720718). Acts as a positive regulator of innate immunity by mediating phosphorylation of RIPK2 downstream of NOD1 and NOD2, thereby enhancing RIPK2 activation (PubMed:27830463). Independent of its kinase activity, inhibits the proteasomal degradation of MAPT, thus promoting MAPT oligomerization and secretion (PubMed:26014385). In addition, has GTPase activity via its Roc domain which regulates LRRK2 kinase activity (PubMed:18230735, PubMed:26824392, PubMed:28720718, PubMed:29125462, PubMed:29212815). Recruited by RAB29/RAB7L1 to overloaded lysosomes where it phosphorylates and stabilizes RAB8A and RAB10 which promote lysosomal content release and suppress lysosomal enlargement through the EHBP1 and EHBP1L1 effector proteins (PubMed:30209220, PubMed:38227290). {ECO:0000269|PubMed:17114044, ECO:0000269|PubMed:18230735, ECO:0000269|PubMed:20949042, ECO:0000269|PubMed:21850687, ECO:0000269|PubMed:22012985, ECO:0000269|PubMed:23395371, ECO:0000269|PubMed:24687852, ECO:0000269|PubMed:25201882, ECO:0000269|PubMed:26014385, ECO:0000269|PubMed:26824392, ECO:0000269|PubMed:27830463, ECO:0000269|PubMed:28720718, ECO:0000269|PubMed:29125462, ECO:0000269|PubMed:29127255, ECO:0000269|PubMed:29212815, ECO:0000269|PubMed:30209220, ECO:0000269|PubMed:30398148, ECO:0000269|PubMed:30635421, ECO:0000269|PubMed:38127736, ECO:0000269|PubMed:38227290}. |
Q8IW41 | MAPKAPK5 | S438 | Sugiyama | MAP kinase-activated protein kinase 5 (MAPK-activated protein kinase 5) (MAPKAP kinase 5) (MAPKAP-K5) (MAPKAPK-5) (MK-5) (MK5) (EC 2.7.11.1) (p38-regulated/activated protein kinase) (PRAK) | Tumor suppressor serine/threonine-protein kinase involved in mTORC1 signaling and post-transcriptional regulation. Phosphorylates FOXO3, ERK3/MAPK6, ERK4/MAPK4, HSP27/HSPB1, p53/TP53 and RHEB. Acts as a tumor suppressor by mediating Ras-induced senescence and phosphorylating p53/TP53. Involved in post-transcriptional regulation of MYC by mediating phosphorylation of FOXO3: phosphorylation of FOXO3 leads to promote nuclear localization of FOXO3, enabling expression of miR-34b and miR-34c, 2 post-transcriptional regulators of MYC that bind to the 3'UTR of MYC transcript and prevent MYC translation. Acts as a negative regulator of mTORC1 signaling by mediating phosphorylation and inhibition of RHEB. Part of the atypical MAPK signaling via its interaction with ERK3/MAPK6 or ERK4/MAPK4: the precise role of the complex formed with ERK3/MAPK6 or ERK4/MAPK4 is still unclear, but the complex follows a complex set of phosphorylation events: upon interaction with atypical MAPK (ERK3/MAPK6 or ERK4/MAPK4), ERK3/MAPK6 (or ERK4/MAPK4) is phosphorylated and then mediates phosphorylation and activation of MAPKAPK5, which in turn phosphorylates ERK3/MAPK6 (or ERK4/MAPK4). Mediates phosphorylation of HSP27/HSPB1 in response to PKA/PRKACA stimulation, inducing F-actin rearrangement. {ECO:0000269|PubMed:17254968, ECO:0000269|PubMed:17728103, ECO:0000269|PubMed:19166925, ECO:0000269|PubMed:21329882, ECO:0000269|PubMed:9628874}. |
P12109 | COL6A1 | S201 | Sugiyama | Collagen alpha-1(VI) chain | Collagen VI acts as a cell-binding protein. |
Q9Y243 | AKT3 | S136 | Sugiyama | RAC-gamma serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase Akt-3) (Protein kinase B gamma) (PKB gamma) (RAC-PK-gamma) (STK-2) | AKT3 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT3 is the least studied AKT isoform. It plays an important role in brain development and is crucial for the viability of malignant glioma cells. AKT3 isoform may also be the key molecule in up-regulation and down-regulation of MMP13 via IL13. Required for the coordination of mitochondrial biogenesis with growth factor-induced increases in cellular energy demands. Down-regulation by RNA interference reduces the expression of the phosphorylated form of BAD, resulting in the induction of caspase-dependent apoptosis. {ECO:0000269|PubMed:18524868, ECO:0000269|PubMed:21191416}. |
Download
reactome_id | name | p | -log10_p |
---|---|---|---|
R-HSA-9705683 | SARS-CoV-2-host interactions | 6.708745e-12 | 11.173 |
R-HSA-111447 | Activation of BAD and translocation to mitochondria | 2.454126e-11 | 10.610 |
R-HSA-9755779 | SARS-CoV-2 targets host intracellular signalling and regulatory pathways | 2.454126e-11 | 10.610 |
R-HSA-75035 | Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 5.183406e-10 | 9.285 |
R-HSA-9694516 | SARS-CoV-2 Infection | 7.543848e-10 | 9.122 |
R-HSA-9735871 | SARS-CoV-1 targets host intracellular signalling and regulatory pathways | 1.110908e-09 | 8.954 |
R-HSA-114452 | Activation of BH3-only proteins | 3.545245e-09 | 8.450 |
R-HSA-9614399 | Regulation of localization of FOXO transcription factors | 7.287466e-09 | 8.137 |
R-HSA-109606 | Intrinsic Pathway for Apoptosis | 1.843609e-08 | 7.734 |
R-HSA-191859 | snRNP Assembly | 2.716234e-08 | 7.566 |
R-HSA-194441 | Metabolism of non-coding RNA | 2.716234e-08 | 7.566 |
R-HSA-9679506 | SARS-CoV Infections | 5.439131e-08 | 7.264 |
R-HSA-69473 | G2/M DNA damage checkpoint | 1.478635e-07 | 6.830 |
R-HSA-1640170 | Cell Cycle | 1.959134e-07 | 6.708 |
R-HSA-2980766 | Nuclear Envelope Breakdown | 3.156552e-07 | 6.501 |
R-HSA-159236 | Transport of Mature mRNA derived from an Intron-Containing Transcript | 1.610110e-06 | 5.793 |
R-HSA-69481 | G2/M Checkpoints | 1.639871e-06 | 5.785 |
R-HSA-1445148 | Translocation of SLC2A4 (GLUT4) to the plasma membrane | 1.610110e-06 | 5.793 |
R-HSA-5619107 | Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC... | 1.766256e-06 | 5.753 |
R-HSA-1855196 | IP3 and IP4 transport between cytosol and nucleus | 2.065253e-06 | 5.685 |
R-HSA-1855229 | IP6 and IP7 transport between cytosol and nucleus | 2.065253e-06 | 5.685 |
R-HSA-109581 | Apoptosis | 1.908709e-06 | 5.719 |
R-HSA-1855170 | IPs transport between nucleus and cytosol | 2.787410e-06 | 5.555 |
R-HSA-159227 | Transport of the SLBP independent Mature mRNA | 2.787410e-06 | 5.555 |
R-HSA-9692914 | SARS-CoV-1-host interactions | 2.907929e-06 | 5.536 |
R-HSA-159230 | Transport of the SLBP Dependant Mature mRNA | 3.218836e-06 | 5.492 |
R-HSA-170822 | Regulation of Glucokinase by Glucokinase Regulatory Protein | 3.218836e-06 | 5.492 |
R-HSA-72202 | Transport of Mature Transcript to Cytoplasm | 3.474690e-06 | 5.459 |
R-HSA-180746 | Nuclear import of Rev protein | 3.703124e-06 | 5.431 |
R-HSA-3301854 | Nuclear Pore Complex (NPC) Disassembly | 4.245095e-06 | 5.372 |
R-HSA-69620 | Cell Cycle Checkpoints | 4.069083e-06 | 5.391 |
R-HSA-9825895 | Regulation of MITF-M-dependent genes involved in DNA replication, damage repair ... | 4.879218e-06 | 5.312 |
R-HSA-180910 | Vpr-mediated nuclear import of PICs | 5.522839e-06 | 5.258 |
R-HSA-165054 | Rev-mediated nuclear export of HIV RNA | 6.269737e-06 | 5.203 |
R-HSA-3700989 | Transcriptional Regulation by TP53 | 6.297031e-06 | 5.201 |
R-HSA-159231 | Transport of Mature mRNA Derived from an Intronless Transcript | 7.096588e-06 | 5.149 |
R-HSA-168276 | NS1 Mediated Effects on Host Pathways | 7.096588e-06 | 5.149 |
R-HSA-159234 | Transport of Mature mRNAs Derived from Intronless Transcripts | 8.009743e-06 | 5.096 |
R-HSA-177243 | Interactions of Rev with host cellular proteins | 8.009743e-06 | 5.096 |
R-HSA-176033 | Interactions of Vpr with host cellular proteins | 8.009743e-06 | 5.096 |
R-HSA-168271 | Transport of Ribonucleoproteins into the Host Nucleus | 9.015880e-06 | 5.045 |
R-HSA-1834949 | Cytosolic sensors of pathogen-associated DNA | 1.352166e-05 | 4.869 |
R-HSA-5357801 | Programmed Cell Death | 1.529789e-05 | 4.815 |
R-HSA-168333 | NEP/NS2 Interacts with the Cellular Export Machinery | 1.569889e-05 | 4.804 |
R-HSA-168274 | Export of Viral Ribonucleoproteins from Nucleus | 1.742241e-05 | 4.759 |
R-HSA-72203 | Processing of Capped Intron-Containing Pre-mRNA | 4.254712e-05 | 4.371 |
R-HSA-5628897 | TP53 Regulates Metabolic Genes | 4.263368e-05 | 4.370 |
R-HSA-68875 | Mitotic Prophase | 5.856564e-05 | 4.232 |
R-HSA-168325 | Viral Messenger RNA Synthesis | 6.727825e-05 | 4.172 |
R-HSA-6784531 | tRNA processing in the nucleus | 7.276252e-05 | 4.138 |
R-HSA-5603029 | IkBA variant leads to EDA-ID | 7.326173e-05 | 4.135 |
R-HSA-1606322 | ZBP1(DAI) mediated induction of type I IFNs | 8.516470e-05 | 4.070 |
R-HSA-9730414 | MITF-M-regulated melanocyte development | 1.093666e-04 | 3.961 |
R-HSA-3371453 | Regulation of HSF1-mediated heat shock response | 1.364681e-04 | 3.865 |
R-HSA-9678108 | SARS-CoV-1 Infection | 1.365996e-04 | 3.865 |
R-HSA-5578749 | Transcriptional regulation by small RNAs | 1.497197e-04 | 3.825 |
R-HSA-9856649 | Transcriptional and post-translational regulation of MITF-M expression and activ... | 1.399450e-04 | 3.854 |
R-HSA-74160 | Gene expression (Transcription) | 1.689827e-04 | 3.772 |
R-HSA-68886 | M Phase | 1.795904e-04 | 3.746 |
R-HSA-1169408 | ISG15 antiviral mechanism | 1.823235e-04 | 3.739 |
R-HSA-162599 | Late Phase of HIV Life Cycle | 1.957529e-04 | 3.708 |
R-HSA-9705671 | SARS-CoV-2 activates/modulates innate and adaptive immune responses | 1.957529e-04 | 3.708 |
R-HSA-1483249 | Inositol phosphate metabolism | 2.392770e-04 | 3.621 |
R-HSA-69278 | Cell Cycle, Mitotic | 2.201052e-04 | 3.657 |
R-HSA-1169410 | Antiviral mechanism by IFN-stimulated genes | 3.166284e-04 | 3.499 |
R-HSA-9824446 | Viral Infection Pathways | 3.347759e-04 | 3.475 |
R-HSA-162587 | HIV Life Cycle | 3.548350e-04 | 3.450 |
R-HSA-3371556 | Cellular response to heat stress | 3.970061e-04 | 3.401 |
R-HSA-162909 | Host Interactions of HIV factors | 4.519864e-04 | 3.345 |
R-HSA-76005 | Response to elevated platelet cytosolic Ca2+ | 7.076941e-04 | 3.150 |
R-HSA-9614085 | FOXO-mediated transcription | 7.973472e-04 | 3.098 |
R-HSA-70171 | Glycolysis | 8.351968e-04 | 3.078 |
R-HSA-1810476 | RIP-mediated NFkB activation via ZBP1 | 9.074109e-04 | 3.042 |
R-HSA-3270619 | IRF3-mediated induction of type I IFN | 9.074109e-04 | 3.042 |
R-HSA-162582 | Signal Transduction | 1.119550e-03 | 2.951 |
R-HSA-211000 | Gene Silencing by RNA | 1.190223e-03 | 2.924 |
R-HSA-3134975 | Regulation of innate immune responses to cytosolic DNA | 1.207885e-03 | 2.918 |
R-HSA-6804114 | TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 1.207885e-03 | 2.918 |
R-HSA-2028269 | Signaling by Hippo | 1.378955e-03 | 2.860 |
R-HSA-1834941 | STING mediated induction of host immune responses | 1.765015e-03 | 2.753 |
R-HSA-5683826 | Surfactant metabolism | 1.789055e-03 | 2.747 |
R-HSA-8953854 | Metabolism of RNA | 1.829464e-03 | 2.738 |
R-HSA-70326 | Glucose metabolism | 1.926554e-03 | 2.715 |
R-HSA-3134963 | DEx/H-box helicases activate type I IFN and inflammatory cytokines production | 2.212689e-03 | 2.655 |
R-HSA-199991 | Membrane Trafficking | 2.424816e-03 | 2.615 |
R-HSA-1169091 | Activation of NF-kappaB in B cells | 2.813663e-03 | 2.551 |
R-HSA-5688890 | Defective CSF2RA causes SMDP4 | 2.871662e-03 | 2.542 |
R-HSA-5688849 | Defective CSF2RB causes SMDP5 | 2.871662e-03 | 2.542 |
R-HSA-8935964 | RUNX1 regulates expression of components of tight junctions | 2.871662e-03 | 2.542 |
R-HSA-162906 | HIV Infection | 3.116796e-03 | 2.506 |
R-HSA-933542 | TRAF6 mediated NF-kB activation | 3.303777e-03 | 2.481 |
R-HSA-114516 | Disinhibition of SNARE formation | 4.430143e-03 | 2.354 |
R-HSA-73857 | RNA Polymerase II Transcription | 4.523626e-03 | 2.345 |
R-HSA-8939246 | RUNX1 regulates transcription of genes involved in differentiation of myeloid ce... | 5.326458e-03 | 2.274 |
R-HSA-380284 | Loss of proteins required for interphase microtubule organization from the centr... | 5.395326e-03 | 2.268 |
R-HSA-380259 | Loss of Nlp from mitotic centrosomes | 5.395326e-03 | 2.268 |
R-HSA-166016 | Toll Like Receptor 4 (TLR4) Cascade | 6.054955e-03 | 2.218 |
R-HSA-8854518 | AURKA Activation by TPX2 | 6.226071e-03 | 2.206 |
R-HSA-170984 | ARMS-mediated activation | 6.298733e-03 | 2.201 |
R-HSA-430116 | GP1b-IX-V activation signalling | 6.298733e-03 | 2.201 |
R-HSA-448706 | Interleukin-1 processing | 6.298733e-03 | 2.201 |
R-HSA-73887 | Death Receptor Signaling | 7.148016e-03 | 2.146 |
R-HSA-1168372 | Downstream signaling events of B Cell Receptor (BCR) | 7.460201e-03 | 2.127 |
R-HSA-168273 | Influenza Viral RNA Transcription and Replication | 7.343205e-03 | 2.134 |
R-HSA-9610379 | HCMV Late Events | 7.745107e-03 | 2.111 |
R-HSA-5663205 | Infectious disease | 8.339653e-03 | 2.079 |
R-HSA-9832991 | Formation of the posterior neural plate | 8.465027e-03 | 2.072 |
R-HSA-163765 | ChREBP activates metabolic gene expression | 8.465027e-03 | 2.072 |
R-HSA-380270 | Recruitment of mitotic centrosome proteins and complexes | 8.484704e-03 | 2.071 |
R-HSA-76002 | Platelet activation, signaling and aggregation | 8.596339e-03 | 2.066 |
R-HSA-380287 | Centrosome maturation | 9.216455e-03 | 2.035 |
R-HSA-5687868 | Defective SFTPA2 causes IPF | 9.702661e-03 | 2.013 |
R-HSA-5619102 | SLC transporter disorders | 9.995771e-03 | 2.000 |
R-HSA-212436 | Generic Transcription Pathway | 1.016967e-02 | 1.993 |
R-HSA-6796648 | TP53 Regulates Transcription of DNA Repair Genes | 1.038928e-02 | 1.983 |
R-HSA-198323 | AKT phosphorylates targets in the cytosol | 1.091698e-02 | 1.962 |
R-HSA-1358803 | Downregulation of ERBB2:ERBB3 signaling | 1.091698e-02 | 1.962 |
R-HSA-5687613 | Diseases associated with surfactant metabolism | 1.091698e-02 | 1.962 |
R-HSA-2565942 | Regulation of PLK1 Activity at G2/M Transition | 1.301523e-02 | 1.886 |
R-HSA-5602358 | Diseases associated with the TLR signaling cascade | 1.126923e-02 | 1.948 |
R-HSA-5260271 | Diseases of Immune System | 1.126923e-02 | 1.948 |
R-HSA-9029558 | NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | 1.224640e-02 | 1.912 |
R-HSA-168179 | Toll Like Receptor TLR1:TLR2 Cascade | 1.114260e-02 | 1.953 |
R-HSA-181438 | Toll Like Receptor 2 (TLR2) Cascade | 1.114260e-02 | 1.953 |
R-HSA-72306 | tRNA processing | 1.101460e-02 | 1.958 |
R-HSA-114608 | Platelet degranulation | 1.320726e-02 | 1.879 |
R-HSA-168255 | Influenza Infection | 1.357226e-02 | 1.867 |
R-HSA-391160 | Signal regulatory protein family interactions | 1.364289e-02 | 1.865 |
R-HSA-72165 | mRNA Splicing - Minor Pathway | 1.627321e-02 | 1.789 |
R-HSA-5693571 | Nonhomologous End-Joining (NHEJ) | 1.789703e-02 | 1.747 |
R-HSA-380320 | Recruitment of NuMA to mitotic centrosomes | 1.550032e-02 | 1.810 |
R-HSA-5607761 | Dectin-1 mediated noncanonical NF-kB signaling | 1.549384e-02 | 1.810 |
R-HSA-5620912 | Anchoring of the basal body to the plasma membrane | 1.657233e-02 | 1.781 |
R-HSA-445989 | TAK1-dependent IKK and NF-kappa-B activation | 1.707425e-02 | 1.768 |
R-HSA-169893 | Prolonged ERK activation events | 1.663139e-02 | 1.779 |
R-HSA-193639 | p75NTR signals via NF-kB | 1.510501e-02 | 1.821 |
R-HSA-9823739 | Formation of the anterior neural plate | 1.510501e-02 | 1.821 |
R-HSA-446353 | Cell-extracellular matrix interactions | 1.510501e-02 | 1.821 |
R-HSA-5099900 | WNT5A-dependent internalization of FZD4 | 1.663139e-02 | 1.779 |
R-HSA-168898 | Toll-like Receptor Cascades | 1.759303e-02 | 1.755 |
R-HSA-5653656 | Vesicle-mediated transport | 1.599285e-02 | 1.796 |
R-HSA-1500931 | Cell-Cell communication | 1.785987e-02 | 1.748 |
R-HSA-4839726 | Chromatin organization | 1.697977e-02 | 1.770 |
R-HSA-72163 | mRNA Splicing - Major Pathway | 1.871363e-02 | 1.728 |
R-HSA-114294 | Activation, translocation and oligomerization of BAX | 1.931177e-02 | 1.714 |
R-HSA-3642279 | TGFBR2 MSI Frameshift Mutants in Cancer | 1.931177e-02 | 1.714 |
R-HSA-9663199 | Defective DNA double strand break response due to BRCA1 loss of function | 1.931177e-02 | 1.714 |
R-HSA-9699150 | Defective DNA double strand break response due to BARD1 loss of function | 1.931177e-02 | 1.714 |
R-HSA-9609690 | HCMV Early Events | 1.948729e-02 | 1.710 |
R-HSA-168928 | DDX58/IFIH1-mediated induction of interferon-alpha/beta | 2.006284e-02 | 1.698 |
R-HSA-1280215 | Cytokine Signaling in Immune system | 2.095047e-02 | 1.679 |
R-HSA-416993 | Trafficking of GluR2-containing AMPA receptors | 2.158250e-02 | 1.666 |
R-HSA-4419969 | Depolymerization of the Nuclear Lamina | 2.158250e-02 | 1.666 |
R-HSA-432722 | Golgi Associated Vesicle Biogenesis | 2.233806e-02 | 1.651 |
R-HSA-72172 | mRNA Splicing | 2.323928e-02 | 1.634 |
R-HSA-193704 | p75 NTR receptor-mediated signalling | 2.329323e-02 | 1.633 |
R-HSA-392517 | Rap1 signalling | 2.335243e-02 | 1.632 |
R-HSA-844456 | The NLRP3 inflammasome | 2.335243e-02 | 1.632 |
R-HSA-1643685 | Disease | 2.481247e-02 | 1.605 |
R-HSA-373753 | Nephrin family interactions | 2.517998e-02 | 1.599 |
R-HSA-6791312 | TP53 Regulates Transcription of Cell Cycle Genes | 2.628416e-02 | 1.580 |
R-HSA-168164 | Toll Like Receptor 3 (TLR3) Cascade | 2.831928e-02 | 1.548 |
R-HSA-176034 | Interactions of Tat with host cellular proteins | 2.882824e-02 | 1.540 |
R-HSA-5602636 | IKBKB deficiency causes SCID | 2.882824e-02 | 1.540 |
R-HSA-5083628 | Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3 | 2.882824e-02 | 1.540 |
R-HSA-5603027 | IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (E... | 2.882824e-02 | 1.540 |
R-HSA-9603505 | NTRK3 as a dependence receptor | 2.882824e-02 | 1.540 |
R-HSA-1227986 | Signaling by ERBB2 | 2.947272e-02 | 1.531 |
R-HSA-3642278 | Loss of Function of TGFBR2 in Cancer | 3.825293e-02 | 1.417 |
R-HSA-3656535 | TGFBR1 LBD Mutants in Cancer | 3.825293e-02 | 1.417 |
R-HSA-3645790 | TGFBR2 Kinase Domain Mutants in Cancer | 3.825293e-02 | 1.417 |
R-HSA-9615933 | Postmitotic nuclear pore complex (NPC) reformation | 3.948177e-02 | 1.404 |
R-HSA-5218921 | VEGFR2 mediated cell proliferation | 3.728542e-02 | 1.428 |
R-HSA-937061 | TRIF (TICAM1)-mediated TLR4 signaling | 3.227518e-02 | 1.491 |
R-HSA-166166 | MyD88-independent TLR4 cascade | 3.227518e-02 | 1.491 |
R-HSA-1266695 | Interleukin-7 signaling | 3.728542e-02 | 1.428 |
R-HSA-2219528 | PI3K/AKT Signaling in Cancer | 4.111414e-02 | 1.386 |
R-HSA-3000170 | Syndecan interactions | 3.304122e-02 | 1.481 |
R-HSA-5674400 | Constitutive Signaling by AKT1 E17K in Cancer | 3.304122e-02 | 1.481 |
R-HSA-1660499 | Synthesis of PIPs at the plasma membrane | 3.170699e-02 | 1.499 |
R-HSA-9022699 | MECP2 regulates neuronal receptors and channels | 3.948177e-02 | 1.404 |
R-HSA-3247509 | Chromatin modifying enzymes | 3.916038e-02 | 1.407 |
R-HSA-168643 | Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signali... | 3.402763e-02 | 1.468 |
R-HSA-6803204 | TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 4.172611e-02 | 1.380 |
R-HSA-983231 | Factors involved in megakaryocyte development and platelet production | 4.236318e-02 | 1.373 |
R-HSA-622312 | Inflammasomes | 4.401729e-02 | 1.356 |
R-HSA-199992 | trans-Golgi Network Vesicle Budding | 4.416307e-02 | 1.355 |
R-HSA-450531 | Regulation of mRNA stability by proteins that bind AU-rich elements | 4.416307e-02 | 1.355 |
R-HSA-913531 | Interferon Signaling | 4.537912e-02 | 1.343 |
R-HSA-9734281 | Defective HPRT1 disrupts guanine and hypoxanthine salvage | 4.758675e-02 | 1.323 |
R-HSA-3249367 | STAT6-mediated induction of chemokines | 4.758675e-02 | 1.323 |
R-HSA-8875513 | MET interacts with TNS proteins | 4.758675e-02 | 1.323 |
R-HSA-5619115 | Disorders of transmembrane transporters | 4.779584e-02 | 1.321 |
R-HSA-1250196 | SHC1 events in ERBB2 signaling | 4.873581e-02 | 1.312 |
R-HSA-8863795 | Downregulation of ERBB2 signaling | 4.873581e-02 | 1.312 |
R-HSA-9609646 | HCMV Infection | 4.994351e-02 | 1.302 |
R-HSA-399719 | Trafficking of AMPA receptors | 5.116097e-02 | 1.291 |
R-HSA-69275 | G2/M Transition | 5.138028e-02 | 1.289 |
R-HSA-109582 | Hemostasis | 5.209254e-02 | 1.283 |
R-HSA-4086400 | PCP/CE pathway | 5.264005e-02 | 1.279 |
R-HSA-453274 | Mitotic G2-G2/M phases | 5.313172e-02 | 1.275 |
R-HSA-111465 | Apoptotic cleavage of cellular proteins | 5.362865e-02 | 1.271 |
R-HSA-399721 | Glutamate binding, activation of AMPA receptors and synaptic plasticity | 5.613782e-02 | 1.251 |
R-HSA-6804758 | Regulation of TP53 Activity through Acetylation | 5.613782e-02 | 1.251 |
R-HSA-1306955 | GRB7 events in ERBB2 signaling | 5.683055e-02 | 1.245 |
R-HSA-3656532 | TGFBR1 KD Mutants in Cancer | 5.683055e-02 | 1.245 |
R-HSA-191650 | Regulation of gap junction activity | 5.683055e-02 | 1.245 |
R-HSA-9705677 | SARS-CoV-2 targets PDZ proteins in cell-cell junction | 5.683055e-02 | 1.245 |
R-HSA-211163 | AKT-mediated inactivation of FOXO1A | 5.683055e-02 | 1.245 |
R-HSA-205025 | NADE modulates death signalling | 5.683055e-02 | 1.245 |
R-HSA-68877 | Mitotic Prometaphase | 5.766140e-02 | 1.239 |
R-HSA-5686938 | Regulation of TLR by endogenous ligand | 6.127650e-02 | 1.213 |
R-HSA-3656534 | Loss of Function of TGFBR1 in Cancer | 6.598520e-02 | 1.181 |
R-HSA-3304356 | SMAD2/3 Phosphorylation Motif Mutants in Cancer | 6.598520e-02 | 1.181 |
R-HSA-8985586 | SLIT2:ROBO1 increases RHOA activity | 7.505155e-02 | 1.125 |
R-HSA-428890 | Role of ABL in ROBO-SLIT signaling | 9.292274e-02 | 1.032 |
R-HSA-9726840 | SHOC2 M1731 mutant abolishes MRAS complex function | 9.292274e-02 | 1.032 |
R-HSA-446107 | Type I hemidesmosome assembly | 1.017292e-01 | 0.993 |
R-HSA-9660537 | Signaling by MRAS-complex mutants | 1.017292e-01 | 0.993 |
R-HSA-9726842 | Gain-of-function MRAS complexes activate RAF signaling | 1.017292e-01 | 0.993 |
R-HSA-198693 | AKT phosphorylates targets in the nucleus | 1.104508e-01 | 0.957 |
R-HSA-2559584 | Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 1.528124e-01 | 0.816 |
R-HSA-9933947 | Formation of the non-canonical BAF (ncBAF) complex | 1.528124e-01 | 0.816 |
R-HSA-8847993 | ERBB2 Activates PTK6 Signaling | 1.610410e-01 | 0.793 |
R-HSA-6785631 | ERBB2 Regulates Cell Motility | 1.691902e-01 | 0.772 |
R-HSA-176412 | Phosphorylation of the APC/C | 1.772607e-01 | 0.751 |
R-HSA-9687136 | Aberrant regulation of mitotic exit in cancer due to RB1 defects | 1.772607e-01 | 0.751 |
R-HSA-72187 | mRNA 3'-end processing | 1.167287e-01 | 0.933 |
R-HSA-2173791 | TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 1.691902e-01 | 0.772 |
R-HSA-5676590 | NIK-->noncanonical NF-kB signaling | 8.042278e-02 | 1.095 |
R-HSA-3304351 | Signaling by TGF-beta Receptor Complex in Cancer | 8.403045e-02 | 1.076 |
R-HSA-69618 | Mitotic Spindle Checkpoint | 9.539758e-02 | 1.020 |
R-HSA-186797 | Signaling by PDGF | 1.494992e-01 | 0.825 |
R-HSA-1606341 | IRF3 mediated activation of type 1 IFN | 6.598520e-02 | 1.181 |
R-HSA-8857538 | PTK6 promotes HIF1A stabilization | 8.403045e-02 | 1.076 |
R-HSA-9828211 | Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | 1.017292e-01 | 0.993 |
R-HSA-9824878 | Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | 1.361138e-01 | 0.866 |
R-HSA-1221632 | Meiotic synapsis | 1.199172e-01 | 0.921 |
R-HSA-167172 | Transcription of the HIV genome | 1.699503e-01 | 0.770 |
R-HSA-9758274 | Regulation of NF-kappa B signaling | 1.772607e-01 | 0.751 |
R-HSA-111457 | Release of apoptotic factors from the mitochondria | 7.505155e-02 | 1.125 |
R-HSA-3304349 | Loss of Function of SMAD2/3 in Cancer | 7.505155e-02 | 1.125 |
R-HSA-9839389 | TGFBR3 regulates TGF-beta signaling | 9.292274e-02 | 1.032 |
R-HSA-8932506 | DAG1 core M1 glycosylations | 9.292274e-02 | 1.032 |
R-HSA-176974 | Unwinding of DNA | 1.104508e-01 | 0.957 |
R-HSA-75896 | Plasmalogen biosynthesis | 1.361138e-01 | 0.866 |
R-HSA-209560 | NF-kB is activated and signals survival | 1.361138e-01 | 0.866 |
R-HSA-141430 | Inactivation of APC/C via direct inhibition of the APC/C complex | 1.852534e-01 | 0.732 |
R-HSA-170968 | Frs2-mediated activation | 1.528124e-01 | 0.816 |
R-HSA-918233 | TRAF3-dependent IRF activation pathway | 1.852534e-01 | 0.732 |
R-HSA-9010642 | ROBO receptors bind AKAP5 | 1.017292e-01 | 0.993 |
R-HSA-9013973 | TICAM1-dependent activation of IRF3/IRF7 | 1.361138e-01 | 0.866 |
R-HSA-936964 | Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | 1.852534e-01 | 0.732 |
R-HSA-187687 | Signalling to ERKs | 6.390401e-02 | 1.194 |
R-HSA-8866654 | E3 ubiquitin ligases ubiquitinate target proteins | 1.167287e-01 | 0.933 |
R-HSA-5693565 | Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at... | 1.394755e-01 | 0.856 |
R-HSA-8932504 | DAG1 core M2 glycosylations | 1.017292e-01 | 0.993 |
R-HSA-9734207 | Nucleotide salvage defects | 1.017292e-01 | 0.993 |
R-HSA-2179392 | EGFR Transactivation by Gastrin | 1.190882e-01 | 0.924 |
R-HSA-450385 | Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 1.691902e-01 | 0.772 |
R-HSA-168927 | TICAM1, RIP1-mediated IKK complex recruitment | 1.691902e-01 | 0.772 |
R-HSA-141405 | Inhibition of the proteolytic activity of APC/C required for the onset of anapha... | 1.852534e-01 | 0.732 |
R-HSA-5607764 | CLEC7A (Dectin-1) signaling | 8.780766e-02 | 1.056 |
R-HSA-9020702 | Interleukin-1 signaling | 9.733599e-02 | 1.012 |
R-HSA-69052 | Switching of origins to a post-replicative state | 1.873292e-01 | 0.727 |
R-HSA-199418 | Negative regulation of the PI3K/AKT network | 1.691774e-01 | 0.772 |
R-HSA-5693606 | DNA Double Strand Break Response | 1.665084e-01 | 0.779 |
R-HSA-9818749 | Regulation of NFE2L2 gene expression | 8.403045e-02 | 1.076 |
R-HSA-8941413 | Events associated with phagocytolytic activity of PMN cells | 1.691902e-01 | 0.772 |
R-HSA-399997 | Acetylcholine regulates insulin secretion | 1.852534e-01 | 0.732 |
R-HSA-5660668 | CLEC7A/inflammasome pathway | 7.505155e-02 | 1.125 |
R-HSA-937039 | IRAK1 recruits IKK complex | 1.445035e-01 | 0.840 |
R-HSA-975144 | IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | 1.445035e-01 | 0.840 |
R-HSA-5684264 | MAP3K8 (TPL2)-dependent MAPK1/3 activation | 1.610410e-01 | 0.793 |
R-HSA-450513 | Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 1.691902e-01 | 0.772 |
R-HSA-73856 | RNA Polymerase II Transcription Termination | 1.461416e-01 | 0.835 |
R-HSA-975138 | TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 1.134044e-01 | 0.945 |
R-HSA-418597 | G alpha (z) signalling events | 1.263579e-01 | 0.898 |
R-HSA-446652 | Interleukin-1 family signaling | 8.589609e-02 | 1.066 |
R-HSA-9006925 | Intracellular signaling by second messengers | 1.440451e-01 | 0.842 |
R-HSA-9762293 | Regulation of CDH11 gene transcription | 1.104508e-01 | 0.957 |
R-HSA-975871 | MyD88 cascade initiated on plasma membrane | 9.156953e-02 | 1.038 |
R-HSA-168142 | Toll Like Receptor 10 (TLR10) Cascade | 9.156953e-02 | 1.038 |
R-HSA-168176 | Toll Like Receptor 5 (TLR5) Cascade | 9.156953e-02 | 1.038 |
R-HSA-446388 | Regulation of cytoskeletal remodeling and cell spreading by IPP complex componen... | 7.505155e-02 | 1.125 |
R-HSA-193692 | Regulated proteolysis of p75NTR | 1.104508e-01 | 0.957 |
R-HSA-9013700 | NOTCH4 Activation and Transmission of Signal to the Nucleus | 1.104508e-01 | 0.957 |
R-HSA-933543 | NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 1.276422e-01 | 0.894 |
R-HSA-9735804 | Diseases of nucleotide metabolism | 1.528124e-01 | 0.816 |
R-HSA-450604 | KSRP (KHSRP) binds and destabilizes mRNA | 1.772607e-01 | 0.751 |
R-HSA-975155 | MyD88 dependent cascade initiated on endosome | 1.154804e-01 | 0.937 |
R-HSA-983705 | Signaling by the B Cell Receptor (BCR) | 9.451863e-02 | 1.024 |
R-HSA-166058 | MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 1.414581e-01 | 0.849 |
R-HSA-168188 | Toll Like Receptor TLR6:TLR2 Cascade | 1.414581e-01 | 0.849 |
R-HSA-168181 | Toll Like Receptor 7/8 (TLR7/8) Cascade | 1.239259e-01 | 0.907 |
R-HSA-168138 | Toll Like Receptor 9 (TLR9) Cascade | 1.304036e-01 | 0.885 |
R-HSA-3000178 | ECM proteoglycans | 1.803459e-01 | 0.744 |
R-HSA-9860276 | SLC15A4:TASL-dependent IRF5 activation | 7.505155e-02 | 1.125 |
R-HSA-9754678 | SARS-CoV-2 modulates host translation machinery | 1.231271e-01 | 0.910 |
R-HSA-376176 | Signaling by ROBO receptors | 1.725685e-01 | 0.763 |
R-HSA-5617833 | Cilium Assembly | 1.485800e-01 | 0.828 |
R-HSA-8853884 | Transcriptional Regulation by VENTX | 8.042278e-02 | 1.095 |
R-HSA-2559583 | Cellular Senescence | 1.310918e-01 | 0.882 |
R-HSA-9033500 | TYSND1 cleaves peroxisomal proteins | 7.505155e-02 | 1.125 |
R-HSA-450520 | HuR (ELAVL1) binds and stabilizes mRNA | 1.104508e-01 | 0.957 |
R-HSA-8941332 | RUNX2 regulates genes involved in cell migration | 1.276422e-01 | 0.894 |
R-HSA-5663202 | Diseases of signal transduction by growth factor receptors and second messengers | 8.035584e-02 | 1.095 |
R-HSA-1433559 | Regulation of KIT signaling | 1.610410e-01 | 0.793 |
R-HSA-5357905 | Regulation of TNFR1 signaling | 9.809175e-02 | 1.008 |
R-HSA-75893 | TNF signaling | 1.296088e-01 | 0.887 |
R-HSA-73893 | DNA Damage Bypass | 1.073000e-01 | 0.969 |
R-HSA-204998 | Cell death signalling via NRAGE, NRIF and NADE | 1.873292e-01 | 0.727 |
R-HSA-9007101 | Rab regulation of trafficking | 1.369987e-01 | 0.863 |
R-HSA-8848021 | Signaling by PTK6 | 1.528724e-01 | 0.816 |
R-HSA-9006927 | Signaling by Non-Receptor Tyrosine Kinases | 1.528724e-01 | 0.816 |
R-HSA-9662834 | CD163 mediating an anti-inflammatory response | 1.276422e-01 | 0.894 |
R-HSA-209543 | p75NTR recruits signalling complexes | 1.445035e-01 | 0.840 |
R-HSA-9909649 | Regulation of PD-L1(CD274) transcription | 1.630791e-01 | 0.788 |
R-HSA-351906 | Apoptotic cleavage of cell adhesion proteins | 1.017292e-01 | 0.993 |
R-HSA-264870 | Caspase-mediated cleavage of cytoskeletal proteins | 1.104508e-01 | 0.957 |
R-HSA-6804759 | Regulation of TP53 Activity through Association with Co-factors | 1.528124e-01 | 0.816 |
R-HSA-446728 | Cell junction organization | 1.674298e-01 | 0.776 |
R-HSA-9006934 | Signaling by Receptor Tyrosine Kinases | 9.271444e-02 | 1.033 |
R-HSA-1483255 | PI Metabolism | 9.929041e-02 | 1.003 |
R-HSA-4420097 | VEGFA-VEGFR2 Pathway | 1.325892e-01 | 0.877 |
R-HSA-9860927 | Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZ... | 6.390401e-02 | 1.194 |
R-HSA-9660826 | Purinergic signaling in leishmaniasis infection | 9.809175e-02 | 1.008 |
R-HSA-9664424 | Cell recruitment (pro-inflammatory response) | 9.809175e-02 | 1.008 |
R-HSA-9706369 | Negative regulation of FLT3 | 1.772607e-01 | 0.751 |
R-HSA-168256 | Immune System | 1.342476e-01 | 0.872 |
R-HSA-194138 | Signaling by VEGF | 1.574370e-01 | 0.803 |
R-HSA-2022090 | Assembly of collagen fibrils and other multimeric structures | 1.394755e-01 | 0.856 |
R-HSA-5633007 | Regulation of TP53 Activity | 9.748096e-02 | 1.011 |
R-HSA-9764790 | Positive Regulation of CDH1 Gene Transcription | 1.190882e-01 | 0.924 |
R-HSA-8983711 | OAS antiviral response | 1.445035e-01 | 0.840 |
R-HSA-9692916 | SARS-CoV-1 activates/modulates innate immune responses | 1.167287e-01 | 0.933 |
R-HSA-8953750 | Transcriptional Regulation by E2F6 | 7.477922e-02 | 1.126 |
R-HSA-3858494 | Beta-catenin independent WNT signaling | 1.884637e-01 | 0.725 |
R-HSA-449147 | Signaling by Interleukins | 1.810640e-01 | 0.742 |
R-HSA-163685 | Integration of energy metabolism | 1.884637e-01 | 0.725 |
R-HSA-2426168 | Activation of gene expression by SREBF (SREBP) | 1.528724e-01 | 0.816 |
R-HSA-9607240 | FLT3 Signaling | 8.042278e-02 | 1.095 |
R-HSA-3214841 | PKMTs methylate histone lysines | 8.042278e-02 | 1.095 |
R-HSA-9755511 | KEAP1-NFE2L2 pathway | 8.449818e-02 | 1.073 |
R-HSA-2262752 | Cellular responses to stress | 8.335032e-02 | 1.079 |
R-HSA-8953897 | Cellular responses to stimuli | 1.052831e-01 | 0.978 |
R-HSA-8878166 | Transcriptional regulation by RUNX2 | 1.414581e-01 | 0.849 |
R-HSA-9856651 | MITF-M-dependent gene expression | 8.311162e-02 | 1.080 |
R-HSA-75153 | Apoptotic execution phase | 9.809175e-02 | 1.008 |
R-HSA-9772755 | Formation of WDR5-containing histone-modifying complexes | 6.390401e-02 | 1.194 |
R-HSA-674695 | RNA Polymerase II Pre-transcription Events | 1.908352e-01 | 0.719 |
R-HSA-176407 | Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 1.931688e-01 | 0.714 |
R-HSA-1963642 | PI3K events in ERBB2 signaling | 1.931688e-01 | 0.714 |
R-HSA-9909505 | Modulation of host responses by IFN-stimulated genes | 1.931688e-01 | 0.714 |
R-HSA-1660517 | Synthesis of PIPs at the late endosome membrane | 1.931688e-01 | 0.714 |
R-HSA-8852135 | Protein ubiquitination | 1.943500e-01 | 0.711 |
R-HSA-3000171 | Non-integrin membrane-ECM interactions | 1.943500e-01 | 0.711 |
R-HSA-5633008 | TP53 Regulates Transcription of Cell Death Genes | 1.943500e-01 | 0.711 |
R-HSA-1257604 | PIP3 activates AKT signaling | 1.952429e-01 | 0.709 |
R-HSA-68882 | Mitotic Anaphase | 1.997859e-01 | 0.699 |
R-HSA-111471 | Apoptotic factor-mediated response | 2.010079e-01 | 0.697 |
R-HSA-9024446 | NR1H2 and NR1H3-mediated signaling | 2.014041e-01 | 0.696 |
R-HSA-2555396 | Mitotic Metaphase and Anaphase | 2.017787e-01 | 0.695 |
R-HSA-1655829 | Regulation of cholesterol biosynthesis by SREBP (SREBF) | 2.084878e-01 | 0.681 |
R-HSA-174048 | APC/C:Cdc20 mediated degradation of Cyclin B | 2.087713e-01 | 0.680 |
R-HSA-9709603 | Impaired BRCA2 binding to PALB2 | 2.087713e-01 | 0.680 |
R-HSA-937041 | IKK complex recruitment mediated by RIP1 | 2.087713e-01 | 0.680 |
R-HSA-881907 | Gastrin-CREB signalling pathway via PKC and MAPK | 2.087713e-01 | 0.680 |
R-HSA-9913635 | Strand-asynchronous mitochondrial DNA replication | 2.087713e-01 | 0.680 |
R-HSA-2995410 | Nuclear Envelope (NE) Reassembly | 2.120395e-01 | 0.674 |
R-HSA-5693607 | Processing of DNA double-strand break ends | 2.155973e-01 | 0.666 |
R-HSA-9701193 | Defective homologous recombination repair (HRR) due to PALB2 loss of function | 2.164597e-01 | 0.665 |
R-HSA-9704646 | Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of... | 2.164597e-01 | 0.665 |
R-HSA-9704331 | Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of... | 2.164597e-01 | 0.665 |
R-HSA-9701192 | Defective homologous recombination repair (HRR) due to BRCA1 loss of function | 2.164597e-01 | 0.665 |
R-HSA-8848584 | Wax and plasmalogen biosynthesis | 2.164597e-01 | 0.665 |
R-HSA-389513 | Co-inhibition by CTLA4 | 2.164597e-01 | 0.665 |
R-HSA-416572 | Sema4D induced cell migration and growth-cone collapse | 2.164597e-01 | 0.665 |
R-HSA-2559582 | Senescence-Associated Secretory Phenotype (SASP) | 2.191605e-01 | 0.659 |
R-HSA-8878171 | Transcriptional regulation by RUNX1 | 2.199740e-01 | 0.658 |
R-HSA-69242 | S Phase | 2.209046e-01 | 0.656 |
R-HSA-166520 | Signaling by NTRKs | 2.209046e-01 | 0.656 |
R-HSA-5668541 | TNFR2 non-canonical NF-kB pathway | 2.227289e-01 | 0.652 |
R-HSA-179409 | APC-Cdc20 mediated degradation of Nek2A | 2.240739e-01 | 0.650 |
R-HSA-202040 | G-protein activation | 2.240739e-01 | 0.650 |
R-HSA-5357786 | TNFR1-induced proapoptotic signaling | 2.240739e-01 | 0.650 |
R-HSA-9939291 | Matriglycan biosynthesis on DAG1 | 2.240739e-01 | 0.650 |
R-HSA-5687128 | MAPK6/MAPK4 signaling | 2.298793e-01 | 0.639 |
R-HSA-1500620 | Meiosis | 2.298793e-01 | 0.639 |
R-HSA-9034015 | Signaling by NTRK3 (TRKC) | 2.316146e-01 | 0.635 |
R-HSA-141444 | Amplification of signal from unattached kinetochores via a MAD2 inhibitory si... | 2.334604e-01 | 0.632 |
R-HSA-141424 | Amplification of signal from the kinetochores | 2.334604e-01 | 0.632 |
R-HSA-8876198 | RAB GEFs exchange GTP for GDP on RABs | 2.334604e-01 | 0.632 |
R-HSA-5693532 | DNA Double-Strand Break Repair | 2.336754e-01 | 0.631 |
R-HSA-69306 | DNA Replication | 2.336754e-01 | 0.631 |
R-HSA-6807505 | RNA polymerase II transcribes snRNA genes | 2.370450e-01 | 0.625 |
R-HSA-6804756 | Regulation of TP53 Activity through Phosphorylation | 2.370450e-01 | 0.625 |
R-HSA-2173788 | Downregulation of TGF-beta receptor signaling | 2.390824e-01 | 0.621 |
R-HSA-166208 | mTORC1-mediated signalling | 2.390824e-01 | 0.621 |
R-HSA-975578 | Reactions specific to the complex N-glycan synthesis pathway | 2.390824e-01 | 0.621 |
R-HSA-392451 | G beta:gamma signalling through PI3Kgamma | 2.464781e-01 | 0.608 |
R-HSA-9634638 | Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 2.464781e-01 | 0.608 |
R-HSA-1855167 | Synthesis of pyrophosphates in the cytosol | 2.464781e-01 | 0.608 |
R-HSA-202424 | Downstream TCR signaling | 2.514096e-01 | 0.600 |
R-HSA-9006936 | Signaling by TGFB family members | 2.517689e-01 | 0.599 |
R-HSA-9665686 | Signaling by ERBB2 TMD/JMD mutants | 2.538024e-01 | 0.596 |
R-HSA-5621575 | CD209 (DC-SIGN) signaling | 2.538024e-01 | 0.596 |
R-HSA-110314 | Recognition of DNA damage by PCNA-containing replication complex | 2.538024e-01 | 0.596 |
R-HSA-9836573 | Mitochondrial RNA degradation | 2.538024e-01 | 0.596 |
R-HSA-8863678 | Neurodegenerative Diseases | 2.538024e-01 | 0.596 |
R-HSA-8862803 | Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's dis... | 2.538024e-01 | 0.596 |
R-HSA-8986944 | Transcriptional Regulation by MECP2 | 2.550055e-01 | 0.593 |
R-HSA-1474244 | Extracellular matrix organization | 2.587408e-01 | 0.587 |
R-HSA-5693554 | Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SD... | 2.610560e-01 | 0.583 |
R-HSA-420029 | Tight junction interactions | 2.610560e-01 | 0.583 |
R-HSA-1660516 | Synthesis of PIPs at the early endosome membrane | 2.610560e-01 | 0.583 |
R-HSA-9932444 | ATP-dependent chromatin remodelers | 2.610560e-01 | 0.583 |
R-HSA-9932451 | SWI/SNF chromatin remodelers | 2.610560e-01 | 0.583 |
R-HSA-400685 | Sema4D in semaphorin signaling | 2.610560e-01 | 0.583 |
R-HSA-2467813 | Separation of Sister Chromatids | 2.622013e-01 | 0.581 |
R-HSA-68867 | Assembly of the pre-replicative complex | 2.657983e-01 | 0.575 |
R-HSA-9703465 | Signaling by FLT3 fusion proteins | 2.682395e-01 | 0.571 |
R-HSA-1660514 | Synthesis of PIPs at the Golgi membrane | 2.682395e-01 | 0.571 |
R-HSA-5689901 | Metalloprotease DUBs | 2.682395e-01 | 0.571 |
R-HSA-525793 | Myogenesis | 2.682395e-01 | 0.571 |
R-HSA-2219530 | Constitutive Signaling by Aberrant PI3K in Cancer | 2.693966e-01 | 0.570 |
R-HSA-1474290 | Collagen formation | 2.693966e-01 | 0.570 |
R-HSA-167243 | Tat-mediated HIV elongation arrest and recovery | 2.753536e-01 | 0.560 |
R-HSA-167238 | Pausing and recovery of Tat-mediated HIV elongation | 2.753536e-01 | 0.560 |
R-HSA-389357 | CD28 dependent PI3K/Akt signaling | 2.753536e-01 | 0.560 |
R-HSA-3928663 | EPHA-mediated growth cone collapse | 2.753536e-01 | 0.560 |
R-HSA-5357956 | TNFR1-induced NF-kappa-B signaling pathway | 2.753536e-01 | 0.560 |
R-HSA-201451 | Signaling by BMP | 2.753536e-01 | 0.560 |
R-HSA-9734009 | Defective Intrinsic Pathway for Apoptosis | 2.753536e-01 | 0.560 |
R-HSA-597592 | Post-translational protein modification | 2.818457e-01 | 0.550 |
R-HSA-167287 | HIV elongation arrest and recovery | 2.823989e-01 | 0.549 |
R-HSA-167290 | Pausing and recovery of HIV elongation | 2.823989e-01 | 0.549 |
R-HSA-5205685 | PINK1-PRKN Mediated Mitophagy | 2.823989e-01 | 0.549 |
R-HSA-5620971 | Pyroptosis | 2.823989e-01 | 0.549 |
R-HSA-5621481 | C-type lectin receptors (CLRs) | 2.832214e-01 | 0.548 |
R-HSA-388841 | Regulation of T cell activation by CD28 family | 2.833115e-01 | 0.548 |
R-HSA-170834 | Signaling by TGF-beta Receptor Complex | 2.837836e-01 | 0.547 |
R-HSA-9909648 | Regulation of PD-L1(CD274) expression | 2.858606e-01 | 0.544 |
R-HSA-5683057 | MAPK family signaling cascades | 2.884468e-01 | 0.540 |
R-HSA-9709570 | Impaired BRCA2 binding to RAD51 | 2.893762e-01 | 0.539 |
R-HSA-9664565 | Signaling by ERBB2 KD Mutants | 2.893762e-01 | 0.539 |
R-HSA-5656169 | Termination of translesion DNA synthesis | 2.893762e-01 | 0.539 |
R-HSA-9759475 | Regulation of CDH11 Expression and Function | 2.893762e-01 | 0.539 |
R-HSA-210745 | Regulation of gene expression in beta cells | 2.893762e-01 | 0.539 |
R-HSA-3214847 | HATs acetylate histones | 2.909691e-01 | 0.536 |
R-HSA-68962 | Activation of the pre-replicative complex | 2.962861e-01 | 0.528 |
R-HSA-9687139 | Aberrant regulation of mitotic cell cycle due to RB1 defects | 2.962861e-01 | 0.528 |
R-HSA-1227990 | Signaling by ERBB2 in Cancer | 2.962861e-01 | 0.528 |
R-HSA-9008059 | Interleukin-37 signaling | 2.962861e-01 | 0.528 |
R-HSA-186763 | Downstream signal transduction | 3.031292e-01 | 0.518 |
R-HSA-936440 | Negative regulators of DDX58/IFIH1 signaling | 3.031292e-01 | 0.518 |
R-HSA-111885 | Opioid Signalling | 3.088901e-01 | 0.510 |
R-HSA-9860931 | Response of endothelial cells to shear stress | 3.088901e-01 | 0.510 |
R-HSA-9711123 | Cellular response to chemical stress | 3.094320e-01 | 0.509 |
R-HSA-9675126 | Diseases of mitotic cell cycle | 3.099062e-01 | 0.509 |
R-HSA-69190 | DNA strand elongation | 3.099062e-01 | 0.509 |
R-HSA-8931838 | DAG1 glycosylations | 3.099062e-01 | 0.509 |
R-HSA-73894 | DNA Repair | 3.130322e-01 | 0.504 |
R-HSA-5685938 | HDR through Single Strand Annealing (SSA) | 3.166177e-01 | 0.499 |
R-HSA-5693568 | Resolution of D-loop Structures through Holliday Junction Intermediates | 3.166177e-01 | 0.499 |
R-HSA-1855204 | Synthesis of IP3 and IP4 in the cytosol | 3.166177e-01 | 0.499 |
R-HSA-176187 | Activation of ATR in response to replication stress | 3.166177e-01 | 0.499 |
R-HSA-9764260 | Regulation of Expression and Function of Type II Classical Cadherins | 3.166177e-01 | 0.499 |
R-HSA-397795 | G-protein beta:gamma signalling | 3.166177e-01 | 0.499 |
R-HSA-69273 | Cyclin A/B1/B2 associated events during G2/M transition | 3.166177e-01 | 0.499 |
R-HSA-71387 | Metabolism of carbohydrates and carbohydrate derivatives | 3.203508e-01 | 0.494 |
R-HSA-69239 | Synthesis of DNA | 3.231643e-01 | 0.491 |
R-HSA-9725370 | Signaling by ALK fusions and activated point mutants | 3.231643e-01 | 0.491 |
R-HSA-9700206 | Signaling by ALK in cancer | 3.231643e-01 | 0.491 |
R-HSA-390522 | Striated Muscle Contraction | 3.232644e-01 | 0.490 |
R-HSA-5693537 | Resolution of D-Loop Structures | 3.232644e-01 | 0.490 |
R-HSA-199220 | Vitamin B5 (pantothenate) metabolism | 3.232644e-01 | 0.490 |
R-HSA-5673000 | RAF activation | 3.298468e-01 | 0.482 |
R-HSA-9675136 | Diseases of DNA Double-Strand Break Repair | 3.298468e-01 | 0.482 |
R-HSA-9701190 | Defective homologous recombination repair (HRR) due to BRCA2 loss of function | 3.298468e-01 | 0.482 |
R-HSA-5205647 | Mitophagy | 3.298468e-01 | 0.482 |
R-HSA-168638 | NOD1/2 Signaling Pathway | 3.298468e-01 | 0.482 |
R-HSA-69002 | DNA Replication Pre-Initiation | 3.302749e-01 | 0.481 |
R-HSA-9648025 | EML4 and NUDC in mitotic spindle formation | 3.302749e-01 | 0.481 |
R-HSA-202403 | TCR signaling | 3.338226e-01 | 0.476 |
R-HSA-5693616 | Presynaptic phase of homologous DNA pairing and strand exchange | 3.363656e-01 | 0.473 |
R-HSA-9658195 | Leishmania infection | 3.379897e-01 | 0.471 |
R-HSA-9824443 | Parasitic Infection Pathways | 3.379897e-01 | 0.471 |
R-HSA-432720 | Lysosome Vesicle Biogenesis | 3.428214e-01 | 0.465 |
R-HSA-9682385 | FLT3 signaling in disease | 3.428214e-01 | 0.465 |
R-HSA-3371511 | HSF1 activation | 3.428214e-01 | 0.465 |
R-HSA-111933 | Calmodulin induced events | 3.428214e-01 | 0.465 |
R-HSA-111997 | CaM pathway | 3.428214e-01 | 0.465 |
R-HSA-8853659 | RET signaling | 3.428214e-01 | 0.465 |
R-HSA-6804757 | Regulation of TP53 Degradation | 3.428214e-01 | 0.465 |
R-HSA-1280218 | Adaptive Immune System | 3.473624e-01 | 0.459 |
R-HSA-5693567 | HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 3.479580e-01 | 0.458 |
R-HSA-9855142 | Cellular responses to mechanical stimuli | 3.479580e-01 | 0.458 |
R-HSA-933541 | TRAF6 mediated IRF7 activation | 3.492147e-01 | 0.457 |
R-HSA-3769402 | Deactivation of the beta-catenin transactivating complex | 3.492147e-01 | 0.457 |
R-HSA-6802948 | Signaling by high-kinase activity BRAF mutants | 3.492147e-01 | 0.457 |
R-HSA-419037 | NCAM1 interactions | 3.492147e-01 | 0.457 |
R-HSA-2173796 | SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 3.492147e-01 | 0.457 |
R-HSA-8948216 | Collagen chain trimerization | 3.492147e-01 | 0.457 |
R-HSA-5693579 | Homologous DNA Pairing and Strand Exchange | 3.555463e-01 | 0.449 |
R-HSA-8875878 | MET promotes cell motility | 3.555463e-01 | 0.449 |
R-HSA-74217 | Purine salvage | 3.555463e-01 | 0.449 |
R-HSA-389948 | Co-inhibition by PD-1 | 3.601086e-01 | 0.444 |
R-HSA-167200 | Formation of HIV-1 elongation complex containing HIV-1 Tat | 3.618167e-01 | 0.442 |
R-HSA-6806003 | Regulation of TP53 Expression and Degradation | 3.618167e-01 | 0.442 |
R-HSA-1266738 | Developmental Biology | 3.642252e-01 | 0.439 |
R-HSA-167246 | Tat-mediated elongation of the HIV-1 transcript | 3.680264e-01 | 0.434 |
R-HSA-167152 | Formation of HIV elongation complex in the absence of HIV Tat | 3.680264e-01 | 0.434 |
R-HSA-73779 | RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 3.680264e-01 | 0.434 |
R-HSA-167169 | HIV Transcription Elongation | 3.680264e-01 | 0.434 |
R-HSA-427389 | ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 3.680264e-01 | 0.434 |
R-HSA-9843743 | Transcriptional regulation of brown and beige adipocyte differentiation | 3.680264e-01 | 0.434 |
R-HSA-9844594 | Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | 3.680264e-01 | 0.434 |
R-HSA-9604323 | Negative regulation of NOTCH4 signaling | 3.680264e-01 | 0.434 |
R-HSA-975576 | N-glycan antennae elongation in the medial/trans-Golgi | 3.680264e-01 | 0.434 |
R-HSA-5693538 | Homology Directed Repair | 3.689707e-01 | 0.433 |
R-HSA-9929491 | SPOP-mediated proteasomal degradation of PD-L1(CD274) | 3.741761e-01 | 0.427 |
R-HSA-5218920 | VEGFR2 mediated vascular permeability | 3.741761e-01 | 0.427 |
R-HSA-9694548 | Maturation of spike protein | 3.741761e-01 | 0.427 |
R-HSA-110313 | Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA templa... | 3.741761e-01 | 0.427 |
R-HSA-195721 | Signaling by WNT | 3.754710e-01 | 0.425 |
R-HSA-2500257 | Resolution of Sister Chromatid Cohesion | 3.793797e-01 | 0.421 |
R-HSA-167161 | HIV Transcription Initiation | 3.802663e-01 | 0.420 |
R-HSA-75953 | RNA Polymerase II Transcription Initiation | 3.802663e-01 | 0.420 |
R-HSA-9656223 | Signaling by RAF1 mutants | 3.802663e-01 | 0.420 |
R-HSA-5674135 | MAP2K and MAPK activation | 3.802663e-01 | 0.420 |
R-HSA-167162 | RNA Polymerase II HIV Promoter Escape | 3.802663e-01 | 0.420 |
R-HSA-6811438 | Intra-Golgi traffic | 3.802663e-01 | 0.420 |
R-HSA-5675221 | Negative regulation of MAPK pathway | 3.802663e-01 | 0.420 |
R-HSA-6811558 | PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 3.862795e-01 | 0.413 |
R-HSA-73762 | RNA Polymerase I Transcription Initiation | 3.862976e-01 | 0.413 |
R-HSA-165159 | MTOR signalling | 3.862976e-01 | 0.413 |
R-HSA-111996 | Ca-dependent events | 3.862976e-01 | 0.413 |
R-HSA-512988 | Interleukin-3, Interleukin-5 and GM-CSF signaling | 3.862976e-01 | 0.413 |
R-HSA-379716 | Cytosolic tRNA aminoacylation | 3.862976e-01 | 0.413 |
R-HSA-73776 | RNA Polymerase II Promoter Escape | 3.922706e-01 | 0.406 |
R-HSA-2173789 | TGF-beta receptor signaling activates SMADs | 3.922706e-01 | 0.406 |
R-HSA-8854214 | TBC/RABGAPs | 3.922706e-01 | 0.406 |
R-HSA-1433557 | Signaling by SCF-KIT | 3.922706e-01 | 0.406 |
R-HSA-69206 | G1/S Transition | 3.965667e-01 | 0.402 |
R-HSA-9907900 | Proteasome assembly | 3.981859e-01 | 0.400 |
R-HSA-76042 | RNA Polymerase II Transcription Initiation And Promoter Clearance | 4.040439e-01 | 0.394 |
R-HSA-1489509 | DAG and IP3 signaling | 4.040439e-01 | 0.394 |
R-HSA-187037 | Signaling by NTRK1 (TRKA) | 4.067749e-01 | 0.391 |
R-HSA-9649948 | Signaling downstream of RAS mutants | 4.098453e-01 | 0.387 |
R-HSA-174084 | Autodegradation of Cdh1 by Cdh1:APC/C | 4.098453e-01 | 0.387 |
R-HSA-6802955 | Paradoxical activation of RAF signaling by kinase inactive BRAF | 4.098453e-01 | 0.387 |
R-HSA-6802946 | Signaling by moderate kinase activity BRAF mutants | 4.098453e-01 | 0.387 |
R-HSA-6802949 | Signaling by RAS mutants | 4.098453e-01 | 0.387 |
R-HSA-9675135 | Diseases of DNA repair | 4.098453e-01 | 0.387 |
R-HSA-9839373 | Signaling by TGFBR3 | 4.098453e-01 | 0.387 |
R-HSA-2514859 | Inactivation, recovery and regulation of the phototransduction cascade | 4.098453e-01 | 0.387 |
R-HSA-174154 | APC/C:Cdc20 mediated degradation of Securin | 4.155905e-01 | 0.381 |
R-HSA-1474165 | Reproduction | 4.169003e-01 | 0.380 |
R-HSA-9843745 | Adipogenesis | 4.202563e-01 | 0.376 |
R-HSA-389356 | Co-stimulation by CD28 | 4.212802e-01 | 0.375 |
R-HSA-1852241 | Organelle biogenesis and maintenance | 4.236908e-01 | 0.373 |
R-HSA-157858 | Gap junction trafficking and regulation | 4.269148e-01 | 0.370 |
R-HSA-9748787 | Azathioprine ADME | 4.324949e-01 | 0.364 |
R-HSA-2162123 | Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 4.324949e-01 | 0.364 |
R-HSA-912446 | Meiotic recombination | 4.380210e-01 | 0.359 |
R-HSA-2514856 | The phototransduction cascade | 4.380210e-01 | 0.359 |
R-HSA-174184 | Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 4.434937e-01 | 0.353 |
R-HSA-112382 | Formation of RNA Pol II elongation complex | 4.434937e-01 | 0.353 |
R-HSA-68949 | Orc1 removal from chromatin | 4.434937e-01 | 0.353 |
R-HSA-6794361 | Neurexins and neuroligins | 4.434937e-01 | 0.353 |
R-HSA-179419 | APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of th... | 4.489133e-01 | 0.348 |
R-HSA-174178 | APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins ... | 4.489133e-01 | 0.348 |
R-HSA-75955 | RNA Polymerase II Transcription Elongation | 4.489133e-01 | 0.348 |
R-HSA-9639288 | Amino acids regulate mTORC1 | 4.489133e-01 | 0.348 |
R-HSA-8948751 | Regulation of PTEN stability and activity | 4.489133e-01 | 0.348 |
R-HSA-6807070 | PTEN Regulation | 4.500072e-01 | 0.347 |
R-HSA-9664417 | Leishmania phagocytosis | 4.532603e-01 | 0.344 |
R-HSA-9664407 | Parasite infection | 4.532603e-01 | 0.344 |
R-HSA-9664422 | FCGR3A-mediated phagocytosis | 4.532603e-01 | 0.344 |
R-HSA-69017 | CDK-mediated phosphorylation and removal of Cdc6 | 4.542806e-01 | 0.343 |
R-HSA-2029482 | Regulation of actin dynamics for phagocytic cup formation | 4.565026e-01 | 0.341 |
R-HSA-176409 | APC/C:Cdc20 mediated degradation of mitotic proteins | 4.595959e-01 | 0.338 |
R-HSA-3214815 | HDACs deacetylate histones | 4.595959e-01 | 0.338 |
R-HSA-176814 | Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 4.648597e-01 | 0.333 |
R-HSA-193648 | NRAGE signals death through JNK | 4.648597e-01 | 0.333 |
R-HSA-9662361 | Sensory processing of sound by outer hair cells of the cochlea | 4.648597e-01 | 0.333 |
R-HSA-2173793 | Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 4.648597e-01 | 0.333 |
R-HSA-2871837 | FCERI mediated NF-kB activation | 4.693610e-01 | 0.328 |
R-HSA-453279 | Mitotic G1 phase and G1/S transition | 4.757226e-01 | 0.323 |
R-HSA-422475 | Axon guidance | 4.758074e-01 | 0.323 |
R-HSA-9033241 | Peroxisomal protein import | 4.803475e-01 | 0.318 |
R-HSA-186712 | Regulation of beta-cell development | 4.803475e-01 | 0.318 |
R-HSA-9758941 | Gastrulation | 4.851785e-01 | 0.314 |
R-HSA-9845323 | Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | 4.854105e-01 | 0.314 |
R-HSA-8943724 | Regulation of PTEN gene transcription | 4.854105e-01 | 0.314 |
R-HSA-1660661 | Sphingolipid de novo biosynthesis | 4.854105e-01 | 0.314 |
R-HSA-9764725 | Negative Regulation of CDH1 Gene Transcription | 4.854105e-01 | 0.314 |
R-HSA-379724 | tRNA Aminoacylation | 4.854105e-01 | 0.314 |
R-HSA-9679191 | Potential therapeutics for SARS | 4.883071e-01 | 0.311 |
R-HSA-450294 | MAP kinase activation | 4.904245e-01 | 0.309 |
R-HSA-112043 | PLC beta mediated events | 4.904245e-01 | 0.309 |
R-HSA-8956321 | Nucleotide salvage | 4.904245e-01 | 0.309 |
R-HSA-1442490 | Collagen degradation | 4.904245e-01 | 0.309 |
R-HSA-176408 | Regulation of APC/C activators between G1/S and early anaphase | 4.953899e-01 | 0.305 |
R-HSA-2559586 | DNA Damage/Telomere Stress Induced Senescence | 4.953899e-01 | 0.305 |
R-HSA-375165 | NCAM signaling for neurite out-growth | 4.953899e-01 | 0.305 |
R-HSA-6790901 | rRNA modification in the nucleus and cytosol | 5.003072e-01 | 0.301 |
R-HSA-373755 | Semaphorin interactions | 5.003072e-01 | 0.301 |
R-HSA-9917777 | Epigenetic regulation by WDR5-containing histone modifying complexes | 5.007031e-01 | 0.300 |
R-HSA-5688426 | Deubiquitination | 5.031976e-01 | 0.298 |
R-HSA-392499 | Metabolism of proteins | 5.066534e-01 | 0.295 |
R-HSA-6802952 | Signaling by BRAF and RAF1 fusions | 5.099995e-01 | 0.292 |
R-HSA-9006931 | Signaling by Nuclear Receptors | 5.147839e-01 | 0.288 |
R-HSA-5685942 | HDR through Homologous Recombination (HRR) | 5.195050e-01 | 0.284 |
R-HSA-112040 | G-protein mediated events | 5.195050e-01 | 0.284 |
R-HSA-1650814 | Collagen biosynthesis and modifying enzymes | 5.241887e-01 | 0.281 |
R-HSA-9662360 | Sensory processing of sound by inner hair cells of the cochlea | 5.241887e-01 | 0.281 |
R-HSA-5218859 | Regulated Necrosis | 5.241887e-01 | 0.281 |
R-HSA-9840310 | Glycosphingolipid catabolism | 5.334207e-01 | 0.273 |
R-HSA-9843940 | Regulation of endogenous retroelements by KRAB-ZFP proteins | 5.334207e-01 | 0.273 |
R-HSA-75105 | Fatty acyl-CoA biosynthesis | 5.334207e-01 | 0.273 |
R-HSA-448424 | Interleukin-17 signaling | 5.334207e-01 | 0.273 |
R-HSA-9764560 | Regulation of CDH1 Gene Transcription | 5.334207e-01 | 0.273 |
R-HSA-69202 | Cyclin E associated events during G1/S transition | 5.334207e-01 | 0.273 |
R-HSA-9675108 | Nervous system development | 5.374605e-01 | 0.270 |
R-HSA-453276 | Regulation of mitotic cell cycle | 5.379696e-01 | 0.269 |
R-HSA-174143 | APC/C-mediated degradation of cell cycle proteins | 5.379696e-01 | 0.269 |
R-HSA-5250913 | Positive epigenetic regulation of rRNA expression | 5.379696e-01 | 0.269 |
R-HSA-3906995 | Diseases associated with O-glycosylation of proteins | 5.379696e-01 | 0.269 |
R-HSA-69656 | Cyclin A:Cdk2-associated events at S phase entry | 5.424746e-01 | 0.266 |
R-HSA-499943 | Interconversion of nucleotide di- and triphosphates | 5.424746e-01 | 0.266 |
R-HSA-4086398 | Ca2+ pathway | 5.469358e-01 | 0.262 |
R-HSA-9013694 | Signaling by NOTCH4 | 5.513539e-01 | 0.259 |
R-HSA-1222556 | ROS and RNS production in phagocytes | 5.513539e-01 | 0.259 |
R-HSA-1236394 | Signaling by ERBB4 | 5.513539e-01 | 0.259 |
R-HSA-983169 | Class I MHC mediated antigen processing & presentation | 5.568692e-01 | 0.254 |
R-HSA-73854 | RNA Polymerase I Promoter Clearance | 5.600619e-01 | 0.252 |
R-HSA-5689603 | UCH proteinases | 5.600619e-01 | 0.252 |
R-HSA-168249 | Innate Immune System | 5.601672e-01 | 0.252 |
R-HSA-2029480 | Fcgamma receptor (FCGR) dependent phagocytosis | 5.625515e-01 | 0.250 |
R-HSA-9694635 | Translation of Structural Proteins | 5.643528e-01 | 0.248 |
R-HSA-983168 | Antigen processing: Ubiquitination & Proteasome degradation | 5.662839e-01 | 0.247 |
R-HSA-73864 | RNA Polymerase I Transcription | 5.686021e-01 | 0.245 |
R-HSA-416482 | G alpha (12/13) signalling events | 5.686021e-01 | 0.245 |
R-HSA-216083 | Integrin cell surface interactions | 5.686021e-01 | 0.245 |
R-HSA-9659379 | Sensory processing of sound | 5.728101e-01 | 0.242 |
R-HSA-9833482 | PKR-mediated signaling | 5.769774e-01 | 0.239 |
R-HSA-6806834 | Signaling by MET | 5.769774e-01 | 0.239 |
R-HSA-5673001 | RAF/MAP kinase cascade | 5.818320e-01 | 0.235 |
R-HSA-1483257 | Phospholipid metabolism | 5.948786e-01 | 0.226 |
R-HSA-375276 | Peptide ligand-binding receptors | 5.953739e-01 | 0.225 |
R-HSA-5684996 | MAPK1/MAPK3 signaling | 5.970275e-01 | 0.224 |
R-HSA-6802957 | Oncogenic MAPK signaling | 5.972156e-01 | 0.224 |
R-HSA-6794362 | Protein-protein interactions at synapses | 5.972156e-01 | 0.224 |
R-HSA-9909615 | Regulation of PD-L1(CD274) Post-translational modification | 6.011463e-01 | 0.221 |
R-HSA-6785807 | Interleukin-4 and Interleukin-13 signaling | 6.110867e-01 | 0.214 |
R-HSA-9663891 | Selective autophagy | 6.127111e-01 | 0.213 |
R-HSA-9645723 | Diseases of programmed cell death | 6.127111e-01 | 0.213 |
R-HSA-1236974 | ER-Phagosome pathway | 6.164915e-01 | 0.210 |
R-HSA-1912408 | Pre-NOTCH Transcription and Translation | 6.239426e-01 | 0.205 |
R-HSA-2682334 | EPH-Ephrin signaling | 6.312499e-01 | 0.200 |
R-HSA-9772573 | Late SARS-CoV-2 Infection Events | 6.312499e-01 | 0.200 |
R-HSA-428157 | Sphingolipid metabolism | 6.337836e-01 | 0.198 |
R-HSA-948021 | Transport to the Golgi and subsequent modification | 6.362411e-01 | 0.196 |
R-HSA-5668914 | Diseases of metabolism | 6.383264e-01 | 0.195 |
R-HSA-2454202 | Fc epsilon receptor (FCERI) signaling | 6.386857e-01 | 0.195 |
R-HSA-6807878 | COPI-mediated anterograde transport | 6.489067e-01 | 0.188 |
R-HSA-381340 | Transcriptional regulation of white adipocyte differentiation | 6.489067e-01 | 0.188 |
R-HSA-212165 | Epigenetic regulation of gene expression | 6.522207e-01 | 0.186 |
R-HSA-422356 | Regulation of insulin secretion | 6.557318e-01 | 0.183 |
R-HSA-112314 | Neurotransmitter receptors and postsynaptic signal transmission | 6.624305e-01 | 0.179 |
R-HSA-9009391 | Extra-nuclear estrogen signaling | 6.657231e-01 | 0.177 |
R-HSA-9842860 | Regulation of endogenous retroelements | 6.689891e-01 | 0.175 |
R-HSA-2559580 | Oxidative Stress Induced Senescence | 6.689891e-01 | 0.175 |
R-HSA-1236975 | Antigen processing-Cross presentation | 6.909800e-01 | 0.161 |
R-HSA-1912422 | Pre-NOTCH Expression and Processing | 7.057930e-01 | 0.151 |
R-HSA-15869 | Metabolism of nucleotides | 7.143298e-01 | 0.146 |
R-HSA-8939211 | ESR-mediated signaling | 7.163408e-01 | 0.145 |
R-HSA-157118 | Signaling by NOTCH | 7.223032e-01 | 0.141 |
R-HSA-9759194 | Nuclear events mediated by NFE2L2 | 7.333352e-01 | 0.135 |
R-HSA-1660662 | Glycosphingolipid metabolism | 7.385280e-01 | 0.132 |
R-HSA-421270 | Cell-cell junction organization | 7.432727e-01 | 0.129 |
R-HSA-1474228 | Degradation of the extracellular matrix | 7.653436e-01 | 0.116 |
R-HSA-9018519 | Estrogen-dependent gene expression | 7.766112e-01 | 0.110 |
R-HSA-5173105 | O-linked glycosylation | 7.787993e-01 | 0.109 |
R-HSA-1632852 | Macroautophagy | 7.873410e-01 | 0.104 |
R-HSA-418594 | G alpha (i) signalling events | 7.900645e-01 | 0.102 |
R-HSA-388396 | GPCR downstream signalling | 7.918433e-01 | 0.101 |
R-HSA-8856828 | Clathrin-mediated endocytosis | 7.935315e-01 | 0.100 |
R-HSA-199977 | ER to Golgi Anterograde Transport | 8.015077e-01 | 0.096 |
R-HSA-2187338 | Visual phototransduction | 8.015077e-01 | 0.096 |
R-HSA-2142753 | Arachidonate metabolism | 8.110487e-01 | 0.091 |
R-HSA-9609507 | Protein localization | 8.129015e-01 | 0.090 |
R-HSA-9612973 | Autophagy | 8.183523e-01 | 0.087 |
R-HSA-9711097 | Cellular response to starvation | 8.218982e-01 | 0.085 |
R-HSA-6791226 | Major pathway of rRNA processing in the nucleolus and cytosol | 8.433278e-01 | 0.074 |
R-HSA-5689880 | Ub-specific processing proteases | 8.478972e-01 | 0.072 |
R-HSA-9764274 | Regulation of Expression and Function of Type I Classical Cadherins | 8.478972e-01 | 0.072 |
R-HSA-9764265 | Regulation of CDH1 Expression and Function | 8.478972e-01 | 0.072 |
R-HSA-9662851 | Anti-inflammatory response favouring Leishmania parasite infection | 8.478972e-01 | 0.072 |
R-HSA-9664433 | Leishmania parasite growth and survival | 8.478972e-01 | 0.072 |
R-HSA-112315 | Transmission across Chemical Synapses | 8.496579e-01 | 0.071 |
R-HSA-8957322 | Metabolism of steroids | 8.508052e-01 | 0.070 |
R-HSA-112316 | Neuronal System | 8.584558e-01 | 0.066 |
R-HSA-372790 | Signaling by GPCR | 8.621284e-01 | 0.064 |
R-HSA-201681 | TCF dependent signaling in response to WNT | 8.621933e-01 | 0.064 |
R-HSA-3781865 | Diseases of glycosylation | 8.635473e-01 | 0.064 |
R-HSA-8868773 | rRNA processing in the nucleus and cytosol | 8.688324e-01 | 0.061 |
R-HSA-9759476 | Regulation of Homotypic Cell-Cell Adhesion | 8.787999e-01 | 0.056 |
R-HSA-6811442 | Intra-Golgi and retrograde Golgi-to-ER traffic | 8.834977e-01 | 0.054 |
R-HSA-397014 | Muscle contraction | 8.975511e-01 | 0.047 |
R-HSA-418990 | Adherens junctions interactions | 9.034560e-01 | 0.044 |
R-HSA-9748784 | Drug ADME | 9.034560e-01 | 0.044 |
R-HSA-8951664 | Neddylation | 9.062803e-01 | 0.043 |
R-HSA-196849 | Metabolism of water-soluble vitamins and cofactors | 9.142700e-01 | 0.039 |
R-HSA-373076 | Class A/1 (Rhodopsin-like receptors) | 9.145291e-01 | 0.039 |
R-HSA-72312 | rRNA processing | 9.159515e-01 | 0.038 |
R-HSA-8978868 | Fatty acid metabolism | 9.230136e-01 | 0.035 |
R-HSA-446203 | Asparagine N-linked glycosylation | 9.318221e-01 | 0.031 |
R-HSA-416476 | G alpha (q) signalling events | 9.388015e-01 | 0.027 |
R-HSA-211945 | Phase I - Functionalization of compounds | 9.467438e-01 | 0.024 |
R-HSA-6798695 | Neutrophil degranulation | 9.488288e-01 | 0.023 |
R-HSA-556833 | Metabolism of lipids | 9.634970e-01 | 0.016 |
R-HSA-196854 | Metabolism of vitamins and cofactors | 9.773877e-01 | 0.010 |
R-HSA-500792 | GPCR ligand binding | 9.832843e-01 | 0.007 |
R-HSA-72766 | Translation | 9.883197e-01 | 0.005 |
R-HSA-211859 | Biological oxidations | 9.954631e-01 | 0.002 |
R-HSA-1430728 | Metabolism | 9.997261e-01 | 0.000 |
R-HSA-9709957 | Sensory Perception | 9.999593e-01 | 0.000 |
Download
kinase | JSD_mean | pearson_surrounding | kinase_max_IC_position | max_position_JSD |
---|---|---|---|---|
COT |
0.836 | 0.109 | 2 | 0.761 |
CDC7 |
0.833 | 0.131 | 1 | 0.877 |
DSTYK |
0.832 | 0.138 | 2 | 0.785 |
IKKB |
0.830 | 0.083 | -2 | 0.700 |
CLK3 |
0.829 | 0.136 | 1 | 0.832 |
BMPR1B |
0.826 | 0.244 | 1 | 0.820 |
PIM3 |
0.826 | 0.074 | -3 | 0.862 |
MOS |
0.825 | 0.086 | 1 | 0.889 |
GRK6 |
0.825 | 0.176 | 1 | 0.866 |
ALK2 |
0.824 | 0.272 | -2 | 0.814 |
ERK5 |
0.824 | 0.147 | 1 | 0.825 |
RAF1 |
0.823 | 0.038 | 1 | 0.830 |
TGFBR1 |
0.823 | 0.194 | -2 | 0.799 |
CAMK1B |
0.821 | 0.050 | -3 | 0.887 |
PRPK |
0.821 | -0.071 | -1 | 0.685 |
BMPR1A |
0.820 | 0.258 | 1 | 0.810 |
RSK2 |
0.820 | 0.085 | -3 | 0.808 |
CAMK2G |
0.820 | 0.010 | 2 | 0.670 |
BMPR2 |
0.820 | 0.049 | -2 | 0.828 |
GCN2 |
0.819 | -0.054 | 2 | 0.659 |
IKKA |
0.819 | 0.064 | -2 | 0.685 |
CAMK2B |
0.818 | 0.097 | 2 | 0.657 |
TGFBR2 |
0.818 | 0.056 | -2 | 0.817 |
FAM20C |
0.818 | 0.064 | 2 | 0.517 |
IKKE |
0.818 | -0.012 | 1 | 0.730 |
TBK1 |
0.817 | -0.049 | 1 | 0.736 |
ALK4 |
0.817 | 0.166 | -2 | 0.820 |
NLK |
0.817 | 0.055 | 1 | 0.798 |
ACVR2B |
0.816 | 0.191 | -2 | 0.808 |
NEK6 |
0.816 | -0.028 | -2 | 0.821 |
PIM1 |
0.816 | 0.079 | -3 | 0.814 |
ATR |
0.816 | 0.020 | 1 | 0.825 |
ACVR2A |
0.815 | 0.158 | -2 | 0.804 |
MAPKAPK2 |
0.815 | 0.100 | -3 | 0.760 |
ATM |
0.815 | 0.084 | 1 | 0.779 |
NDR2 |
0.815 | -0.011 | -3 | 0.867 |
PRKD1 |
0.815 | 0.039 | -3 | 0.832 |
P90RSK |
0.814 | 0.050 | -3 | 0.810 |
NEK7 |
0.814 | -0.050 | -3 | 0.817 |
GRK5 |
0.814 | -0.026 | -3 | 0.848 |
PDHK4 |
0.814 | -0.176 | 1 | 0.835 |
CAMLCK |
0.814 | 0.062 | -2 | 0.797 |
GRK1 |
0.813 | 0.060 | -2 | 0.688 |
MTOR |
0.813 | -0.080 | 1 | 0.776 |
SKMLCK |
0.813 | 0.068 | -2 | 0.767 |
PLK1 |
0.812 | 0.063 | -2 | 0.816 |
PKN3 |
0.812 | -0.007 | -3 | 0.856 |
HUNK |
0.811 | -0.024 | 2 | 0.690 |
DAPK2 |
0.811 | 0.050 | -3 | 0.882 |
PRKD2 |
0.811 | 0.061 | -3 | 0.803 |
GRK4 |
0.811 | 0.001 | -2 | 0.742 |
ULK2 |
0.811 | -0.156 | 2 | 0.642 |
NIK |
0.810 | -0.032 | -3 | 0.897 |
CDKL1 |
0.810 | 0.009 | -3 | 0.822 |
CAMK2D |
0.810 | 0.000 | -3 | 0.845 |
PLK3 |
0.810 | 0.085 | 2 | 0.651 |
NUAK2 |
0.810 | 0.017 | -3 | 0.873 |
P70S6KB |
0.810 | 0.034 | -3 | 0.829 |
MAPKAPK3 |
0.809 | 0.044 | -3 | 0.794 |
GRK7 |
0.809 | 0.098 | 1 | 0.824 |
RSK3 |
0.808 | 0.032 | -3 | 0.801 |
PDHK1 |
0.808 | -0.172 | 1 | 0.825 |
MLK1 |
0.808 | -0.057 | 2 | 0.719 |
CAMK2A |
0.808 | 0.061 | 2 | 0.687 |
NDR1 |
0.807 | -0.026 | -3 | 0.864 |
KIS |
0.807 | 0.025 | 1 | 0.673 |
MSK1 |
0.806 | 0.091 | -3 | 0.764 |
DLK |
0.805 | -0.025 | 1 | 0.818 |
CLK4 |
0.805 | 0.092 | -3 | 0.813 |
CDKL5 |
0.804 | 0.009 | -3 | 0.812 |
AURC |
0.804 | 0.056 | -2 | 0.651 |
LATS2 |
0.804 | -0.023 | -5 | 0.695 |
RSK4 |
0.804 | 0.070 | -3 | 0.790 |
CLK2 |
0.804 | 0.151 | -3 | 0.799 |
SMG1 |
0.804 | 0.162 | 1 | 0.770 |
MARK4 |
0.804 | -0.060 | 4 | 0.788 |
LATS1 |
0.804 | 0.038 | -3 | 0.876 |
CAMK4 |
0.804 | 0.010 | -3 | 0.852 |
RIPK3 |
0.804 | -0.053 | 3 | 0.715 |
NEK9 |
0.804 | -0.074 | 2 | 0.698 |
AURA |
0.804 | 0.083 | -2 | 0.637 |
MSK2 |
0.803 | 0.030 | -3 | 0.755 |
MST4 |
0.803 | -0.055 | 2 | 0.762 |
MYLK4 |
0.803 | 0.098 | -2 | 0.728 |
ULK1 |
0.803 | -0.149 | -3 | 0.804 |
TSSK2 |
0.803 | -0.002 | -5 | 0.793 |
PKACG |
0.802 | 0.002 | -2 | 0.707 |
CHAK2 |
0.801 | -0.089 | -1 | 0.648 |
AMPKA1 |
0.801 | -0.055 | -3 | 0.874 |
PKCD |
0.801 | -0.027 | 2 | 0.694 |
WNK1 |
0.801 | -0.075 | -2 | 0.752 |
ANKRD3 |
0.801 | -0.105 | 1 | 0.840 |
PKACB |
0.800 | 0.074 | -2 | 0.664 |
PKN2 |
0.800 | -0.030 | -3 | 0.862 |
CHK1 |
0.800 | 0.043 | -3 | 0.845 |
MEK1 |
0.799 | -0.009 | 2 | 0.716 |
JNK2 |
0.799 | 0.080 | 1 | 0.583 |
AURB |
0.798 | 0.049 | -2 | 0.654 |
MASTL |
0.798 | -0.191 | -2 | 0.732 |
ICK |
0.798 | -0.042 | -3 | 0.854 |
CLK1 |
0.798 | 0.073 | -3 | 0.799 |
YSK4 |
0.798 | -0.032 | 1 | 0.758 |
TSSK1 |
0.798 | -0.027 | -3 | 0.890 |
BCKDK |
0.798 | -0.161 | -1 | 0.610 |
PKR |
0.797 | -0.028 | 1 | 0.812 |
JNK3 |
0.797 | 0.059 | 1 | 0.630 |
DRAK1 |
0.797 | 0.064 | 1 | 0.737 |
PRKD3 |
0.797 | 0.030 | -3 | 0.782 |
TTBK2 |
0.797 | -0.118 | 2 | 0.552 |
WNK3 |
0.796 | -0.180 | 1 | 0.799 |
PAK1 |
0.796 | 0.000 | -2 | 0.713 |
NIM1 |
0.796 | -0.084 | 3 | 0.817 |
AMPKA2 |
0.796 | -0.037 | -3 | 0.851 |
DNAPK |
0.796 | 0.036 | 1 | 0.694 |
SRPK1 |
0.796 | -0.004 | -3 | 0.781 |
MLK3 |
0.796 | -0.051 | 2 | 0.670 |
PRKX |
0.795 | 0.083 | -3 | 0.742 |
MLK2 |
0.795 | -0.137 | 2 | 0.702 |
HIPK4 |
0.795 | -0.050 | 1 | 0.730 |
TLK2 |
0.795 | -0.035 | 1 | 0.770 |
PAK6 |
0.795 | 0.049 | -2 | 0.691 |
PERK |
0.794 | -0.029 | -2 | 0.825 |
DYRK2 |
0.793 | 0.015 | 1 | 0.657 |
PAK3 |
0.792 | -0.033 | -2 | 0.718 |
PLK2 |
0.792 | 0.090 | -3 | 0.806 |
MELK |
0.792 | -0.038 | -3 | 0.837 |
MNK2 |
0.792 | -0.020 | -2 | 0.744 |
BRAF |
0.792 | -0.025 | -4 | 0.785 |
PIM2 |
0.792 | 0.037 | -3 | 0.785 |
P38B |
0.792 | 0.037 | 1 | 0.632 |
NUAK1 |
0.792 | -0.044 | -3 | 0.833 |
PAK2 |
0.791 | -0.015 | -2 | 0.709 |
MLK4 |
0.791 | -0.073 | 2 | 0.634 |
CDK8 |
0.791 | -0.044 | 1 | 0.627 |
P38A |
0.790 | 0.020 | 1 | 0.688 |
RIPK1 |
0.790 | -0.157 | 1 | 0.785 |
QSK |
0.790 | -0.042 | 4 | 0.757 |
PASK |
0.790 | 0.080 | -3 | 0.866 |
PKG2 |
0.789 | 0.023 | -2 | 0.662 |
AKT2 |
0.789 | 0.037 | -3 | 0.733 |
MARK2 |
0.789 | -0.044 | 4 | 0.700 |
MAPKAPK5 |
0.789 | -0.031 | -3 | 0.719 |
SRPK2 |
0.788 | -0.007 | -3 | 0.708 |
NEK2 |
0.788 | -0.125 | 2 | 0.683 |
VRK2 |
0.788 | -0.193 | 1 | 0.854 |
SIK |
0.788 | -0.038 | -3 | 0.798 |
MEKK3 |
0.788 | -0.050 | 1 | 0.781 |
GRK2 |
0.788 | -0.038 | -2 | 0.651 |
CK2A2 |
0.788 | 0.102 | 1 | 0.708 |
BRSK1 |
0.787 | -0.038 | -3 | 0.824 |
MNK1 |
0.787 | -0.018 | -2 | 0.756 |
PKACA |
0.787 | 0.062 | -2 | 0.627 |
QIK |
0.787 | -0.103 | -3 | 0.849 |
P38D |
0.787 | 0.061 | 1 | 0.535 |
MARK3 |
0.786 | -0.034 | 4 | 0.715 |
HRI |
0.786 | -0.099 | -2 | 0.817 |
SRPK3 |
0.786 | -0.023 | -3 | 0.751 |
PKCB |
0.786 | -0.067 | 2 | 0.667 |
DCAMKL1 |
0.786 | -0.011 | -3 | 0.829 |
TLK1 |
0.786 | -0.045 | -2 | 0.783 |
ERK2 |
0.786 | -0.003 | 1 | 0.646 |
PHKG1 |
0.785 | -0.083 | -3 | 0.850 |
SGK3 |
0.785 | -0.005 | -3 | 0.792 |
CAMKK1 |
0.785 | 0.049 | -2 | 0.769 |
DYRK4 |
0.785 | 0.065 | 1 | 0.585 |
PKCA |
0.784 | -0.072 | 2 | 0.658 |
ERK1 |
0.784 | -0.004 | 1 | 0.606 |
CDK1 |
0.784 | -0.012 | 1 | 0.600 |
CDK7 |
0.784 | -0.053 | 1 | 0.640 |
CDK19 |
0.784 | -0.044 | 1 | 0.587 |
MARK1 |
0.784 | -0.045 | 4 | 0.739 |
PLK4 |
0.784 | -0.111 | 2 | 0.498 |
GAK |
0.783 | 0.101 | 1 | 0.852 |
P70S6K |
0.783 | 0.002 | -3 | 0.735 |
CAMK1D |
0.783 | 0.032 | -3 | 0.732 |
NEK5 |
0.783 | -0.064 | 1 | 0.818 |
IRE1 |
0.783 | -0.187 | 1 | 0.760 |
PKCH |
0.783 | -0.084 | 2 | 0.639 |
PKCG |
0.783 | -0.089 | 2 | 0.665 |
P38G |
0.782 | 0.003 | 1 | 0.518 |
SMMLCK |
0.782 | 0.015 | -3 | 0.843 |
PINK1 |
0.782 | -0.092 | 1 | 0.779 |
IRE2 |
0.782 | -0.155 | 2 | 0.623 |
DCAMKL2 |
0.782 | -0.013 | -3 | 0.855 |
CAMK1G |
0.781 | -0.029 | -3 | 0.795 |
BRSK2 |
0.781 | -0.089 | -3 | 0.840 |
DAPK3 |
0.781 | 0.054 | -3 | 0.837 |
PRP4 |
0.780 | -0.001 | -3 | 0.773 |
MEKK2 |
0.780 | -0.109 | 2 | 0.676 |
NEK8 |
0.780 | -0.054 | 2 | 0.698 |
CDK2 |
0.780 | -0.035 | 1 | 0.700 |
PKCZ |
0.780 | -0.121 | 2 | 0.669 |
CDK13 |
0.780 | -0.058 | 1 | 0.618 |
MEKK1 |
0.780 | -0.166 | 1 | 0.801 |
GRK3 |
0.779 | -0.023 | -2 | 0.609 |
MEK5 |
0.779 | -0.195 | 2 | 0.701 |
CHAK1 |
0.779 | -0.182 | 2 | 0.625 |
ZAK |
0.779 | -0.153 | 1 | 0.766 |
TTBK1 |
0.778 | -0.077 | 2 | 0.484 |
SNRK |
0.778 | -0.140 | 2 | 0.560 |
CK2A1 |
0.778 | 0.087 | 1 | 0.679 |
CAMKK2 |
0.778 | 0.002 | -2 | 0.765 |
AKT1 |
0.778 | 0.032 | -3 | 0.749 |
JNK1 |
0.778 | 0.053 | 1 | 0.584 |
ERK7 |
0.778 | 0.012 | 2 | 0.494 |
TAO3 |
0.778 | -0.074 | 1 | 0.777 |
GSK3B |
0.777 | 0.003 | 4 | 0.491 |
DAPK1 |
0.777 | 0.061 | -3 | 0.817 |
CDK5 |
0.777 | -0.050 | 1 | 0.665 |
GSK3A |
0.776 | 0.012 | 4 | 0.501 |
DYRK1A |
0.775 | -0.027 | 1 | 0.701 |
HIPK1 |
0.775 | -0.029 | 1 | 0.672 |
TAK1 |
0.775 | 0.068 | 1 | 0.791 |
CDK18 |
0.775 | -0.046 | 1 | 0.579 |
CDK9 |
0.775 | -0.058 | 1 | 0.625 |
DYRK3 |
0.775 | 0.018 | 1 | 0.669 |
MST3 |
0.775 | -0.069 | 2 | 0.757 |
MST2 |
0.774 | -0.039 | 1 | 0.798 |
PHKG2 |
0.773 | -0.062 | -3 | 0.847 |
PAK5 |
0.773 | 0.005 | -2 | 0.620 |
DYRK1B |
0.773 | -0.013 | 1 | 0.626 |
HIPK2 |
0.773 | -0.021 | 1 | 0.562 |
CDK14 |
0.772 | -0.020 | 1 | 0.621 |
EEF2K |
0.772 | -0.040 | 3 | 0.765 |
MRCKA |
0.772 | 0.053 | -3 | 0.797 |
CDK17 |
0.772 | -0.046 | 1 | 0.527 |
WNK4 |
0.772 | -0.177 | -2 | 0.745 |
LKB1 |
0.772 | -0.038 | -3 | 0.816 |
CDK12 |
0.771 | -0.063 | 1 | 0.589 |
SSTK |
0.770 | -0.090 | 4 | 0.751 |
TAO2 |
0.770 | -0.100 | 2 | 0.729 |
PKCT |
0.769 | -0.091 | 2 | 0.642 |
CHK2 |
0.769 | 0.032 | -3 | 0.685 |
PAK4 |
0.769 | 0.002 | -2 | 0.631 |
HIPK3 |
0.768 | -0.054 | 1 | 0.681 |
IRAK4 |
0.768 | -0.171 | 1 | 0.776 |
CDK3 |
0.768 | -0.015 | 1 | 0.549 |
MRCKB |
0.767 | 0.040 | -3 | 0.783 |
CAMK1A |
0.767 | 0.017 | -3 | 0.706 |
NEK4 |
0.767 | -0.110 | 1 | 0.767 |
NEK11 |
0.767 | -0.172 | 1 | 0.772 |
CDK16 |
0.766 | -0.028 | 1 | 0.551 |
SGK1 |
0.766 | 0.026 | -3 | 0.650 |
GCK |
0.766 | -0.056 | 1 | 0.764 |
PDK1 |
0.766 | -0.102 | 1 | 0.783 |
NEK1 |
0.766 | -0.058 | 1 | 0.790 |
CK1E |
0.765 | -0.083 | -3 | 0.529 |
IRAK1 |
0.765 | -0.194 | -1 | 0.604 |
PKCI |
0.765 | -0.090 | 2 | 0.652 |
BUB1 |
0.764 | 0.047 | -5 | 0.777 |
MEK2 |
0.764 | -0.113 | 2 | 0.663 |
ALPHAK3 |
0.763 | 0.067 | -1 | 0.625 |
ROCK2 |
0.763 | 0.015 | -3 | 0.825 |
SBK |
0.763 | 0.033 | -3 | 0.616 |
MST1 |
0.763 | -0.074 | 1 | 0.774 |
VRK1 |
0.763 | -0.100 | 2 | 0.700 |
AKT3 |
0.762 | 0.017 | -3 | 0.665 |
LOK |
0.761 | -0.081 | -2 | 0.715 |
CDK10 |
0.761 | -0.030 | 1 | 0.602 |
PKCE |
0.761 | -0.050 | 2 | 0.652 |
CK1G1 |
0.760 | -0.089 | -3 | 0.538 |
CK1D |
0.760 | -0.066 | -3 | 0.475 |
PKN1 |
0.760 | -0.038 | -3 | 0.755 |
TNIK |
0.760 | -0.107 | 3 | 0.814 |
HPK1 |
0.760 | -0.061 | 1 | 0.749 |
SLK |
0.760 | -0.073 | -2 | 0.649 |
RIPK2 |
0.759 | -0.132 | 1 | 0.722 |
TTK |
0.758 | -0.005 | -2 | 0.810 |
LRRK2 |
0.758 | -0.187 | 2 | 0.713 |
MPSK1 |
0.757 | -0.133 | 1 | 0.754 |
DMPK1 |
0.757 | 0.045 | -3 | 0.812 |
MINK |
0.757 | -0.151 | 1 | 0.761 |
HGK |
0.756 | -0.151 | 3 | 0.802 |
CDK4 |
0.756 | -0.038 | 1 | 0.576 |
CK1A2 |
0.755 | -0.077 | -3 | 0.476 |
MEKK6 |
0.755 | -0.201 | 1 | 0.793 |
PBK |
0.754 | -0.024 | 1 | 0.796 |
MAP3K15 |
0.754 | -0.212 | 1 | 0.754 |
MAK |
0.753 | -0.011 | -2 | 0.628 |
PKG1 |
0.753 | -0.003 | -2 | 0.589 |
CDK6 |
0.753 | -0.051 | 1 | 0.599 |
BIKE |
0.752 | 0.045 | 1 | 0.749 |
KHS2 |
0.752 | -0.075 | 1 | 0.752 |
ROCK1 |
0.751 | 0.011 | -3 | 0.795 |
CRIK |
0.751 | 0.010 | -3 | 0.739 |
OSR1 |
0.751 | -0.078 | 2 | 0.691 |
YSK1 |
0.751 | -0.145 | 2 | 0.693 |
KHS1 |
0.750 | -0.114 | 1 | 0.752 |
MOK |
0.750 | -0.032 | 1 | 0.704 |
STK33 |
0.749 | -0.170 | 2 | 0.514 |
PDHK3_TYR |
0.749 | 0.159 | 4 | 0.871 |
NEK3 |
0.745 | -0.191 | 1 | 0.749 |
YANK3 |
0.744 | -0.062 | 2 | 0.339 |
MAP2K4_TYR |
0.743 | 0.076 | -1 | 0.710 |
MAP2K6_TYR |
0.743 | 0.112 | -1 | 0.693 |
PDHK4_TYR |
0.742 | 0.116 | 2 | 0.767 |
TXK |
0.740 | 0.215 | 1 | 0.847 |
EPHB4 |
0.739 | 0.147 | -1 | 0.720 |
TAO1 |
0.738 | -0.124 | 1 | 0.707 |
EPHA4 |
0.738 | 0.156 | 2 | 0.683 |
PDHK1_TYR |
0.738 | 0.039 | -1 | 0.710 |
SRMS |
0.737 | 0.213 | 1 | 0.897 |
BMPR2_TYR |
0.737 | 0.013 | -1 | 0.674 |
EPHA6 |
0.737 | 0.085 | -1 | 0.703 |
MYO3B |
0.736 | -0.134 | 2 | 0.702 |
FER |
0.736 | 0.109 | 1 | 0.916 |
ASK1 |
0.736 | -0.183 | 1 | 0.747 |
EPHB1 |
0.736 | 0.170 | 1 | 0.893 |
MAP2K7_TYR |
0.736 | -0.097 | 2 | 0.724 |
TESK1_TYR |
0.735 | -0.107 | 3 | 0.887 |
EPHB3 |
0.735 | 0.158 | -1 | 0.713 |
STLK3 |
0.734 | -0.128 | 1 | 0.734 |
EPHB2 |
0.734 | 0.165 | -1 | 0.714 |
AAK1 |
0.733 | 0.059 | 1 | 0.652 |
ABL2 |
0.733 | 0.076 | -1 | 0.694 |
MYO3A |
0.732 | -0.151 | 1 | 0.745 |
RET |
0.732 | -0.033 | 1 | 0.811 |
HASPIN |
0.732 | -0.121 | -1 | 0.507 |
YES1 |
0.732 | 0.101 | -1 | 0.712 |
PINK1_TYR |
0.732 | -0.124 | 1 | 0.833 |
TEC |
0.730 | 0.173 | -1 | 0.693 |
ITK |
0.730 | 0.155 | -1 | 0.691 |
TYRO3 |
0.730 | 0.035 | 3 | 0.787 |
BMX |
0.728 | 0.142 | -1 | 0.652 |
MERTK |
0.728 | 0.133 | 3 | 0.779 |
HCK |
0.728 | 0.093 | -1 | 0.707 |
BLK |
0.727 | 0.130 | -1 | 0.700 |
ABL1 |
0.727 | 0.047 | -1 | 0.693 |
PKMYT1_TYR |
0.727 | -0.218 | 3 | 0.850 |
LCK |
0.726 | 0.093 | -1 | 0.693 |
FGR |
0.726 | -0.002 | 1 | 0.877 |
TYK2 |
0.726 | -0.127 | 1 | 0.820 |
INSRR |
0.725 | -0.012 | 3 | 0.746 |
EPHA5 |
0.725 | 0.143 | 2 | 0.670 |
MST1R |
0.724 | -0.086 | 3 | 0.798 |
LIMK2_TYR |
0.724 | -0.123 | -3 | 0.891 |
ROS1 |
0.724 | -0.077 | 3 | 0.759 |
EPHA7 |
0.724 | 0.096 | 2 | 0.671 |
CSF1R |
0.723 | -0.035 | 3 | 0.755 |
JAK2 |
0.723 | -0.109 | 1 | 0.812 |
FGFR2 |
0.723 | -0.030 | 3 | 0.791 |
DDR1 |
0.723 | -0.081 | 4 | 0.806 |
BTK |
0.723 | 0.129 | -1 | 0.700 |
FYN |
0.723 | 0.109 | -1 | 0.653 |
CK1A |
0.722 | -0.094 | -3 | 0.388 |
TEK |
0.721 | 0.039 | 3 | 0.730 |
AXL |
0.721 | 0.023 | 3 | 0.772 |
FRK |
0.721 | 0.112 | -1 | 0.749 |
EPHA3 |
0.720 | 0.043 | 2 | 0.643 |
TNK2 |
0.720 | 0.008 | 3 | 0.746 |
FLT3 |
0.720 | -0.042 | 3 | 0.764 |
PTK2B |
0.719 | 0.088 | -1 | 0.689 |
KIT |
0.719 | -0.028 | 3 | 0.760 |
JAK3 |
0.718 | -0.105 | 1 | 0.790 |
PTK6 |
0.718 | -0.041 | -1 | 0.631 |
LTK |
0.718 | -0.001 | 3 | 0.731 |
NTRK1 |
0.717 | -0.045 | -1 | 0.669 |
LIMK1_TYR |
0.717 | -0.269 | 2 | 0.703 |
FGFR3 |
0.716 | -0.007 | 3 | 0.765 |
EPHA8 |
0.716 | 0.059 | -1 | 0.666 |
FGFR1 |
0.715 | -0.097 | 3 | 0.766 |
LYN |
0.715 | 0.071 | 3 | 0.685 |
CK1G3 |
0.715 | -0.060 | -3 | 0.346 |
FLT1 |
0.714 | -0.030 | -1 | 0.670 |
ALK |
0.714 | -0.050 | 3 | 0.709 |
NEK10_TYR |
0.714 | -0.085 | 1 | 0.663 |
EPHA1 |
0.714 | 0.038 | 3 | 0.745 |
EPHA2 |
0.714 | 0.087 | -1 | 0.657 |
SYK |
0.713 | 0.078 | -1 | 0.617 |
EGFR |
0.713 | 0.025 | 1 | 0.740 |
ERBB2 |
0.713 | -0.041 | 1 | 0.803 |
PDGFRB |
0.713 | -0.161 | 3 | 0.780 |
MET |
0.713 | -0.057 | 3 | 0.780 |
KDR |
0.712 | -0.099 | 3 | 0.722 |
SRC |
0.710 | 0.045 | -1 | 0.665 |
PTK2 |
0.710 | 0.040 | -1 | 0.609 |
FGFR4 |
0.710 | 0.004 | -1 | 0.652 |
NTRK3 |
0.710 | -0.061 | -1 | 0.634 |
YANK2 |
0.709 | -0.090 | 2 | 0.352 |
JAK1 |
0.709 | -0.111 | 1 | 0.749 |
CSK |
0.708 | -0.024 | 2 | 0.658 |
NTRK2 |
0.707 | -0.104 | 3 | 0.736 |
TNK1 |
0.707 | -0.155 | 3 | 0.778 |
INSR |
0.706 | -0.096 | 3 | 0.729 |
FLT4 |
0.706 | -0.104 | 3 | 0.723 |
PDGFRA |
0.706 | -0.184 | 3 | 0.772 |
MATK |
0.705 | -0.054 | -1 | 0.612 |
TNNI3K_TYR |
0.703 | -0.164 | 1 | 0.798 |
DDR2 |
0.703 | -0.046 | 3 | 0.718 |
WEE1_TYR |
0.701 | -0.118 | -1 | 0.618 |
IGF1R |
0.700 | -0.049 | 3 | 0.685 |
ERBB4 |
0.699 | 0.022 | 1 | 0.765 |
CK1G2 |
0.698 | -0.065 | -3 | 0.447 |
MUSK |
0.695 | -0.066 | 1 | 0.743 |
FES |
0.691 | -0.014 | -1 | 0.616 |
ZAP70 |
0.686 | 0.004 | -1 | 0.533 |